

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING APPLICATION UNDER RULE 60**

A18

jc491 U.S. PTO



Pursuant to 37 CFR 1.60, please file a
Continuation/☒ divisional
of the pending prior PATENT APPLICATION of:
Inventor: MAERTENS, et al.
Serial No. 08/612,973
Filed: March 11, 1996
For: PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE
Hon. Commissioner of Patents and Trademarks
Washington, DC 20231

Atty Dkt.: 1487-17
C# M#
Date: September 12, 1997
Group: 1815
Examiner: Woodward, M.

Sir:
This request for filing under Rule 60 is made by the following named inventor(s) (using the above-identified title):
Inventor(s): MAERTENS, et al.

- ☒ Attached is a true copy of the prior application as originally filed including the specification, claims, Oath/Declaration and drawings (if any) and abstract (if any). No amendments (if any) referenced in the Oath or Declaration filed to complete the prior application introduced new matter.
- ☒ Priority is hereby claimed under 35 USC 119 based on the following foreign applications:

Application Number	Country	Day/Month/Year Filed
PCT/EP95/03031	Pct	31/07/1995
94870132.1	EP	29/07/1994

☐ certified copy(ies) of foreign application(s) attached or
☐ already filed on _____ in prior appln no. _____

☒ already filed in 08/612,973

filed _____
filed March 11, 1996

- ☐ Please amend the specification by inserting before the first line: -- This application claims the benefit of U.S. Provisional Application No. _____, filed _____
- ☒ The prior application is assigned to Innogenetics NV, Ghent, Belgium.
- ☒ Power of Attorney has been granted to Thomas E. Byrne, et al, Reg. No. 32,205 of Nixon & Vanderhye P.C., 1100 North Glebe Road, 8th Floor, Arlington, Virginia 22201.
- ☒ Address all future communications to: Nixon & Vanderhye P.C., 1100 North Glebe Road, 8th Floor, Arlington, Virginia 22201.
- ☒ Please amend the specification by inserting before the first line --This is a divisional of application Serial No. 08/612,973, filed March 11, 1996.--
- ☒ "Small entity" statement of record. ☒ "Small entity" statement attached.
- ☐ Petition filed in prior application to extend its life to insure copendency.
- ☒ The Examiner's attention is directed to the prior art cited in the parent application by applicant and/or Examiner for the reasons stated therein. The Examiner is requested to acknowledge consideration of same by returning an initialed copy of the attached PTO 1449 pursuant to MPEP §609.
- ☒ Please enter the attached and/or below preliminary amendment prior to calculation of filing fee:

FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY HERewith CANCELED

Basic Filing Fee		\$	770.00
Total effective claims	10 - 20 (at least 20) = 0	x \$	22.00
Independent claims	4 - 3 (at least 3) = 1	x \$	80.00
If any proper multiple dependent claims now added for first time, add \$260.00 (ignore improper)		\$	0.00
		SUBTOTAL	\$ 850.00
If "small entity," then enter half (1/2) of subtotal and subtract		-\$	425.00
		SECOND SUBTOTAL	\$ 425.00
Assignment Recording Fee (\$40.00)		\$	0.00
		TOTAL FEE ENCLOSED	\$ 425.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No. 14-1140**. A duplicate copy of this sheet is attached.

1100 North Glebe Road
8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4091
Facsimile: (703) 816-4100
BJS:msg

NIXON & VANDERHYE P.C.
By Atty: B.J. Sadoff, Reg. No. 36,663

Signature:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of

Atty Ref.: 1487-17

MAERTENS, et al.

Group: Unassigned

Application No.: NOT YET ASSIGNED
(DIVISIONAL OF APPLICATION NO. 08/612,973)

Examiner: Unassigned

Filed: Herewith

For: PURIFIED HEPATITIS C VIRUS ENVELOPE
PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE

September 12, 1997

PRELIMINARY AMENDMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

Preliminarily amend the above-identified application as follows.

IN THE SPECIFICATION:

Amend the specification as follows.

Insert the attached SEQUENCE LISTING before the claims pages and renumber subsequent pages accordingly.

Please insert the attached "ABSTRACT" after the claims pages.

IN THE CLAIMS:

Amend the claims as follows.

Cancel claims 1-48, without prejudice.

Add the following new claims.

--49. A vaccine composition obtained by immunizing a mammal with an effective amount of:

a composition comprising purified recombinant HCV single or specific oligomeric recombinant envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2; and optionally a pharmaceutically acceptable adjuvant.

50. A composition according to claim 49 wherein said recombinant HCV envelope proteins are produced by recombinant mammalian cells.

51. A composition according to claim 49 wherein said recombinant HCV envelope proteins are produced by recombinant yeast cells.

52. A vaccine composition obtained by immunizing a mammal with an effective amount of a composition comprising purified recombinant HCV single or specific oligomeric recombinant envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2, and optionally a pharmaceutically acceptable adjuvant;

said proteins being the expression product of at least one recombinant vector selected from the group consisting of:

a) a recombinant vector comprising a vector sequence, a prokaryotic, eukaryotic or viral promoter sequence followed by a nucleotide sequence allowing the expression of said single or specific oligomeric E1 and/or E2 and/or E1/E2 protein;

b) a recombinant vector according to (a), with said nucleotide sequence being characterized further in that it encodes a single HCV E1 protein starting in the region between amino acid positions 1 and 192 and ending in the region between amino acid positions 250 and 400;

c) a recombinant vector according to (b), with said nucleotide sequence being characterized further in that it encodes a single HCV E1 protein starting in the region between amino acid positions 117 and 192 and ending in the region between amino acid positions 263 and 400;

d) a recombinant vector according to (b) or (c), with said nucleotide sequence being characterized further in that it encodes a single HCV E1 protein bearing a deletion of the first hydrophobic domain between positions 264 to 293, plus or minus 8 amino acids;

e) a recombinant vector according to (a), with said nucleotide sequence being characterized further in that it encodes a single HCV E2 protein starting in the region between amino acid positions 290 and 406 and ending in the region between amino acid positions 600 and 820;

f) a recombinant vector according to (e), with said nucleotide sequence being characterized further in that it ends at any of amino acid positions 623, 650, 661, 673, 710, 715, 720, 746 or 809;

g) a recombinant vector according to any one of (b)-(f), said nucleotide sequence further comprising a 5'-terminal ATG codon and a 3'-terminal stop codon; and

h) a recombinant vector according to any one of (b)-(g) further comprising a factor Xa cleavage site and/or 3 to 10 histidine codons positioned 3'-terminally to said nucleotide sequence.

53. A vaccine composition obtained by immunizing a mammal with an effective amount of a composition comprising at least one of the following E1 and/or E2 peptides:

E1-31 (SEQ ID NO:56) spanning amino acids 181 to 200 of the Core/E1 V1 region,

E1-33 (SEQ ID NO:57) spanning amino acids 193 to 212 of the E1 region,

E1-35 (SEQ ID NO:58) spanning amino acids 205 to 224 of the E1 V2 region (epitope B),

E1-35A (SEQ ID NO:59) spanning amino acids 208 to 227 of the E1 V2 region (epitope B),

1bE1 (SEQ ID NO:53) spanning amino acids 192 to 228 of E1 regions V1, C1, and V2 regions (containing epitope B),

E1-51 (SEQ ID NO:66) spanning amino acids 301 to 320 of the E1 region,

E1-53 (SEQ ID NO:67) spanning amino acids 313 to 332 of the E1 C4 region (epitope A),

E1-55 (SEQ ID NO:68) spanning amino acids 325 to 344 of the E1 region,

Env 67 or E2-67 (SEQ ID NO:72) spanning amino acid positions 397 to 418 of the E2 region (epitope A),

Env 69 or E2-69 (SEQ ID NO:73) spanning amino acid positions 409 to 428 of the E2 region (epitope A),

Env 23 or E2-23 (SEQ ID NO:86) spanning positions 583 to 602 of the E2 region (epitope E),

Env 25 or E2-25 (SEQ ID NO:87) spanning positions 595 to 614 of the E2 region (epitope E),

Env 27 or E2-27 (SEQ ID NO:88) spanning positions 607 to 626 of the E2 region (epitope E),

Env 178 or E2-178 (SEQ ID NO:83) spanning positions 547 to 586 of the E2 region (epitope D), and

Env 13B or E2-13B (SEQ ID NO:82) spanning positions 523 to 542 of the E2 region (epitope C).

54. A vaccine composition obtained by immunizing a mammal with an effective amount of a composition comprising at least one E2 conformational epitope selected from the group consisting of

epitope F recognized by monoclonal antibodies 15C8C1, 12D11F1, and 8G10D1H9,
epitope G recognized by monoclonal antibody 9G3E6,
epitope H (or C) recognized by monoclonal antibodies 10D3C4 and 4H6B2, and
epitope I recognized by monoclonal antibody 17F2C2.

55. A method of immunizing a mammal against HCV comprising administering an effective amount of a composition according to any one of claims 49-51 and, optionally, a pharmaceutically acceptable adjuvant.

56. The method of claim 53 wherein said mammal is a human.--

REMARKS

Claims 1-48 have been canceled, without prejudice.

Claims 49-56 have been added. The present divisional application has been filed to pursue the allegedly distinct invention of Group X (claim 37) of the restriction requirement of May 28, 1997 in the parent Application No. 08/612,973.

The attached paper copy of the SEQUENCE LISTING is the same as the paper and computer readable form of the SEQUENCE LISTING filed in the parent Application No. 08/612,973. No new matter has been added. Pursuant to Rule 822(e) no further computer readable copy of the SEQUENCE LISTING is believed required. A separate "Letter" is attached as required by the same Rule. The Office is requested to contact the undersigned if anything further is required at this time.

An early and favorable action on the merits is requested.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

By: 

B.J. Sadoff

Reg. No. 36,663

Tel. No. (703) 816-4091

Fax No. (703) 816-4100

1100 North Glebe Road; 8th Floor
Arlington, Virginia 22201-4714
Tel. No. (703) 816-4000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of

Atty Ref.: 1487-17

MAERTENS, et al.

Group: Unassigned

Application No.: NOT YET ASSIGNED
(DIVISIONAL OF APPLICATION NO. 08/612,973)

Examiner: Unassigned

Filed: Herewith

For: PURIFIED HEPATITIS C VIRUS ENVELOPE
PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE

September 12, 1997

LETTER

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

Pursuant to Rule 822(e), the applicants note the computer readable form of the Sequence Listing of this new application is identical with the computer readable form of another application of the applicant on file in the Office. That other application is Application No. 08/612,973, filed March 11, 1996. This reference to the other application and computer readable form is being made in lieu of filing a duplicate computer readable form in this new application.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

By: 

B.J. Sadoff

Reg. No. 36,663

Tel. No. (703) 816-4091

Fax No. (703) 816-4100

1100 North Glebe Road; 8th Floor
Arlington, Virginia 22201-4714

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: MAERTENS, GEERT
BOSMAN, FONS
DE MARTYNOFF, GUY
BUYSE, MARIE-ANGE

(ii) TITLE OF INVENTION: PURIFIED HEPATITIS C VIRUS ENVELOPE
PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE

(iii) NUMBER OF SEQUENCES: 111

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: NIXON & VANDERHYE P.C.
(B) STREET: 1100 NORTH GLEBE ROAD
(C) CITY: ARLINGTON
(D) STATE: VIRGINIA
(E) COUNTRY: U.S.A.
(F) ZIP: 22201-4714

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/612,973
(B) FILING DATE: 11-MAR-1996
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: BYRNE, THOMAS E.
(B) REGISTRATION NUMBER: 32,205
(C) REFERENCE/DOCKET NUMBER: 1487-10

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (703) 816-4000
(B) TELEFAX: (703) 816-4100

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GGCATGCAAG CTTAATTAAT T

21

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 68 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CCGGGGAGGC CTGCACGTGA TCGAGGGCAG ACACCATCAC CACCATCACT AATAGTTAAT

60

TAACTGCA

68

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 642 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..639

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 1..636

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

ATG CCC GGT TGC TCT TTC TCT ATC TTC CTC TTG GCT TTA CTG TCC TGT
Met Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys
1 5 10 15

48

CTG ACC ATT CCA GCT TCC GCT TAT GAG GTG CGC AAC GTG TCC GGG ATG
Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Met
20 25 30

96

TAC CAT GTC ACG AAC GAC TGC TCC AAC TCA AGC ATT GTG TAT GAG GCA

144

Tyr	His	Val	Thr	Asn	Asp	Cys	Ser	Asn	Ser	Ser	Ile	Val	Tyr	Glu	Ala		
		35					40					45					
GCG	GAC	ATG	ATC	ATG	CAC	ACC	CCC	GGG	TGC	GTG	CCC	TGC	GTT	CGG	GAG	192	
Ala	Asp	Met	Ile	Met	His	Thr	Pro	Gly	Cys	Val	Pro	Cys	Val	Arg	Glu		
		50				55					60						
AAC	AAC	TCT	TCC	CGC	TGC	TGG	GTA	GCG	CTC	ACC	CCC	ACG	CTC	GCA	GCT	240	
Asn	Asn	Ser	Ser	Arg	Cys	Trp	Val	Ala	Leu	Thr	Pro	Thr	Leu	Ala	Ala		
		65			70					75					80		
AGG	AAC	GCC	AGC	GTC	CCC	ACC	ACG	ACA	ATA	CGA	CGC	CAC	GTC	GAT	TTG	288	
Arg	Asn	Ala	Ser	Val	Pro	Thr	Thr	Thr	Ile	Arg	Arg	His	Val	Asp	Leu		
				85					90					95			
CTC	GTT	GGG	GCG	GCT	GCT	CTC	TGT	TCC	GCT	ATG	TAC	GTG	GGG	GAT	CTC	336	
Leu	Val	Gly	Ala	Ala	Ala	Leu	Cys	Ser	Ala	Met	Tyr	Val	Gly	Asp	Leu		
			100					105					110				
TGC	GGA	TCT	GTC	TTC	CTC	GTC	TCC	CAG	CTG	TTC	ACC	ATC	TCG	CCT	CGC	384	
Cys	Gly	Ser	Val	Phe	Leu	Val	Ser	Gln	Leu	Phe	Thr	Ile	Ser	Pro	Arg		
		115					120					125					
CGG	CAT	GAG	ACG	GTG	CAG	GAC	TGC	AAT	TGC	TCA	ATC	TAT	CCC	GGC	CAC	432	
Arg	His	Glu	Thr	Val	Gln	Asp	Cys	Asn	Cys	Ser	Ile	Tyr	Pro	Gly	His		
		130				135					140						
ATA	ACA	GGT	CAC	CGT	ATG	GCT	TGG	GAT	ATG	ATG	ATG	AAC	TGG	TCG	CCT	480	
Ile	Thr	Gly	His	Arg	Met	Ala	Trp	Asp	Met	Met	Met	Asn	Trp	Ser	Pro		
		145			150				155						160		
ACA	ACG	GCC	CTG	GTG	GTA	TCG	CAG	CTG	CTC	CGG	ATC	CCA	CAA	GCT	GTC	528	
Thr	Thr	Ala	Leu	Val	Val	Ser	Gln	Leu	Leu	Arg	Ile	Pro	Gln	Ala	Val		
			165					170						175			
GTG	GAC	ATG	GTG	GCG	GGG	GCC	CAT	TGG	GGA	GTC	CTG	GCG	GGC	CTC	GCC	576	
Val	Asp	Met	Val	Ala	Gly	Ala	His	Trp	Gly	Val	Leu	Ala	Gly	Leu	Ala		
			180					185					190				
TAC	TAT	TCC	ATG	GTG	GGG	AAC	TGG	GCT	AAG	GTT	TTG	ATT	GTG	ATG	CTA	624	
Tyr	Tyr	Ser	Met	Val	Gly	Asn	Trp	Ala	Lys	Val	Leu	Ile	Val	Met	Leu		
		195				200					205						
CTC	TTT	GCT	CTC	TAATAG												642	
Leu	Phe	Ala	Leu														
		210															

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 212 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met	Pro	Gly	Cys	Ser	Phe	Ser	Ile	Phe	Leu	Leu	Ala	Leu	Leu	Ser	Cys
1				5				10						15	

Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Met
 20 25 30
 Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala
 35 40 45
 Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu
 50 55 60
 Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala
 65 70 75 80
 Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His Val Asp Leu
 85 90 95
 Leu Val Gly Ala Ala Ala Leu Cys Ser Ala Met Tyr Val Gly Asp Leu
 100 105 110
 Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile Ser Pro Arg
 115 120 125
 Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His
 130 135 140
 Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp Ser Pro
 145 150 155 160
 Thr Thr Ala Leu Val Val Ser Gln Leu Leu Arg Ile Pro Gln Ala Val
 165 170 175
 Val Asp Met Val Ala Gly Ala His Trp Gly Val Leu Ala Gly Leu Ala
 180 185 190
 Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val Leu Ile Val Met Leu
 195 200 205
 Leu Phe Ala Leu
 210

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 795 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..792

(ix) FEATURE:

(A) NAME/KEY: mat_peptide
(B) LOCATION: 1..789

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

ATG TTG GGT AAG GTC ATC GAT ACC CTT ACA TGC GGC TTC GCC GAC CTC	48
Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu	
1 5 10 15	
GTG GGG TAC ATT CCG CTC GTC GGC GCC CCC CTA GGG GGC GCT GCC AGG	96
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg	
20 25 30	
GCC CTG GCG CAT GGC GTC CGG GTT CTG GAG GAC GGC GTG AAC TAT GCA	144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala	
35 40 45	
ACA GGG AAT TTG CCC GGT TGC TCT TTC TCT ATC TTC CTC TTG GCT TTG	192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu	
50 55 60	
CTG TCC TGT CTG ACC GTT CCA GCT TCC GCT TAT GAA GTG CGC AAC GTG	240
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val	
65 70 75 80	
TCC GGG ATG TAC CAT GTC ACG AAC GAC TGC TCC AAC TCA AGC ATT GTG	288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val	
85 90 95	
TAT GAG GCA GCG GAC ATG ATC ATG CAC ACC CCC GGG TGC GTG CCC TGC	336
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys	
100 105 110	
GTT CGG GAG AAC AAC TCT TCC CGC TGC TGG GTA GCG CTC ACC CCC ACG	384
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr	
115 120 125	
CTC GCA GCT AGG AAC GCC AGC GTC CCC ACC ACG ACA ATA CGA CGC CAC	432
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His	
130 135 140	
GTC GAT TTG CTC GTT GGG GCG GCT GCT TTC TGT TCC GCT ATG TAC GTG	480
Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val	
145 150 155 160	
GGG GAC CTC TGC GGA TCT GTC TTC CTC GTC TCC CAG CTG TTC ACC ATC	528
Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile	
165 170 175	
TCG CCT CGC CGG CAT GAG ACG GTG CAG GAC TGC AAT TGC TCA ATC TAT	576
Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr	
180 185 190	
CCC GGC CAC ATA ACG GGT CAC CGT ATG GCT TGG GAT ATG ATG ATG AAC	624
Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn	
195 200 205	
TGG TCG CCT ACA ACG GCC CTG GTG GTA TCG CAG CTG CTC CGG ATC CCA	672
Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln Leu Leu Arg Ile Pro	
210 215 220	

CAA GCT GTC GTG GAC ATG GTG GCG GGG GCC CAT TGG GGA GTC CTG GCG	720
Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly Val Leu Ala	
225 230 235 240	
GGT CTC GCC TAC TAT TCC ATG GTG GGG AAC TGG GCT AAG GTT TTG ATT	768
Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val Leu Ile	
245 250 255	
GTG ATG CTA CTC TTT GCT CCC TAATAG	795
Val Met Leu Leu Phe Ala Pro	
260	

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 263 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met	Leu	Gly	Lys	Val	Ile	Asp	Thr	Leu	Thr	Cys	Gly	Phe	Ala	Asp	Leu
1				5				10						15	
Val	Gly	Tyr	Ile	Pro	Leu	Val	Gly	Ala	Pro	Leu	Gly	Gly	Ala	Ala	Arg
			20					25					30		
Ala	Leu	Ala	His	Gly	Val	Arg	Val	Leu	Glu	Asp	Gly	Val	Asn	Tyr	Ala
		35					40					45			
Thr	Gly	Asn	Leu	Pro	Gly	Cys	Ser	Phe	Ser	Ile	Phe	Leu	Leu	Ala	Leu
	50					55					60				
Leu	Ser	Cys	Leu	Thr	Val	Pro	Ala	Ser	Ala	Tyr	Glu	Val	Arg	Asn	Val
65					70					75				80	
Ser	Gly	Met	Tyr	His	Val	Thr	Asn	Asp	Cys	Ser	Asn	Ser	Ser	Ile	Val
				85					90					95	
Tyr	Glu	Ala	Ala	Asp	Met	Ile	Met	His	Thr	Pro	Gly	Cys	Val	Pro	Cys
		100						105					110		
Val	Arg	Glu	Asn	Asn	Ser	Ser	Arg	Cys	Trp	Val	Ala	Leu	Thr	Pro	Thr
		115					120					125			
Leu	Ala	Ala	Arg	Asn	Ala	Ser	Val	Pro	Thr	Thr	Thr	Ile	Arg	Arg	His
		130				135					140				
Val	Asp	Leu	Leu	Val	Gly	Ala	Ala	Ala	Phe	Cys	Ser	Ala	Met	Tyr	Val
145					150					155				160	
Gly	Asp	Leu	Cys	Gly	Ser	Val	Phe	Leu	Val	Ser	Gln	Leu	Phe	Thr	Ile
			165					170						175	
Ser	Pro	Arg	Arg	His	Glu	Thr	Val	Gln	Asp	Cys	Asn	Cys	Ser	Ile	Tyr
			180					185					190		

Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn
195 200 205

Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln Leu Leu Arg Ile Pro
210 215 220

Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly Val Leu Ala
225 230 235 240

Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val Leu Ile
245 250 255

Val Met Leu Leu Phe Ala Pro
260

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 633 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..630

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 1..627

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

ATG TTG GGT AAG GTC ATC GAT ACC CTT ACG TGC GGC TTC GCC GAC CTC	48
Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu	
1 5 10 15	
ATG GGG TAC ATT CCG CTC GTC GGC GCC CCC CTA GGG GGT GCT GCC AGA	96
Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg	
20 25 30	
GCC CTG GCG CAT GGC GTC CGG GTT CTG GAA GAC GGC GTG AAC TAT GCA	144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala	
35 40 45	
ACA GGG AAT TTG CCT GGT TGC TCT TTC TCT ATC TTC CTC TTG GCT TTA	192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu	
50 55 60	
CTG TCC TGT CTG ACC ATT CCA GCT TCC GCT TAT GAG GTG CGC AAC GTG	240
Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val	
65 70 75 80	

TCC GGG ATG TAC CAT GTC ACG AAC GAC TGC TCC AAC TCA AGC ATT GTG	288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val	
85 90 95	
TAT GAG GCA GCG GAC ATG ATC ATG CAC ACC CCC GGG TGC GTG CCC TGC	336
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys	
100 105 110	
GTT CGG GAG AAC AAC TCT TCC CGC TGC TGG GTA GCG CTC ACC CCC ACG	384
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr	
115 120 125	
CTC GCA GCT AGG AAC GCC AGC GTC CCC ACT ACG ACA ATA CGA CGC CAC	432
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His	
130 135 140	
GTC GAT TTG CTC GTT GGG GCG GCT GCT TTC TGT TCC GCT ATG TAC GTG	480
Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val	
145 150 155 160	
GGG GAT CTC TGC GGA TCT GTC TTC CTC GTC TCC CAG CTG TTC ACC ATC	528
Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile	
165 170 175	
TCG CCT CGC CGG CAT GAG ACG GTG CAG GAC TGC AAT TGC TCA ATC TAT	576
Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr	
180 185 190	
CCC GGC CAC ATA ACA GGT CAC CGT ATG GCT TGG GAT ATG ATG ATG AAC	624
Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn	
195 200 205	
TGG TAATAG	633
Trp	
210	

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 209 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
1 5 10 15
Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
20 25 30
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
35 40 45
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
50 55 60

Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65 70 75 80
 Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
 85 90 95
 Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
 100 105 110
 Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
 115 120 125
 Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
 130 135 140
 Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val
 145 150 155 160
 Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile
 165 170 175
 Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr
 180 185 190
 Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn
 195 200 205

Trp

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 483 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..480

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 1..477

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

ATG CCC GGT TGC TCT TTC TCT ATC TTC CTC TTG GCC CTG CTG TCC TGT	48
Met Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys	
1 5 10 15	
CTG ACC ATA CCA GCT TCC GCT TAT GAA GTG CGC AAC GTG TCC GGG GTG	96

Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Val	
20 25 30	
TAC CAT GTC ACG AAC GAC TGC TCC AAC TCA AGC ATA GTG TAT GAG GCA	144
Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala	
35 40 45	
GCG GAC ATG ATC ATG CAC ACC CCC GGG TGC GTG CCC TGC GTT CGG GAG	192
Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu	
50 55 60	
GGC AAC TCC TCC CGT TGC TGG GTG GCG CTC ACT CCC ACG CTC GCG GCC	240
Gly Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala	
65 70 75 80	
AGG AAC GCC AGC GTC CCC ACA ACG ACA ATA CGA CGC CAC GTC GAT TTG	288
Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His Val Asp Leu	
85 90 95	
CTC GTT GGG GCT GCT GCT TTC TGT TCC GCT ATG TAC GTG GGG GAT CTC	336
Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val Gly Asp Leu	
100 105 110	
TGC GGA TCT GTT TTC CTT GTT TCC CAG CTG TTC ACC TTC TCA CCT CGC	384
Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Phe Ser Pro Arg	
115 120 125	
CGG CAT CAA ACA GTA CAG GAC TGC AAC TGC TCA ATC TAT CCC GGC CAT	432
Arg His Gln Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His	
130 135 140	
GTA TCA GGT CAC CGC ATG GCT TGG GAT ATG ATG ATG AAC TGG TCC TAATAG	483
Val Ser Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp Ser	
145 150 155 160	

(2) INFORMATION FOR SEQ ID NO: 10:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 159 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Met Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys	
1 5 10 15	
Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Val	
20 25 30	
Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala	
35 40 45	
Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu	
50 55 60	
Gly Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala	
65 70 75 80	

Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His Val Asp Leu
85 90 95

Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val Gly Asp Leu
100 105 110

Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Phe Ser Pro Arg
115 120 125

Arg His Gln Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His
130 135 140

Val Ser Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp Ser
145 150 155

(2) INFORMATION FOR SEQ ID NO: 11:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 480 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

- (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..477

- (ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 1..474

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

ATG TCC GGT TGC TCT TTC TCT ATC TTC CTC TTG GCC CTG CTG TCC TGT	48
Met Ser Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys	
1 5 10 15	
CTG ACC ATA CCA GCT TCC GCT TAT GAA GTG CGC AAC GTG TCC GGG GTG	96
Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Val	
20 25 30	
TAC CAT GTC ACG AAC GAC TGC TCC AAC TCA AGC ATA GTG TAT GAG GCA	144
Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala	
35 40 45	
GCG GAC ATG ATC ATG CAC ACC CCC GGG TGC GTG CCC TGC GTT CGG GAG	192
Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu	
50 55 60	
GGC AAC TCC TCC CGT TGC TGG GTG GCG CTC ACT CCC ACG CTC GCG GCC	240
Gly Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala	
65 70 75 80	

AGG AAC GCC AGC GTC CCC ACA ACG ACA ATA CGA CGC CAC GTC GAT TTG	288
Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His Val Asp Leu	
85 90 95	
CTC GTT GGG GCT GCT GCT TTC TGT TCC GCT ATG TAC GTG GGG GAT CTC	336
Leu Val Gly Ala Ala Phe Cys Ser Ala Met Tyr Val Gly Asp Leu	
100 105 110	
TGC GGA TCT GTT TTC CTT GTT TCC CAG CTG TTC ACC TTC TCA CCT CGC	384
Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Phe Ser Pro Arg	
115 120 125	
CGG CAT CAA ACA GTA CAG GAC TGC AAC TGC TCA ATC TAT CCC GGC CAT	432
Arg His Gln Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His	
130 135 140	
GTA TCA GGT CAC CGC ATG GCT TGG GAT ATG ATG ATG AAC TGG TAATAG	480
Val Ser Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp	
145 150 155	

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 158 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Met Ser Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys	
1 5 10 15	
Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val Ser Gly Val	
20 25 30	
Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala	
35 40 45	
Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys Val Arg Glu	
50 55 60	
Gly Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr Leu Ala Ala	
65 70 75 80	
Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His Val Asp Leu	
85 90 95	
Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val Gly Asp Leu	
100 105 110	
Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Phe Ser Pro Arg	
115 120 125	
Arg His Gln Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His	
130 135 140	
Val Ser Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp	
145 150 155	

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 636 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..633

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 1..630

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

ATG CTG GGT AAG GCC ATC GAT ACC CTT ACG TGC GGC TTC GCC GAC CTC 48
Met Leu Gly Lys Ala Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
1 5 10 15

GTG GGG TAC ATT CCG CTC GTC GGC GCC CCC CTA GGG GGC GCT GCC AGG 96
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
20 25 30

GCC CTG GCG CAT GGC GTC CGG GTT CTG GAA GAC GGC GTG AAC TAT GCA 144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
35 40 45

ACA GGG AAT TTG CCT GGT TGC TCT TTC TCT ATC TTC CTC TTG GCT TTA 192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
50 55 60

CTG TCC TGT CTA ACC ATT CCA GCT TCC GCT TAC GAG GTG CGC AAC GTG 240
Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
65 70 75 80

TCC GGG ATG TAC CAT GTC ACG AAC GAC TGC TCC AAC TCA AGC ATT GTG 288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
85 90 95

TAT GAG GCA GCG GAC ATG ATC ATG CAC ACC CCC GGG TGC GTG CCC TGC 336
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
100 105 110

GTT CGG GAG AAC AAC TCT TCC CGC TGC TGG GTA GCG CTC ACC CCC ACG 384
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
115 120 125

CTC GCG GCT AGG AAC GCC AGC ATC CCC ACT ACA ACA ATA CGA CGC CAC 432

Leu	Ala	Ala	Arg	Asn	Ala	Ser	Ile	Pro	Thr	Thr	Thr	Ile	Arg	Arg	His	
130						135						140				
GTC	GAT	TTG	CTC	GTT	GGG	GCG	GCT	GCT	TTC	TGT	TCC	GCT	ATG	TAC	GTG	480
Val	Asp	Leu	Leu	Val	Gly	Ala	Ala	Ala	Phe	Cys	Ser	Ala	Met	Tyr	Val	
145					150					155					160	
GGG	GAT	CTC	TGC	GGA	TCT	GTC	TTC	CTC	GTC	TCC	CAG	CTG	TTC	ACC	ATC	528
Gly	Asp	Leu	Cys	Gly	Ser	Val	Phe	Leu	Val	Ser	Gln	Leu	Phe	Thr	Ile	
				165					170					175		
TCG	CCT	CGC	CGG	CAT	GAG	ACG	GTG	CAG	GAC	TGC	AAT	TGC	TCA	ATC	TAT	576
Ser	Pro	Arg	Arg	His	Glu	Thr	Val	Gln	Asp	Cys	Asn	Cys	Ser	Ile	Tyr	
				180				185					190			
CCC	GGC	CAC	ATA	ACG	GGT	CAC	CGT	ATG	GCT	TGG	GAT	ATG	ATG	ATG	AAC	624
Pro	Gly	His	Ile	Thr	Gly	His	Arg	Met	Ala	Trp	Asp	Met	Met	Met	Asn	
		195					200					205				
TGG	TAC	TAATAG														640
Trp	Tyr															
		210														

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 210 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Met	Leu	Gly	Lys	Ala	Ile	Asp	Thr	Leu	Thr	Cys	Gly	Phe	Ala	Asp	Leu
1				5					10					15	
Val	Gly	Tyr	Ile	Pro	Leu	Val	Gly	Ala	Pro	Leu	Gly	Gly	Ala	Ala	Arg
			20					25					30		
Ala	Leu	Ala	His	Gly	Val	Arg	Val	Leu	Glu	Asp	Gly	Val	Asn	Tyr	Ala
		35					40					45			
Thr	Gly	Asn	Leu	Pro	Gly	Cys	Ser	Phe	Ser	Ile	Phe	Leu	Leu	Ala	Leu
		50				55					60				
Leu	Ser	Cys	Leu	Thr	Ile	Pro	Ala	Ser	Ala	Tyr	Glu	Val	Arg	Asn	Val
65					70					75				80	
Ser	Gly	Met	Tyr	His	Val	Thr	Asn	Asp	Cys	Ser	Asn	Ser	Ser	Ile	Val
				85					90					95	
Tyr	Glu	Ala	Ala	Asp	Met	Ile	Met	His	Thr	Pro	Gly	Cys	Val	Pro	Cys
			100					105					110		
Val	Arg	Glu	Asn	Asn	Ser	Ser	Arg	Cys	Trp	Val	Ala	Leu	Thr	Pro	Thr
			115				120					125			
Leu	Ala	Ala	Arg	Asn	Ala	Ser	Ile	Pro	Thr	Thr	Thr	Ile	Arg	Arg	His

130	135	140
Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val		
145	150	155 160
Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile		
	165	170 175
Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr		
	180	185 190
Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn		
	195	200 205
Trp Tyr		
210		

(2) INFORMATION FOR SEQ ID NO: 15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

ATGCCCGGTT GCTCTTTCTC TATCTT

26

(2) INFORMATION FOR SEQ ID NO: 16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

ATGTTGGGTA AGGTCATCGA TACCCT

26

(2) INFORMATION FOR SEQ ID NO: 17:

- (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

CTATTAGGAC CAGTTCATCA TCATATCCCA

30

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

CTATTACCAG TTCATCATCA TATCCCA

27

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

ATACGACGCC ACGTCGATTC CCAGCTGTTC ACCATC

36

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

GATGGTGAAC AGCTGGGAAT CGACGTGGCG TCGTAT

36

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 723 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION: 1..720

(ix) FEATURE:

(A) NAME/KEY: mat_peptide
 (B) LOCATION: 1..717

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

ATG TTG GGT AAG GTC ATC GAT ACC CTT ACA TGC GGC TTC GCC GAC CTC	48
Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu	
1 5 10 15	
GTG GGG TAC ATT CCG CTC GTC GGC GCC CCC CTA GGG GGC GCT GCC AGG	96
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg	
20 25 30	
GCC CTG GCG CAT GGC GTC CGG GTT CTG GAG GAC GGC GTG AAC TAT GCA	144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala	
35 40 45	
ACA GGG AAT TTG CCC GGT TGC TCT TTC TCT ATC TTC CTC TTG GCT TTG	192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu	
50 55 60	
CTG TCC TGT CTG ACC GTT CCA GCT TCC GCT TAT GAA GTG CGC AAC GTG	240
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val	
65 70 75 80	

TCC GGG ATG TAC CAT GTC ACG AAC GAC TGC TCC AAC TCA AGC ATT GTG	288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val	
85 90 95	
TAT GAG GCA GCG GAC ATG ATC ATG CAC ACC CCC GGG TGC GTG CCC TGC	336
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys	
100 105 110	
GTT CGG GAG AAC AAC TCT TCC CGC TGC TGG GTA GCG CTC ACC CCC ACG	384
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr	
115 120 125	
CTC GCA GCT AGG AAC GCC AGC GTC CCC ACC ACG ACA ATA CGA CGC CAC	432
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His	
130 135 140	
GTC GAT TCC CAG CTG TTC ACC ATC TCG CCT CGC CGG CAT GAG ACG GTG	480
Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val	
145 150 155 160	
CAG GAC TGC AAT TGC TCA ATC TAT CCC GGC CAC ATA ACG GGT CAC CGT	528
Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg	
165 170 175	
ATG GCT TGG GAT ATG ATG ATG AAC TGG TCG CCT ACA ACG GCC CTG GTG	576
Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val	
180 185 190	
GTA TCG CAG CTG CTC CGG ATC CCA CAA GCT GTC GTG GAC ATG GTG GCG	624
Val Ser Gln Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala	
195 200 205	
GGG GCC CAT TGG GGA GTC CTG GCG GGT CTC GCC TAC TAT TCC ATG GTG	672
Gly Ala His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val	
210 215 220	
GGG AAC TGG GCT AAG GTT TTG ATT GTG ATG CTA CTC TTT GCT CCC TAATAG	723
Gly Asn Trp Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Pro	
225 230 235 240	

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 239 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Met	Leu	Gly	Lys	Val	Ile	Asp	Thr	Leu	Thr	Cys	Gly	Phe	Ala	Asp	Leu
1				5					10					15	
Val	Gly	Tyr	Ile	Pro	Leu	Val	Gly	Ala	Pro	Leu	Gly	Gly	Ala	Ala	Arg
	20							25					30		
Ala	Leu	Ala	His	Gly	Val	Arg	Val	Leu	Glu	Asp	Gly	Val	Asn	Tyr	Ala
	35						40					45			

Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
 50 55 60
 Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
 65 70 75 80
 Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
 85 90 95
 Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
 100 105 110
 Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
 115 120 125
 Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
 130 135 140
 Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val
 145 150 155 160
 Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg
 165 170 175
 Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val
 180 185 190
 Val Ser Gln Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala
 195 200 205
 Gly Ala His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val
 210 215 220
 Gly Asn Trp Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Pro
 225 230 235

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 561 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..558

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 1..555

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

ATG TTG GGT AAG GTC ATC GAT ACC CTT ACA TGC GGC TTC GCC GAC CTC	48
Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu	
1 5 10 15	
GTG GGG TAC ATT CCG CTC GTC GGC GCC CCC CTA GGG GGC GCT GCC AGG	96
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg	
20 25 30	
GCC CTG GCG CAT GGC GTC CGG GTT CTG GAG GAC GGC GTG AAC TAT GCA	144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala	
35 40 45	
ACA GGG AAT TTG CCC GGT TGC TCT TTC TCT ATC TTC CTC TTG GCT TTG	192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu	
50 55 60	
CTG TCC TGT CTG ACC GTT CCA GCT TCC GCT TAT GAA GTG CGC AAC GTG	240
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val	
65 70 75 80	
TCC GGG ATG TAC CAT GTC ACG AAC GAC TGC TCC AAC TCA AGC ATT GTG	288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val	
85 90 95	
TAT GAG GCA GCG GAC ATG ATC ATG CAC ACC CCC GGG TGC GTG CCC TGC	336
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys	
100 105 110	
GTT CGG GAG AAC AAC TCT TCC CGC TGC TGG GTA GCG CTC ACC CCC ACG	384
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr	
115 120 125	
CTC GCA GCT AGG AAC GCC AGC GTC CCC ACC ACG ACA ATA CGA CGC CAC	432
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His	
130 135 140	
GTC GAT TCC CAG CTG TTC ACC ATC TCG CCT CGC CGG CAT GAG ACG GTG	480
Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val	
145 150 155 160	
CAG GAC TGC AAT TGC TCA ATC TAT CCC GGC CAC ATA ACG GGT CAC CGT	528
Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg	
165 170 175	
ATG GCT TGG GAT ATG ATG ATG AAC TGG TAATAG	561
Met Ala Trp Asp Met Met Met Asn Trp	
180 185	

(2) INFORMATION FOR SEQ ID NO: 24:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 185 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu

1	5	10	15
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg	20	25	30
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala	35	40	45
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu	50	55	60
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val	65	70	75
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val	85	90	95
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys	100	105	110
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr	115	120	125
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His	130	135	140
Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val	145	150	155
Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg	165	170	175
Met Ala Trp Asp Met Met Met Asn Trp	180	185	

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 606 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..603

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 1..600

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

ATG TTG GGT AAG GTC ATC GAT ACC CTT ACA TGC GGC TTC GCC GAC CTC	48
Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu	
1 5 10 15	
GTG GGG TAC ATT CCG CTC GTC GGC GCC CCC CTA GGG GGC GCT GCC AGG	96
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg	
20 25 30	
GCC CTG GCG CAT GGC GTC CGG GTT CTG GAG GAC GGC GTG AAC TAT GCA	144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala	
35 40 45	
ACA GGG AAT TTG CCC GGT TGC TCT TTC TCT ATC TTC CTC TTG GCT TTG	192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu	
50 55 60	
CTG TCC TGT CTG ACC GTT CCA GCT TCC GCT TAT GAA GTG CGC AAC GTG	240
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val	
65 70 75 80	
TCC GGG ATG TAC CAT GTC ACG AAC GAC TGC TCC AAC TCA AGC ATT GTG	288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val	
85 90 95	
TAT GAG GCA GCG GAC ATG ATC ATG CAC ACC CCC GGG TGC GTG CCC TGC	336
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys	
100 105 110	
GTT CGG GAG AAC AAC TCT TCC CGC TGC TGG GTA GCG CTC ACC CCC ACG	384
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr	
115 120 125	
CTC GCA GCT AGG AAC GCC AGC GTC CCC ACC ACG ACA ATA CGA CGC CAC	432
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His	
130 135 140	
GTC GAT TCC CAG CTG TTC ACC ATC TCG CCT CGC CGG CAT GAG ACG GTG	480
Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val	
145 150 155 160	
CAG GAC TGC AAT TGC TCA ATC TAT CCC GGC CAC ATA ACG GGT CAC CGT	528
Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg	
165 170 175	
ATG GCT TGG GAT ATG ATG ATG AAC TGG TCG CCT ACA ACG GCC CTG GTG	576
Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val	
180 185 190	
GTA TCG CAG CTG CTC CGG ATC CTC TAATAG	606
Val Ser Gln Leu Leu Arg Ile Leu	
195 200	

(2) INFORMATION FOR SEQ ID NO: 26:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 200 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
1 5 10 15
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
20 25 30
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
35 40 45
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
50 55 60
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
65 70 75 80
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
85 90 95
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
100 105 110
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
115 120 125
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
130 135 140
Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val
145 150 155 160
Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg
165 170 175
Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val
180 185 190
Val Ser Gln Leu Leu Arg Ile Leu
195 200

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 636 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..633

(ix) FEATURE:

(A) NAME/KEY: mat_peptide

(B) LOCATION: 1..630

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

ATG TTG GGT AAG GTC ATC GAT ACC CTT ACA TGC GGC TTC GCC GAC CTC	48
Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu	
1 5 10 15	
GTG GGG TAC ATT CCG CTC GTC GGC GCC CCC CTA GGG GGC GCT GCC AGG	96
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg	
20 25 30	
GCC CTG GCG CAT GGC GTC CGG GTT CTG GAG GAC GGC GTG AAC TAT GCA	144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala	
35 40 45	
ACA GGG AAT TTG CCC GGT TGC TCT TTC TCT ATC TTC CTC TTG GCT TTG	192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu	
50 55 60	
CTG TCC TGT CTG ACC GTT CCA GCT TCC GCT TAT GAA GTG CGC AAC GTG	240
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val	
65 70 75 80	
TCC GGG ATG TAC CAT GTC ACG AAC GAC TGC TCC AAC TCA AGC ATT GTG	288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val	
85 90 95	
TAT GAG GCA GCG GAC ATG ATC ATG CAC ACC CCC GGG TGC GTG CCC TGC	336
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys	
100 105 110	
GTT CGG GAG AAC AAC TCT TCC CGC TGC TGG GTA GCG CTC ACC CCC ACG	384
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr	
115 120 125	
CTC GCA GCT AGG AAC GCC AGC GTC CCC ACC ACG ACA ATA CGA CGC CAC	432
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His	
130 135 140	
GTC GAT TCC CAG CTG TTC ACC ATC TCG CCT CGC CGG CAT GAG ACG GTG	480
Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val	
145 150 155 160	
CAG GAC TGC AAT TGC TCA ATC TAT CCC GGC CAC ATA ACG GGT CAC CGT	528
Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg	
165 170 175	
ATG GCT TGG GAT ATG ATG ATG AAC TGG TCG CCT ACA ACG GCC CTG GTG	576
Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val	
180 185 190	
GTA TCG CAG CTG CTC CGG ATC GTG ATC GAG GGC AGA CAC CAT CAC CAC	624
Val Ser Gln Leu Leu Arg Ile Val Ile Glu Gly Arg His His His His	
195 200 205	
CAT CAC TAATAG	636
His His	

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 210 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

Met Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu
1 5 10 15
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg
20 25 30
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala
35 40 45
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu
50 55 60
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val
65 70 75 80
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val
85 90 95
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys
100 105 110
Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
115 120 125
Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
130 135 140
Val Asp Ser Gln Leu Phe Thr Ile Ser Pro Arg Arg His Glu Thr Val
145 150 155 160
Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg
165 170 175
Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val
180 185 190
Val Ser Gln Leu Leu Arg Ile Val Ile Glu Gly Arg His His His His
195 200 205
His His
210

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 630 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 1..627

(ix) FEATURE:

(A) NAME/KEY: mat_peptide
(B) LOCATION: 1..624

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

ATG GGT AAG GTC ATC GAT ACC CTT ACG TGC GGA TTC GCC GAT CTC ATG 48
Met Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met
1 5 10 15

GGG TAC ATC CCG CTC GTC GGC GCT CCC GTA GGA GGC GTC GCA AGA GCC 96
Gly Tyr Ile Pro Leu Val Gly Ala Pro Val Gly Gly Val Ala Arg Ala
20 25 30

CTT GCG CAT GGC GTG AGG GCC CTT GAA GAC GGG ATA AAT TTC GCA ACA 144
Leu Ala His Gly Val Arg Ala Leu Glu Asp Gly Ile Asn Phe Ala Thr
35 40 45

GGG AAT TTG CCC GGT TGC TCC TTT TCT ATT TTC CTT CTC GCT CTG TTC 192
Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Phe
50 55 60

TCT TGC TTA ATT CAT CCA GCA GCT AGT CTA GAG TGG CGG AAT ACG TCT 240
Ser Cys Leu Ile His Pro Ala Ala Ser Leu Glu Trp Arg Asn Thr Ser
65 70 75 80

GGC CTC TAT GTC CTT ACC AAC GAC TGT TCC AAT AGC AGT ATT GTG TAC 288
Gly Leu Tyr Val Leu Thr Asn Asp Cys Ser Asn Ser Ser Ile Val Tyr
85 90 95

GAG GCC GAT GAC GTT ATT CTG CAC ACA CCC GGC TGC ATA CCT TGT GTC 336
Glu Ala Asp Asp Val Ile Leu His Thr Pro Gly Cys Ile Pro Cys Val
100 105 110

CAG GAC GGC AAT ACA TCC ACG TGC TGG ACC CCA GTG ACA CCT ACA GTG 384
Gln Asp Gly Asn Thr Ser Thr Cys Trp Thr Pro Val Thr Pro Thr Val
115 120 125

GCA GTC AAG TAC GTC GGA GCA ACC ACC GCT TCG ATA CGC AGT CAT GTG 432
Ala Val Lys Tyr Val Gly Ala Thr Thr Ala Ser Ile Arg Ser His Val
130 135 140

GAC CTA TTA GTG GGC GCG GCC ACG ATG TGC TCT GCG CTC TAC GTG GGT 480
Asp Leu Leu Val Gly Ala Ala Thr Met Cys Ser Ala Leu Tyr Val Gly
145 150 155 160

GAC ATG TGT GGG GCT GTC TTC CTC GTG GGA CAA GCC TTC ACG TTC AGA	528
Asp Met Cys Gly Ala Val Phe Leu Val Gly Gln Ala Phe Thr Phe Arg	
165 170 175	
CCT CGT CGC CAT CAA ACG GTC CAG ACC TGT AAC TGC TCG CTG TAC CCA	576
Pro Arg Arg His Gln Thr Val Gln Thr Cys Asn Cys Ser Leu Tyr Pro	
180 185 190	
GGC CAT CTT TCA GGA CAT CGA ATG GCT TGG GAT ATG ATG ATG AAC TGG	624
Gly His Leu Ser Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp	
195 200 205	
TAATAG	634

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 208 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

Met	Gly	Lys	Val	Ile	Asp	Thr	Leu	Thr	Cys	Gly	Phe	Ala	Asp	Leu	Met
1				5					10					15	
Gly	Tyr	Ile	Pro	Leu	Val	Gly	Ala	Pro	Val	Gly	Gly	Val	Ala	Arg	Ala
			20					25					30		
Leu	Ala	His	Gly	Val	Arg	Ala	Leu	Glu	Asp	Gly	Ile	Asn	Phe	Ala	Thr
		35					40					45			
Gly	Asn	Leu	Pro	Gly	Cys	Ser	Phe	Ser	Ile	Phe	Leu	Leu	Ala	Leu	Phe
	50					55					60				
Ser	Cys	Leu	Ile	His	Pro	Ala	Ala	Ser	Leu	Glu	Trp	Arg	Asn	Thr	Ser
65					70					75				80	
Gly	Leu	Tyr	Val	Leu	Thr	Asn	Asp	Cys	Ser	Asn	Ser	Ser	Ile	Val	Tyr
				85					90					95	
Glu	Ala	Asp	Asp	Val	Ile	Leu	His	Thr	Pro	Gly	Cys	Ile	Pro	Cys	Val
			100					105					110		
Gln	Asp	Gly	Asn	Thr	Ser	Thr	Cys	Trp	Thr	Pro	Val	Thr	Pro	Thr	Val
		115					120					125			
Ala	Val	Lys	Tyr	Val	Gly	Ala	Thr	Thr	Ala	Ser	Ile	Arg	Ser	His	Val
	130					135					140				
Asp	Leu	Leu	Val	Gly	Ala	Ala	Thr	Met	Cys	Ser	Ala	Leu	Tyr	Val	Gly
145				150					155						160
Asp	Met	Cys	Gly	Ala	Val	Phe	Leu	Val	Gly	Gln	Ala	Phe	Thr	Phe	Arg
				165					170					175	

Pro Arg Arg His Gln Thr Val Gln Thr Cys Asn Cys Ser Leu Tyr Pro
 180 185 190

Gly His Leu Ser Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp
 195 200 205

(2) INFORMATION FOR SEQ ID NO: 31:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 630 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

- (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..627

- (ix) FEATURE:
 (A) NAME/KEY: mat_peptide
 (B) LOCATION: 1..624

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

ATG GGT AAG GTC ATC GAT ACC CTA ACG TGC GGA TTC GCC GAT CTC ATG 48
 Met Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met
 1 5 10 15

GGG TAT ATC CCG CTC GTA GGC GGC CCC ATT GGG GGC GTC GCA AGG GCT 96
 Gly Tyr Ile Pro Leu Val Gly Gly Pro Ile Gly Gly Val Ala Arg Ala
 20 25 30

CTC GCA CAC GGT GTG AGG GTC CTT GAG GAC GGG GTA AAC TAT GCA ACA 144
 Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala Thr
 35 40 45

GGG AAT TTA CCC GGT TGC TCT TTC TCT ATC TTT ATT CTT GCT CTT CTC 192
 Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Ile Leu Ala Leu Leu
 50 55 60

TCG TGT CTG ACC GTT CCG GCC TCT GCA GTT CCC TAC CGA AAT GCC TCT 240
 Ser Cys Leu Thr Val Pro Ala Ser Ala Val Pro Tyr Arg Asn Ala Ser
 65 70 75 80

GGG ATT TAT CAT GTT ACC AAT GAT TGC CCA AAC TCT TCC ATA GTC TAT 288
 Gly Ile Tyr His Val Thr Asn Asp Cys Pro Asn Ser Ser Ile Val Tyr
 85 90 95

GAG GCA GAT AAC CTG ATC CTA CAC GCA CCT GGT TGC GTG CCT TGT GTC 336

Glu Ala Asp Asn Leu Ile Leu His Ala Pro Gly Cys Val Pro Cys Val	
100 105 110	
ATG ACA GGT AAT GTG AGT AGA TGC TGG GTC CAA ATT ACC CCT ACA CTG	384
Met Thr Gly Asn Val Ser Arg Cys Trp Val Gln Ile Thr Pro Thr Leu	
115 120 125	
TCA GCC CCG AGC CTC GGA GCA GTC ACG GCT CCT CTT CGG AGA GCC GTT	432
Ser Ala Pro Ser Leu Gly Ala Val Thr Ala Pro Leu Arg Arg Ala Val	
130 135 140	
GAC TAC CTA GCG GGA GGG GCT GCC CTC TGC TCC GCG TTA TAC GTA GGA	480
Asp Tyr Leu Ala Gly Gly Ala Ala Leu Cys Ser Ala Leu Tyr Val Gly	
145 150 155 160	
GAC GCG TGT GGG GCA CTA TTC TTG GTA GGC CAA ATG TTC ACC TAT AGG	528
Asp Ala Cys Gly Ala Leu Phe Leu Val Gly Gln Met Phe Thr Tyr Arg	
165 170 175	
CCT CGC CAG CAC GCT ACG GTG CAG AAC TGC AAC TGT TCC ATT TAC AGT	576
Pro Arg Gln His Ala Thr Val Gln Asn Cys Asn Cys Ser Ile Tyr Ser	
180 185 190	
GGC CAT GTT ACC GGC CAC CGG ATG GCA TGG GAT ATG ATG ATG AAC TGG	624
Gly His Val Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp	
195 200 205	
TAATAG	630

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 208 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

Met Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met	
1 5 10 15	
Gly Tyr Ile Pro Leu Val Gly Gly Pro Ile Gly Gly Val Ala Arg Ala	
20 25 30	
Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala Thr	
35 40 45	
Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Ile Leu Ala Leu Leu	
50 55 60	
Ser Cys Leu Thr Val Pro Ala Ser Ala Val Pro Tyr Arg Asn Ala Ser	
65 70 75 80	
Gly Ile Tyr His Val Thr Asn Asp Cys Pro Asn Ser Ser Ile Val Tyr	
85 90 95	

Glu	Ala	Asp	Asn	Leu	Ile	Leu	His	Ala	Pro	Gly	Cys	Val	Pro	Cys	Val
			100					105					110		
Met	Thr	Gly	Asn	Val	Ser	Arg	Cys	Trp	Val	Gln	Ile	Thr	Pro	Thr	Leu
		115					120					125			
Ser	Ala	Pro	Ser	Leu	Gly	Ala	Val	Thr	Ala	Pro	Leu	Arg	Arg	Ala	Val
	130					135					140				
Asp	Tyr	Leu	Ala	Gly	Gly	Ala	Ala	Leu	Cys	Ser	Ala	Leu	Tyr	Val	Gly
145					150					155					160
Asp	Ala	Cys	Gly	Ala	Leu	Phe	Leu	Val	Gly	Gln	Met	Phe	Thr	Tyr	Arg
			165						170					175	
Pro	Arg	Gln	His	Ala	Thr	Val	Gln	Asn	Cys	Asn	Cys	Ser	Ile	Tyr	Ser
			180					185					190		
Gly	His	Val	Thr	Gly	His	Arg	Met	Ala	Trp	Asp	Met	Met	Met	Asn	Trp
		195					200					205			

(2) INFORMATION FOR SEQ ID NO: 33:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

TGGGATATGA TGATGAACTG GTC

23

(2) INFORMATION FOR SEQ ID NO: 34:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

CTATTATGGT GGTAAGCCAC AGAGCAGGAG

30

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1476 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1473

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 1..1470

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

TGG GAT ATG ATG ATG AAC TGG TCG CCT ACA ACG GCC CTG GTG GTA TCG 48
Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser
1 5 10 15

CAG CTG CTC CGG ATC CCA CAA GCT GTC GTG GAC ATG GTG GCG GGG GCC 96
Gln Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala
20 25 30

GAT TGG GGA GTC CTG GCG GGC CTC GCC TAC TAT TCC ATG GTG GGG AAC 144
His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn
35 40 45

TGG GCT AAG GTT TTG GTT GTG ATG CTA CTC TTT GCC GGC GTC GAC GGG 192
Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly
50 55 60

CAT ACC CGC GTG TCA GGA GGG GCA GCA GCC TCC GAT ACC AGG GGC CTT 240
His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu
65 70 75 80

GTG TCC CTC TTT AGC CCC GGG TCG GCT CAG AAA ATC CAG CTC GTA AAC 288
Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn
85 90 95

ACC AAC GGC AGT TGG CAC ATC AAC AGG ACT GCC CTG AAC TGC AAC GAC 336
Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp
100 105 110

TCC CTC CAA ACA GGG TTC TTT GCC GCA CTA TTC TAC AAA CAC AAA TTC 384
Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe
115 120 125

AAC TCG TCT GGA TGC CCA GAG CGC TTG GCC AGC TGT CGC TCC ATC GAC 432

Asn	Ser	Ser	Gly	Cys	Pro	Glu	Arg	Leu	Ala	Ser	Cys	Arg	Ser	Ile	Asp	
130						135					140					
AAG	TTC	GCT	CAG	GGG	TGG	GGT	CCC	CTC	ACT	TAC	ACT	GAG	CCT	AAC	AGC	480
Lys	Phe	Ala	Gln	Gly	Trp	Gly	Pro	Leu	Thr	Tyr	Thr	Glu	Pro	Asn	Ser	
145					150					155					160	
TCG	GAC	CAG	AGG	CCC	TAC	TGC	TGG	CAC	TAC	GCG	CCT	CGA	CCG	TGT	GGT	528
Ser	Asp	Gln	Arg	Pro	Tyr	Cys	Trp	His	Tyr	Ala	Pro	Arg	Pro	Cys	Gly	
				165					170					175		
ATT	GTA	CCC	GCG	TCT	CAG	GTG	TGC	GGT	CCA	GTG	TAT	TGC	TTC	ACC	CCG	576
Ile	Val	Pro	Ala	Ser	Gln	Val	Cys	Gly	Pro	Val	Tyr	Cys	Phe	Thr	Pro	
			180					185					190			
AGC	CCT	GTT	GTG	GTG	GGG	ACG	ACC	GAT	CGG	TTT	GGT	GTC	CCC	ACG	TAT	624
Ser	Pro	Val	Val	Val	Gly	Thr	Thr	Asp	Arg	Phe	Gly	Val	Pro	Thr	Tyr	
		195					200					205				
AAC	TGG	GGG	GCG	AAC	GAC	TCG	GAT	GTG	CTG	ATT	CTC	AAC	AAC	ACG	CGG	672
Asn	Trp	Gly	Ala	Asn	Asp	Ser	Asp	Val	Leu	Ile	Leu	Asn	Asn	Thr	Arg	
	210					215					220					
CCG	CCG	CGA	GGC	AAC	TGG	TTC	GGC	TGT	ACA	TGG	ATG	AAT	GGC	ACT	GGG	720
Pro	Pro	Arg	Gly	Asn	Trp	Phe	Gly	Cys	Thr	Trp	Met	Asn	Gly	Thr	Gly	
225					230					235					240	
TTC	ACC	AAG	ACG	TGT	GGG	GGC	CCC	CCG	TGC	AAC	ATC	GGG	GGG	GCC	GGC	768
Phe	Thr	Lys	Thr	Cys	Gly	Gly	Pro	Pro	Cys	Asn	Ile	Gly	Gly	Ala	Gly	
				245					250					255		
AAC	AAC	ACC	TTG	ACC	TGC	CCC	ACT	GAC	TGT	TTT	CGG	AAG	CAC	CCC	GAG	816
Asn	Asn	Thr	Leu	Thr	Cys	Pro	Thr	Asp	Cys	Phe	Arg	Lys	His	Pro	Glu	
			260					265					270			
GCC	ACC	TAC	GCC	AGA	TGC	GGT	TCT	GGG	CCC	TGG	CTG	ACA	CCT	AGG	TGT	864
Ala	Thr	Tyr	Ala	Arg	Cys	Gly	Ser	Gly	Pro	Trp	Leu	Thr	Pro	Arg	Cys	
		275					280					285				
ATG	GTT	CAT	TAC	CCA	TAT	AGG	CTC	TGG	CAC	TAC	CCC	TGC	ACT	GTC	AAC	912
Met	Val	His	Tyr	Pro	Tyr	Arg	Leu	Trp	His	Tyr	Pro	Cys	Thr	Val	Asn	
	290					295					300					
TTC	ACC	ATC	TTC	AAG	GTT	AGG	ATG	TAC	GTG	GGG	GGC	GTG	GAG	CAC	AGG	960
Phe	Thr	Ile	Phe	Lys	Val	Arg	Met	Tyr	Val	Gly	Gly	Val	Glu	His	Arg	
305					310					315					320	
TTC	GAA	GCC	GCA	TGC	AAT	TGG	ACT	CGA	GGA	GAG	CGT	TGT	GAC	TTG	GAG	1008
Phe	Glu	Ala	Ala	Cys	Asn	Trp	Thr	Arg	Gly	Glu	Arg	Cys	Asp	Leu	Glu	
				325					330					335		
GAC	AGG	GAT	AGA	TCA	GAG	CTT	AGC	CCG	CTG	CTG	CTG	TCT	ACA	ACA	GAG	1056
Asp	Arg	Asp	Arg	Ser	Glu	Leu	Ser	Pro	Leu	Leu	Leu	Ser	Thr	Thr	Glu	
				340				345					350			
TGG	CAG	ATA	CTG	CCC	TGT	TCC	TTC	ACC	ACC	CTG	CCG	GCC	CTA	TCC	ACC	1104
Trp	Gln	Ile	Leu	Pro	Cys	Ser	Phe	Thr	Thr	Leu	Pro	Ala	Leu	Ser	Thr	
		355					360					365				
GGC	CTG	ATC	CAC	CTC	CAT	CAG	AAC	ATC	GTG	GAC	GTG	CAA	TAC	CTG	TAC	1152
Gly	Leu	Ile	His	Leu	His	Gln	Asn	Ile	Val	Asp	Val	Gln	Tyr	Leu	Tyr	
	370					375					380					

GGT GTA GGG TCG GCG GTT GTC TCC CTT GTC ATC AAA TGG GAG TAT GTC 1200
Gly Val Gly Ser Ala Val Val Ser Leu Val Ile Lys Trp Glu Tyr Val
385 390 395 400

CTG TTG CTC TTC CTT CTC CTG GCA GAC GCG CGC ATC TGC GCC TGC TTA 1248
Leu Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu
405 410 415

TGG ATG ATG CTG CTG ATA GCT CAA GCT GAG GCC GCC TTA GAG AAC CTG 1296
Trp Met Met Leu Leu Ile Ala Gln Ala Glu Ala Ala Leu Glu Asn Leu
420 425 430

GTG GTC CTC AAT GCG GCG GCC GTG GCC GGG GCG CAT GGC ACT CTT TCC 1344
Val Val Leu Asn Ala Ala Ala Val Ala Gly Ala His Gly Thr Leu Ser
435 440 445

TTC CTT GTG TTC TTC TGT GCT GCC TGG TAC ATC AAG GGC AGG CTG GTC 1392
Phe Leu Val Phe Phe Cys Ala Ala Trp Tyr Ile Lys Gly Arg Leu Val
450 455 460

CCT GGT GCG GCA TAC GCC TTC TAT GGC GTG TGG CCG CTG CTC CTG CTT 1440
Pro Gly Ala Ala Tyr Ala Phe Tyr Gly Val Trp Pro Leu Leu Leu Leu
465 470 475 480

CTG CTG GCC TTA CCA CCA CGA GCT TAT GCC TAGTAA 1476
Leu Leu Ala Leu Pro Pro Arg Ala Tyr Ala
485 490

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 490 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser
.1 5 10 15
Gln Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala
20 25 30
His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn
35 40 45
Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly
50 55 60
His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu
65 70 75 80
Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn
85 90 95
Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp
100 105 110

Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe
 115 120 125
 Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp
 130 135 140
 Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser
 145 150 155 160
 Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly
 165 170 175
 Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro
 180 185 190
 Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr
 195 200 205
 Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg
 210 215 220
 Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly
 225 230 235 240
 Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly
 245 250 255
 Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu
 260 265 270
 Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys
 275 280 285
 Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn
 290 295 300
 Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg
 305 310 315 320
 Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu
 325 330 335
 Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu
 340 345 350
 Trp Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr
 355 360 365
 Gly Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr
 370 375 380
 Gly Val Gly Ser Ala Val Val Ser Leu Val Ile Lys Trp Glu Tyr Val
 385 390 395 400
 Leu Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu
 405 410 415
 Trp Met Met Leu Leu Ile Ala Gln Ala Glu Ala Ala Leu Glu Asn Leu
 420 425 430
 Val Val Leu Asn Ala Ala Ala Val Ala Gly Ala His Gly Thr Leu Ser

435

440

445

Phe Leu Val Phe Phe Cys Ala Ala Trp Tyr Ile Lys Gly Arg Leu Val
450 455 460

Pro Gly Ala Ala Tyr Ala Phe Tyr Gly Val Trp Pro Leu Leu Leu Leu
465 470 475 480

Leu Leu Ala Leu Pro Pro Arg Ala Tyr Ala
485 490

(2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1021 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 2..1018

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 2..1015

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

G ATC CCA CAA GCT GTC GTG GAC ATG GTG GCG GGG GCC CAT TGG GGA 46
Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly
1 5 10 15

GTC CTG GCG GGC CTC GCC TAC TAT TCC ATG GTG GGG AAC TGG GCT AAG 94
Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys
20 25 30

GTT TTG GTT GTG ATG CTA CTC TTT GCC GGC GTC GAC GGG CAT ACC CGC 142
Val Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly His Thr Arg
35 40 45

GTG TCA GGA GGG GCA GCA GCC TCC GAT ACC AGG GGC CTT GTG TCC CTC 190
Val Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu Val Ser Leu
50 55 60

TTT AGC CCC GGG TCG GCT CAG AAA ATC CAG CTC GTA AAC ACC AAC GGC 238
Phe Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr Asn Gly
65 70 75

AGT TGG CAC ATC AAC AGG ACT GCC CTG AAC TGC AAC GAC TCC CTC CAA 286
Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser Leu Gln
80 85 90 95

ACA GGG TTC TTT GCC GCA CTA TTC TAC AAA CAC AAA TTC AAC TCG TCT	334
Thr Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe Asn Ser Ser	
100 105 110	
GGA TGC CCA GAG CGC TTG GCC AGC TGT CGC TCC ATC GAC AAG TTC GCT	382
Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp Lys Phe Ala	
115 120 125	
CAG GGG TGG GGT CCC CTC ACT TAC ACT GAG CCT AAC AGC TCG GAC CAG	430
Gln Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser Ser Asp Gln	
130 135 140	
AGG CCC TAC TGC TGG CAC TAC GCG CCT CGA CCG TGT GGT ATT GTA CCC	478
Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile Val Pro	
145 150 155	
GCG TCT CAG GTG TGC GGT CCA GTG TAT TGC TTC ACC CCG AGC CCT GTT	526
Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val	
160 165 170 175	
GTG GTG GGG ACG ACC GAT CGG TTT GGT GTC CCC ACG TAT AAC TGG GGG	574
Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn Trp Gly	
180 185 190	
GCG AAC GAC TCG GAT GTG CTG ATT CTC AAC AAC ACG CGG CCG CCG CGA	622
Ala Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro Pro Arg	
195 200 205	
GGC AAC TGG TTC GGC TGT ACA TGG ATG AAT GGC ACT GGG TTC ACC AAG	670
Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe Thr Lys	
210 215 220	
ACG TGT GGG GGC CCC CCG TGC AAC ATC GGG GGG GCC GGC AAC AAC ACC	718
Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr	
225 230 235	
TTG ACC TGC CCC ACT GAC TGT TTT CGG AAG CAC CCC GAG GCC ACC TAC	766
Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr	
240 245 250 255	
GCC AGA TGC GGT TCT GGG CCC TGG CTG ACA CCT AGG TGT ATG GTT CAT	814
Ala Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His	
260 265 270	
TAC CCA TAT AGG CTC TGG CAC TAC CCC TGC ACT GTC AAC TTC ACC ATC	862
Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile	
275 280 285	
TTC AAG GTT AGG ATG TAC GTG GGG GGC GTG GAG CAC AGG TTC GAA GCC	910
Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala	
290 295 300	
GCA TGC AAT TGG ACT CGA GGA GAG CGT TGT GAC TTG GAG GAC AGG GAT	958
Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp	
305 310 315	
AGA TCA GAG CTT AGC CCG CTG CTG CTG TCT ACA ACA GAG TGG CAG AGT	1006
Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp Gln Ser	
320 325 330 335	
GGC AGA GCT TAATTA	1021

Gly Arg Ala

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 338 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly Val
1 5 10 15
Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val
20 25 30
Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly His Thr Arg Val
35 40 45
Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu Val Ser Leu Phe
50 55 60
Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr Asn Gly Ser
65 70 75 80
Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser Leu Gln Thr
85 90 95
Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe Asn Ser Ser Gly
100 105 110
Cys Pro Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp Lys Phe Ala Gln
115 120 125
Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser Ser Asp Gln Arg
130 135 140
Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile Val Pro Ala
145 150 155 160
Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val Val
165 170 175
Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn Trp Gly Ala
180 185 190
Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro Pro Arg Gly
195 200 205
Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe Thr Lys Thr
210 215 220
Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr Leu
225 230 235 240
Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr Ala
245 250 255

Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His Tyr
260 265 270

Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe
275 280 285

Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala Ala
290 295 300

Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg
305 310 315 320

Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp Gln Ser Gly
325 330 335

Arg Ala

(2) INFORMATION FOR SEQ ID NO: 39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1034 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 2..1032

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 2..1029

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

G ATC CCA CAA GCT GTC GTG GAC ATG GTG GCG GGG GCC CAT TGG GGA	46
Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly	
1 5 10 15	
GTC CTG GCG GGC CTC GCC TAC TAT TCC ATG GTG GGG AAC TGG GCT AAG	94
Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys	
20 25 30	
GTT TTG GTT GTG ATG CTA CTC TTT GCC GGC GTC GAC GGG CAT ACC CGC	142
Val Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly His Thr Arg	
35 40 45	
GTG TCA GGA GGG GCA GCA GCC TCC GAT ACC AGG GGC CTT GTG TCC CTC	190
Val Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu Val Ser Leu	
50 55 60	

TTT AGC CCC GGG TCG GCT CAG AAA ATC CAG CTC GTA AAC ACC AAC GGC	238
Phe Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr Asn Gly	
65 70 75	
AGT TGG CAC ATC AAC AGG ACT GCC CTG AAC TGC AAC GAC TCC CTC CAA	286
Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser Leu Gln	
80 85 90 95	
ACA GGG TTC TTT GCC GCA CTA TTC TAC AAA CAC AAA TTC AAC TCG TCT	334
Thr Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe Asn Ser Ser	
100 105 110	
GGA TGC CCA GAG CGC TTG GCC AGC TGT CGC TCC ATC GAC AAG TTC GCT	382
Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp Lys Phe Ala	
115 120 125	
CAG GGG TGG GGT CCC CTC ACT TAC ACT GAG CCT AAC AGC TCG GAC CAG	430
Gln Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser Asp Gln	
130 135 140	
AGG CCC TAC TGC TGG CAC TAC GCG CCT CGA CCG TGT GGT ATT GTA CCC	478
Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile Val Pro	
145 150 155	
GCG TCT CAG GTG TGC GGT CCA GTG TAT TGC TTC ACC CCG AGC CCT GTT	526
Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val	
160 165 170 175	
GTG GTG GGG ACG ACC GAT CGG TTT GGT GTC CCC ACG TAT AAC TGG GGG	574
Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn Trp Gly	
180 185 190	
GCG AAC GAC TCG GAT GTG CTG ATT CTC AAC AAC ACG CGG CCG CCG CGA	622
Ala Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro Pro Arg	
195 200 205	
GGC AAC TGG TTC GGC TGT ACA TGG ATG AAT GGC ACT GGG TTC ACC AAG	670
Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe Thr Lys	
210 215 220	
ACG TGT GGG GGC CCC CCG TGC AAC ATC GGG GGG GCC GGC AAC AAC ACC	718
Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr	
225 230 235	
TTG ACC TGC CCC ACT GAC TGT TTT CGG AAG CAC CCC GAG GCC ACC TAC	766
Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr	
240 245 250 255	
GCC AGA TGC GGT TCT GGG CCC TGG CTG ACA CCT AGG TGT ATG GTT CAT	814
Ala Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His	
260 265 270	
TAC CCA TAT AGG CTC TGG CAC TAC CCC TGC ACT GTC AAC TTC ACC ATC	862
Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile	
275 280 285	
TTC AAG GTT AGG ATG TAC GTG GGG GGC GTG GAG CAC AGG TTC GAA GCC	910
Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala	
290 295 300	
GCA TGC AAT TGG ACT CGA GGA GAG CGT TGT GAC TTG GAG GAC AGG GAT	958
Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp	

305

310

315

AGA TCA GAG CTT AGC CCG CTG CTG CTG TCT ACA ACA GGT GAT CGA GGG 1006
 Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gly Asp Arg Gly
 320 325 330 335

CAG ACA CCA TCA CCA CCA TCA CTA AT AG 1034
 Gln Thr Pro Ser Pro Pro Ser Leu
 340

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 343 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly Val
 1 5 10 15
 Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val
 20 25 30
 Leu Val Val Met Leu Leu Phe Ala Gly Val Asp Gly His Thr Arg Val
 35 40 45
 Ser Gly Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu Val Ser Leu Phe
 50 55 60
 Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr Asn Gly Ser
 65 70 75 80
 Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser Leu Gln Thr
 85 90 95
 Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe Asn Ser Ser Gly
 100 105 110
 Cys Pro Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp Lys Phe Ala Gln
 115 120 125
 Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser Ser Asp Gln Arg
 130 135 140
 Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile Val Pro Ala
 145 150 155 160
 Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val Val
 165 170 175
 Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn Trp Gly Ala
 180 185 190
 Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro Pro Arg Gly
 195 200 205

Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe Thr Lys Thr
 210 215 220
 Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr Leu
 225 230 235 240
 Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr Ala
 245 250 255
 Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His Tyr
 260 265 270
 Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe
 275 280 285
 Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala Ala
 290 295 300
 Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg
 305 310 315 320
 Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gly Asp Arg Gly Gln
 325 330 335
 Thr Pro Ser Pro Pro Ser Leu
 340

(2) INFORMATION FOR SEQ ID NO: 41:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 945 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..942
- (ix) FEATURE:
 - (A) NAME/KEY: mat_peptide
 - (B) LOCATION: 1..939

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

ATG GTG GGG AAC TGG GCT AAG GTT TTG GTT GTG ATG CTA CTC TTT GCC	48
Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala	
1 5 10 15	
GGC GTC GAC GGG CAT ACC CGC GTG TCA GGA GGG GCA GCA GCC TCC GAT	96
Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp	
20 25 30	

ACC AGG GGC CTT GTG TCC CTC TTT AGC CCC GGG TCG GCT CAG AAA ATC	144
Thr Arg Gly Leu Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile	
35 40 45	
CAG CTC GTA AAC ACC AAC GGC AGT TGG CAC ATC AAC AGG ACT GCC CTG	192
Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu	
50 55 60	
AAC TGC AAC GAC TCC CTC CAA ACA GGG TTC TTT GCC GCA CTA TTC TAC	240
Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr	
65 70 75 80	
AAA CAC AAA TTC AAC TCG TCT GGA TGC CCA GAG CGC TTG GCC AGC TGT	288
Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys	
85 90 95	
CGC TCC ATC GAC AAG TTC GCT CAG GGG TGG GGT CCC CTC ACT TAC ACT	336
Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr	
100 105 110	
GAG CCT AAC AGC TCG GAC CAG AGG CCC TAC TGC TGG CAC TAC GCG CCT	384
Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro	
115 120 125	
CGA CCG TGT GGT ATT GTA CCC GCG TCT CAG GTG TGC GGT CCA GTG TAT	432
Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr	
130 135 140	
TGC TTC ACC CCG AGC CCT GTT GTG GTG GGG ACG ACC GAT CGG TTT GGT	480
Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly	
145 150 155 160	
GTC CCC ACG TAT AAC TGG GGG GCG AAC GAC TCG GAT GTG CTG ATT CTC	528
Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu	
165 170 175	
AAC AAC ACG CGG CCG CCG CGA GGC AAC TGG TTC GGC TGT ACA TGG ATG	576
Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met	
180 185 190	
AAT GGC ACT GGG TTC ACC AAG ACG TGT GGG GGC CCC CCG TGC AAC ATC	624
Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile	
195 200 205	
GGG GGG GCC GGC AAC AAC ACC TTG ACC TGC CCC ACT GAC TGT TTT CGG	672
Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg	
210 215 220	
AAG CAC CCC GAG GCC ACC TAC GCC AGA TGC GGT TCT GGG CCC TGG CTG	720
Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu	
225 230 235 240	
ACA CCT AGG TGT ATG GTT CAT TAC CCA TAT AGG CTC TGG CAC TAC CCC	768
Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro	
245 250 255	
TGC ACT GTC AAC TTC ACC ATC TTC AAG GTT AGG ATG TAC GTG GGG GGC	816
Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly	
260 265 270	
GTG GAG CAC AGG TTC GAA GCC GCA TGC AAT TGG ACT CGA GGA GAG CGT	864

Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg
275 280 285

TGT GAC TTG GAG GAC AGG GAT AGA TCA GAG CTT AGC CCG CTG CTG CTG 912
Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu
290 295 300

TCT ACA ACA GAG TGG CAG AGC TTA ATT AAT TAG 945
Ser Thr Thr Glu Trp Gln Ser Leu Ile Asn
305 310

(2) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 314 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala
1 5 10 15
Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp
20 25 30
Thr Arg Gly Leu Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile
35 40 45
Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu
50 55 60
Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr
65 70 75 80
Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys
85 90 95
Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr
100 105 110
Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro
115 120 125
Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr
130 135 140
Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly
145 150 155 160
Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu
165 170 175
Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met
180 185 190
Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile
195 200 205

Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg
 210 215 220

Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu
 225 230 235 240

Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro
 245 250 255

Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly
 260 265 270

Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg
 275 280 285

Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu
 290 295 300

Ser Thr Thr Glu Trp Gln Ser Leu Ile Asn
 305 310

(2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 961 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..958

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 1..955

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

ATG GTG GGG AAC TGG GCT AAG GTT TTG GTT GTG ATG CTA CTC TTT GCC	48
Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala	
1 5 10 15	
GGC GTC GAC GGG CAT ACC CGC GTG TCA GGA GGG GCA GCA GCC TCC GAT	96
Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp	
20 25 30	
ACC AGG GGC CTT GTG TCC CTC TTT AGC CCC GGG TCG GCT CAG AAA ATC	144
Thr Arg Gly Leu Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile	
35 40 45	
CAG CTC GTA AAC ACC AAC GGC AGT TGG CAC ATC AAC AGG ACT GCC CTG	192

Gln 50	Leu	Val	Asn	Thr	Asn	Gly 55	Ser	Trp	His	Ile	Asn 60	Arg	Thr	Ala	Leu	
AAC Asn 65	TGC Cys	AAC Asn	GAC Asp	TCC Ser	CTC Leu	CAA Gln	ACA Thr	GGG Gly	TTC Phe	TTT Phe	GCC Ala	GCA Ala	CTA Leu	TTC Phe	TAC Tyr	240
AAA Lys	CAC His	AAA Lys	TTC Phe	AAC Asn	TCG Ser	TCT Ser	GGA Gly	TGC Cys	CCA Pro	GAG Glu	CGC Arg	TTG Leu	GCC Ala	AGC Ser	TGT Cys	288
CGC Arg	TCC Ser	ATC Ile	GAC Asp	AAG Lys	TTC Phe	GCT Ala	CAG Gln	GGG Gly	TGG Trp	GGT Gly	CCC Pro	CTC Leu	ACT Thr	TAC Tyr	ACT Thr	336
GAG Glu	CCT Pro	AAC Asn	AGC Ser	TCG Ser	GAC Asp	CAG Gln	AGG Arg	CCC Pro	TAC Tyr	TGC Cys	TGG Trp	CAC His	TAC Tyr	GCG Ala	CCT Pro	384
CGA Arg	CCG Pro	TGT Cys	GGT Gly	ATT Ile	GTA Val	CCC Pro	GCG Ala	TCT Ser	CAG Gln	GTG Val	TGC Cys	GGT Gly	CCA Pro	GTG Val	TAT Tyr	432
TGC Cys 145	TTC Phe	ACC Thr	CCG Pro	AGC Ser	CCT Pro	GTT Val	GTG Val	GTG Val	GGG Gly	ACG Thr	ACC Thr	GAT Asp	CGG Arg	TTT Phe	GGT Gly	480
GTC Val	CCC Pro	ACG Thr	TAT Tyr	AAC Asn	TGG Trp	GGG Gly	GCG Ala	AAC Asn	GAC Asp	TCG Ser	GAT Asp	GTG Val	CTG Leu	ATT Ile	CTC Leu	528
AAC Asn	AAC Asn	ACG Thr	CGG Arg	CCG Pro	CCG Pro	CGA Arg	GGC Gly	AAC Asn	TGG Trp	TTC Phe	GGC Gly	TGT Cys	ACA Thr	TGG Trp	ATG Met	576
AAT Asn	GGC Gly	ACT Thr	GGG Gly	TTC Phe	ACC Thr	AAG Lys	ACG Thr	TGT Cys	GGG Gly	GGC Gly	CCC Pro	CCG Pro	TGC Cys	AAC Asn	ATC Ile	624
GGG Gly	GGG Gly	GCC Ala	GGC Gly	AAC Asn	AAC Asn	ACC Thr	TTG Leu	ACC Thr	TGC Cys	CCC Pro	ACT Thr	GAC Asp	TGT Cys	TTT Phe	CGG Arg	672
AAG Lys	CAC His	CCC Pro	GAG Glu	GCC Ala	ACC Thr	TAC Tyr	GCC Ala	AGA Arg	TGC Cys	GGT Gly	TCT Ser	GGG Gly	CCC Pro	TGG Trp	CTG Leu	720
ACA Thr	CCT Pro	AGG Arg	TGT Cys	ATG Met	GTT Val	CAT His	TAC Tyr	CCA Pro	TAT Tyr	AGG Arg	CTC Leu	TGG Trp	CAC His	TAC Tyr	CCC Pro	768
TGC Cys	ACT Thr	GTC Val	AAC Asn	TTC Phe	ACC Thr	ATC Ile	TTC Phe	AAG Lys	GTT Val	AGG Arg	ATG Met	TAC Tyr	GTG Val	GGG Gly	GGC Gly	816
GTG Val	GAG Glu	CAC His	AGG Arg	TTC Phe	GAA Glu	GCC Ala	GCA Ala	TGC Cys	AAT Asn	TGG Trp	ACT Thr	CGA Arg	GGA Gly	GAG Glu	CGT Arg	864
TGT Cys	GAC Asp	TTG Leu	GAG Glu	GAC Asp	AGG Arg	GAT Asp	AGA Arg	TCA Ser	GAG Glu	CTT Leu	AGC Ser	CCG Pro	CTG Leu	CTG Leu	CTG Leu	912

290	295	300	
TCT ACA ACA GGT GAT CGA GGG CAG ACA CCA TCA CCA CCA TCA CTA A			958
Ser Thr Thr Gly Asp Arg Gly Gln Thr Pro Ser Pro Pro Ser Leu			
305	310	315	
TAG			961

(2) INFORMATION FOR SEQ ID NO: 44:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 319 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe Ala
 1 5 10 15

Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser Asp
 20 25 30

Thr Arg Gly Leu Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile
 35 40 45

Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu
 50 55 60

Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr
 65 70 75 80

Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys
 85 90 95

Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr
 100 105 110

Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro
 115 120 125

Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr
 130 135 140

Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly
 145 150 155 160

Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu
 165 170 175

Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met
 180 185 190

Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile
 195 200 205

Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg
 210 215 220

Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu

225	230	235	240
Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro	245	250	255
Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly	260	265	270
Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg	275	280	285
Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu	290	295	300
Ser Thr Thr Gly Asp Arg Gly Gln Thr Pro Ser Pro Pro Ser Leu	305	310	315

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1395 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1392

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 1..1389

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

ATG GTG GCG GGG GCC CAT TGG GGA GTC CTG GCG GGC CTC GCC TAC TAT	48
Met Val Ala Gly Ala His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr	
1 5 10 15	
TCC ATG GTG GGG AAC TGG GCT AAG GTT TTG GTT GTG ATG CTA CTC TTT	96
Ser Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe	
20 25 30	
GCC GGC GTC GAC GGG CAT ACC CGC GTG TCA GGA GGG GCA GCA GCC TCC	144
Ala Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser	
35 40 45	
GAT ACC AGG GGC CTT GTG TCC CTC TTT AGC CCC GGG TCG GCT CAG AAA	192
Asp Thr Arg Gly Leu Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys	
50 55 60	
ATC CAG CTC GTA AAC ACC AAC GGC AGT TGG CAC ATC AAC AGG ACT GCC	240
Ile Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala	
65 70 75 80	

20250325 15:22:30

CTG AAC TGC AAC GAC TCC CTC CAA ACA GGG TTC TTT GCC GCA CTA TTC	288
Leu Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe	
85 90 95	
TAC AAA CAC AAA TTC AAC TCG TCT GGA TGC CCA GAG CGC TTG GCC AGC	336
Tyr Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser	
100 105 110	
TGT CGC TCC ATC GAC AAG TTC GCT CAG GGG TGG GGT CCC CTC ACT TAC	384
Cys Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr	
115 120 125	
ACT GAG CCT AAC AGC TCG GAC CAG AGG CCC TAC TGC TGG CAC TAC GCG	432
Thr Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala	
130 135 140	
CCT CGA CCG TGT GGT ATT GTA CCC GCG TCT CAG GTG TGC GGT CCA GTG	480
Pro Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val	
145 150 155 160	
TAT TGC TTC ACC CCG AGC CCT GTT GTG GTG GGG ACG ACC GAT CGG TTT	528
Tyr Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe	
165 170 175	
GGT GTC CCC ACG TAT AAC TGG GGG GCG AAC GAC TCG GAT GTG CTG ATT	576
Gly Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile	
180 185 190	
CTC AAC AAC ACG CGG CCG CCG CGA GGC AAC TGG TTC GGC TGT ACA TGG	624
Leu Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp	
195 200 205	
ATG AAT GGC ACT GGG TTC ACC AAG ACG TGT GGG GGC CCC CCG TGC AAC	672
Met Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn	
210 215 220	
ATC GGG GGG GCC GGC AAC AAC ACC TTG ACC TGC CCC ACT GAC TGT TTT	720
Ile Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe	
225 230 235 240	
CGG AAG CAC CCC GAG GCC ACC TAC GCC AGA TGC GGT TCT GGG CCC TGG	768
Arg Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp	
245 250 255	
CTG ACA CCT AGG TGT ATG GTT CAT TAC CCA TAT AGG CTC TGG CAC TAC	816
Leu Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr	
260 265 270	
CCC TGC ACT GTC AAC TTC ACC ATC TTC AAG GTT AGG ATG TAC GTG GGG	864
Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly	
275 280 285	
GGC GTG GAG CAC AGG TTC GAA GCC GCA TGC AAT TGG ACT CGA GGA GAG	912
Gly Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu	
290 295 300	
CGT TGT GAC TTG GAG GAC AGG GAT AGA TCA GAG CTT AGC CCG CTG CTG	960
Arg Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu	
305 310 315 320	
CTG TCT ACA ACA GAG TGG CAG ATA CTG CCC TGT TCC TTC ACC ACC CTG	1008

Leu Ser Thr Thr	Glu Trp Gln Ile	Leu Pro Cys Ser Phe Thr Thr	Leu	
	325	330	335	
CCG GCC CTA TCC ACC GGC CTG ATC CAC CTC CAT CAG AAC ATC GTG GAC				1056
Pro Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp	340	345	350	
GTG CAA TAC CTG TAC GGT GTA GGG TCG GCG GTT GTC TCC CTT GTC ATC				1104
Val Gln Tyr Leu Tyr Gly Val Gly Ser Ala Val Val Ser Leu Val Ile	355	360	365	
AAA TGG GAG TAT GTC CTG TTG CTC TTC CTT CTC CTG GCA GAC GCG CGC				1152
Lys Trp Glu Tyr Val Leu Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg	370	375	380	
ATC TGC GCC TGC TTA TGG ATG ATG CTG CTG ATA GCT CAA GCT GAG GCC				1200
Ile Cys Ala Cys Leu Trp Met Met Leu Leu Ile Ala Gln Ala Glu Ala	385	390	395	400
GCC TTA GAG AAC CTG GTG GTC CTC AAT GCG GCG GCC GTG GCC GGG GCG				1248
Ala Leu Glu Asn Leu Val Val Leu Asn Ala Ala Ala Val Ala Gly Ala	405	410	415	
CAT GGC ACT CTT TCC TTC CTT GTG TTC TTC TGT GCT GCC TGG TAC ATC				1296
His Gly Thr Leu Ser Phe Leu Val Phe Phe Cys Ala Ala Trp Tyr Ile	420	425	430	
AAG GGC AGG CTG GTC CCT GGT GCG GCA TAC GCC TTC TAT GGC GTG TGG				1344
Lys Gly Arg Leu Val Pro Gly Ala Ala Tyr Ala Phe Tyr Gly Val Trp	435	440	445	
CCG CTG CTC CTG CTT CTG CTG GCC TTA CCA CCA CGA GCT TAT GCC TAGTAA				1395
Pro Leu Leu Leu Leu Leu Leu Ala Leu Pro Pro Arg Ala Tyr Ala	450	455	460	

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 463 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

Met Val Ala Gly Ala His Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr	
1 5 10 15	
Ser Met Val Gly Asn Trp Ala Lys Val Leu Val Val Met Leu Leu Phe	
20 25 30	
Ala Gly Val Asp Gly His Thr Arg Val Ser Gly Gly Ala Ala Ala Ser	
35 40 45	
Asp Thr Arg Gly Leu Val Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys	
50 55 60	
Ile Gln Leu Val Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala	
65 70 75 80	

Leu Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe
85 90 95

Tyr Lys His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser
100 105 110

Cys Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr
115 120 125

Thr Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala
130 135 140

Pro Arg Pro Cys Gly Ile Val Pro Ala Ser Gln Val Cys Gly Pro Val
145 150 155 160

Tyr Cys Phe Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Phe
165 170 175

Gly Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp Ser Asp Val Leu Ile
180 185 190

Leu Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp
195 200 205

Met Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn
210 215 220

Ile Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe
225 230 235 240

Arg Lys His Pro Glu Ala Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp
245 250 255

Leu Thr Pro Arg Cys Met Val His Tyr Pro Tyr Arg Leu Trp His Tyr
260 265 270

Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly
275 280 285

Gly Val Glu His Arg Phe Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu
290 295 300

Arg Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu
305 310 315 320

Leu Ser Thr Thr Glu Trp Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu
325 330 335

Pro Ala Leu Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp
340 345 350

Val Gln Tyr Leu Tyr Gly Val Gly Ser Ala Val Val Ser Leu Val Ile
355 360 365

Lys Trp Glu Tyr Val Leu Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg
370 375 380

Ile Cys Ala Cys Leu Trp Met Met Leu Leu Ile Ala Gln Ala Glu Ala
385 390 395 400

Ala Leu Glu Asn Leu Val Val Leu Asn Ala Ala Ala Val Ala Gly Ala

405

410

415

His Gly Thr Leu Ser Phe Leu Val Phe Phe Cys Ala Ala Trp Tyr Ile
 420 425 430

Lys Gly Arg Leu Val Pro Gly Ala Ala Tyr Ala Phe Tyr Gly Val Trp
 435 440 445

Pro Leu Leu Leu Leu Leu Ala Leu Pro Pro Arg Ala Tyr Ala
 450 455 460

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2082 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..2079

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 1..2076

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

AAT TTG GGT AAG GTC ATC GAT ACC CTT ACA TGC GGC TTC GCC GAC CTC	48
Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu	
1 5 10 15	
GTG GGG TAC ATT CCG CTC GTC GGC GCC CCC CTA GGG GGC GCT GCC AGG	96
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg	
20 25 30	
GCC CTG GCG CAT GGC GTC CGG GTT CTG GAG GAC GGC GTG AAC TAT GCA	144
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala	
35 40 45	
ACA GGG AAT TTG CCC GGT TGC TCT TTC TCT ATC TTC CTC TTG GCT TTG	192
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu	
50 55 60	
CTG TCC TGT CTG ACC GTT CCA GCT TCC GCT TAT GAA GTG CGC AAC GTG	240
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val	
65 70 75 80	
TCC GGG ATG TAC CAT GTC ACG AAC GAC TGC TCC AAC TCA AGC ATT GTG	288
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val	
85 90 95	

TAT	GAG	GCA	GCG	GAC	ATG	ATC	ATG	CAC	ACC	CCC	GGG	TGC	GTG	CCC	TGC	336
Tyr	Glu	Ala	Ala	Asp	Met	Ile	Met	His	Thr	Pro	Gly	Cys	Val	Pro	Cys	
			100					105							110	
GTT	CGG	GAG	AAC	AAC	TCT	TCC	CGC	TGC	TGG	GTA	GCG	CTC	ACC	CCC	ACG	384
Val	Arg	Glu	Asn	Asn	Ser	Ser	Arg	Cys	Trp	Val	Ala	Leu	Thr	Pro	Thr	
		115					120					125				
CTC	GCA	GCT	AGG	AAC	GCC	AGC	GTC	CCC	ACC	ACG	ACA	ATA	CGA	CGC	CAC	432
Leu	Ala	Ala	Arg	Asn	Ala	Ser	Val	Pro	Thr	Thr	Thr	Ile	Arg	Arg	His	
		130					135					140				
GTC	GAT	TTG	CTC	GTT	GGG	GCG	GCT	GCT	TTC	TGT	TCC	GCT	ATG	TAC	GTG	480
Val	Asp	Leu	Leu	Val	Gly	Ala	Ala	Ala	Phe	Cys	Ser	Ala	Met	Tyr	Val	
		145			150					155					160	
GGG	GAC	CTC	TGC	GGA	TCT	GTC	TTC	CTC	GTC	TCC	CAG	CTG	TTC	ACC	ATC	528
Gly	Asp	Leu	Cys	Gly	Ser	Val	Phe	Leu	Val	Ser	Gln	Leu	Phe	Thr	Ile	
			165						170					175		
TCG	CCT	CGC	CGG	CAT	GAG	ACG	GTG	CAG	GAC	TGC	AAT	TGC	TCA	ATC	TAT	576
Ser	Pro	Arg	Arg	His	Glu	Thr	Val	Gln	Asp	Cys	Asn	Cys	Ser	Ile	Tyr	
			180					185					190			
CCC	GGC	CAC	ATA	ACG	GGT	CAC	CGT	ATG	GCT	TGG	GAT	ATG	ATG	ATG	AAC	624
Pro	Gly	His	Ile	Thr	Gly	His	Arg	Met	Ala	Trp	Asp	Met	Met	Met	Asn	
		195					200					205				
TGG	TCG	CCT	ACA	ACG	GCC	CTG	GTG	GTA	TCG	CAG	CTG	CTC	CGG	ATC	CCA	672
Trp	Ser	Pro	Thr	Thr	Ala	Leu	Val	Val	Ser	Gln	Leu	Leu	Arg	Ile	Pro	
		210				215					220					
CAA	GCT	GTC	GTG	GAC	ATG	GTG	GCG	GGG	GCC	CAT	TGG	GGA	GTC	CTG	GCG	720
Gln	Ala	Val	Val	Asp	Met	Val	Ala	Gly	Ala	His	Trp	Gly	Val	Leu	Ala	
		225			230					235				240		
GGC	CTC	GCC	TAC	TAT	TCC	ATG	GTG	GGG	AAC	TGG	GCT	AAG	GTT	TTG	GTT	768
Gly	Leu	Ala	Tyr	Tyr	Ser	Met	Val	Gly	Asn	Trp	Ala	Lys	Val	Leu	Val	
			245						250					255		
GTG	ATG	CTA	CTC	TTT	GCC	GGC	GTC	GAC	GGG	CAT	ACC	CGC	GTG	TCA	GGA	816
Val	Met	Leu	Leu	Phe	Ala	Gly	Val	Asp	Gly	His	Thr	Arg	Val	Ser	Gly	
			260					265					270			
GGG	GCA	GCA	GCC	TCC	GAT	ACC	AGG	GGC	CTT	GTG	TCC	CTC	TTT	AGC	CCC	864
Gly	Ala	Ala	Ala	Ser	Asp	Thr	Arg	Gly	Leu	Val	Ser	Leu	Phe	Ser	Pro	
		275					280					285				
GGG	TCG	GCT	CAG	AAA	ATC	CAG	CTC	GTA	AAC	ACC	AAC	GGC	AGT	TGG	CAC	912
Gly	Ser	Ala	Gln	Lys	Ile	Gln	Leu	Val	Asn	Thr	Asn	Gly	Ser	Trp	His	
		290														

Glu	Arg	Leu	Ala	Ser	Cys	Arg	Ser	Ile	Asp	Lys	Phe	Ala	Gln	Gly	Trp		
			340					345					350				
GGT	CCC	CTC	ACT	TAC	ACT	GAG	CCT	AAC	AGC	TCG	GAC	CAG	AGG	CCC	TAC	1104	
Gly	Pro	Leu	Thr	Tyr	Thr	Glu	Pro	Asn	Ser	Ser	Asp	Gln	Arg	Pro	Tyr		
		355					360					365					
TGC	TGG	CAC	TAC	GCG	CCT	CGA	CCG	TGT	GGT	ATT	GTA	CCC	GCG	TCT	CAG	1152	
Cys	Trp	His	Tyr	Ala	Pro	Arg	Pro	Cys	Gly	Ile	Val	Pro	Ala	Ser	Gln		
	370					375					380						
GTG	TGC	GGT	CCA	GTG	TAT	TGC	TTC	ACC	CCG	AGC	CCT	GTT	GTG	GTG	GGG	1200	
Val	Cys	Gly	Pro	Val	Tyr	Cys	Phe	Thr	Pro	Ser	Pro	Val	Val	Val	Gly		
	385				390					395					400		
ACG	ACC	GAT	CGG	TTT	GGT	GTC	CCC	ACG	TAT	AAC	TGG	GGG	GCG	AAC	GAC	1248	
Thr	Thr	Asp	Arg	Phe	Gly	Val	Pro	Thr	Tyr	Asn	Trp	Gly	Ala	Asn	Asp		
				405					410					415			
TCG	GAT	GTG	CTG	ATT	CTC	AAC	AAC	ACG	CGG	CCG	CCG	CGA	GGC	AAC	TGG	1296	
Ser	Asp	Val	Leu	Ile	Leu	Asn	Asn	Thr	Arg	Pro	Pro	Arg	Gly	Asn	Trp		
			420					425					430				
TTC	GGC	TGT	ACA	TGG	ATG	AAT	GGC	ACT	GGG	TTC	ACC	AAG	ACG	TGT	GGG	1344	
Phe	Gly	Cys	Thr	Trp	Met	Asn	Gly	Thr	Gly	Phe	Thr	Lys	Thr	Cys	Gly		
		435					440					445					
GGC	CCC	CCG	TGC	AAC	ATC	GGG	GGG	GCC	GGC	AAC	AAC	ACC	TTG	ACC	TGC	1392	
Gly	Pro	Pro	Cys	Asn	Ile	Gly	Gly	Ala	Gly	Asn	Asn	Thr	Leu	Thr	Cys		
	450					455					460						
CCC	ACT	GAC	TGT	TTT	CGG	AAG	CAC	CCC	GAG	GCC	ACC	TAC	GCC	AGA	TGC	1440	
Pro	Thr	Asp	Cys	Phe	Arg	Lys	His	Pro	Glu	Ala	Thr	Tyr	Ala	Arg	Cys		
	465				470				475						480		
GGT	TCT	GGG	CCC	TGG	CTG	ACA	CCT	AGG	TGT	ATG	GTT	CAT	TAC	CCA	TAT	1488	
Gly	Ser	Gly	Pro	Trp	Leu	Thr	Pro	Arg	Cys	Met	Val	His	Tyr	Pro	Tyr		
				485					490					495			
AGG	CTC	TGG	CAC	TAC	CCC	TGC	ACT	GTC	AAC	TTC	ACC	ATC	TTC	AAG	GTT	1536	
Arg	Leu	Trp	His	Tyr	Pro	Cys	Thr	Val	Asn	Phe	Thr	Ile	Phe	Lys	Val		
			500					505					510				
AGG	ATG	TAC	GTG	GGG	GGC	GTG	GAG	CAC	AGG	TTC	GAA	GCC	GCA	TGC	AAT	1584	
Arg	Met	Tyr	Val	Gly	Gly	Val	Glu	His	Arg	Phe	Glu	Ala	Ala	Cys	Asn		
		515					520					525					
TGG	ACT	CGA	GGA	GAG	CGT	TGT	GAC	TTG	GAG	GAC	AGG	GAT	AGA	TCA	GAG	1632	
Trp	Thr	Arg	Gly	Glu	Arg	Cys	Asp	Leu	Glu	Asp	Arg	Asp	Arg	Ser	Glu		
	530					535					540						
CTT	AGC	CCG	CTG	CTG	CTG	TCT	ACA	ACA	GAG	TGG	CAG	ATA	CTG	CCC	TGT	1680	
Leu	Ser	Pro	Leu	Leu	Leu	Ser	Thr	Thr	Glu	Trp	Gln	Ile	Leu	Pro	Cys		
	545				550					555					560		
TCC	TTC	ACC	ACC	CTG	CCG	GCC	CTA	TCC	ACC	GGC	CTG	ATC	CAC	CTC	CAT	1728	
Ser	Phe	Thr	Thr	Leu	Pro	Ala	Leu	Ser	Thr	Gly	Leu	Ile	His	Leu	His		
				565					570					575			
CAG	AAC	ATC	GTG	GAC	GTG	CAA	TAC	CTG	TAC	GGT	GTA	GGG	TCG	GCG	GTT	1776	
Gln	Asn	Ile	Val	Asp	Val	Gln	Tyr	Leu	Tyr	Gly	Val	Gly	Ser	Ala	Val		
			580					585					590				

252760 2523580

GTC TCC CTT GTC ATC AAA TGG GAG TAT GTC CTG TTG CTC TTC CTT CTC	1824
Val Ser Leu Val Ile Lys Trp Glu Tyr Val Leu Leu Leu Phe Leu Leu	
595 600 605	
CTG GCA GAC GCG CGC ATC TGC GCC TGC TTA TGG ATG ATG CTG CTG ATA	1872
Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu Trp Met Met Leu Leu Ile	
610 615 620	
GCT CAA GCT GAG GCC GCC TTA GAG AAC CTG GTG GTC CTC AAT GCG GCG	1920
Ala Gln Ala Glu Ala Ala Leu Glu Asn Leu Val Val Leu Asn Ala Ala	
625 630 635 640	
GCC GTG GCC GGG GCG CAT GGC ACT CTT TCC TTC CTT GTG TTC TTC TGT	1968
Ala Val Ala Gly Ala His Gly Thr Leu Ser Phe Leu Val Phe Phe Cys	
645 650 655	
GCT GCC TGG TAC ATC AAG GGC AGG CTG GTC CCT GGT GCG GCA TAC GCC	2016
Ala Ala Trp Tyr Ile Lys Gly Arg Leu Val Pro Gly Ala Ala Tyr Ala	
660 665 670	
TTC TAT GGC GTG TGG CCG CTG CTC CTG CTT CTG CTG GCC TTA CCA CCA	2064
Phe Tyr Gly Val Trp Pro Leu Leu Leu Leu Leu Ala Leu Pro Pro	
675 680 685	
CGA GCT TAT GCC TAGTAA	2082
Arg Ala Tyr Ala	
690	

(2) INFORMATION FOR SEQ ID NO: 48:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 692 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu	
1 5 10 15	
Val Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg	
20 25 30	
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala	
35 40 45	
Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu	
50 55 60	
Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Glu Val Arg Asn Val	
65 70 75 80	
Ser Gly Met Tyr His Val Thr Asn Asp Cys Ser Asn Ser Ser Ile Val	
85 90 95	
Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro Gly Cys Val Pro Cys	
100 105 110	

Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val Ala Leu Thr Pro Thr
 115 120 125
 Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr Thr Ile Arg Arg His
 130 135 140
 Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys Ser Ala Met Tyr Val
 145 150 155 160
 Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser Gln Leu Phe Thr Ile
 165 170 175
 Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys Asn Cys Ser Ile Tyr
 180 185 190
 Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn
 195 200 205
 Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln Leu Leu Arg Ile Pro
 210 215 220
 Gln Ala Val Val Asp Met Val Ala Gly Ala His Trp Gly Val Leu Ala
 225 230 235 240
 Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp Ala Lys Val Leu Val
 245 250 255
 Val Met Leu Leu Phe Ala Gly Val Asp Gly His Thr Arg Val Ser Gly
 260 265 270
 Gly Ala Ala Ala Ser Asp Thr Arg Gly Leu Val Ser Leu Phe Ser Pro
 275 280 285
 Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr Asn Gly Ser Trp His
 290 295 300
 Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser Leu Gln Thr Gly Phe
 305 310 315 320
 Phe Ala Ala Leu Phe Tyr Lys His Lys Phe Asn Ser Ser Gly Cys Pro
 325 330 335
 Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp Lys Phe Ala Gln Gly Trp
 340 345 350
 Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser Ser Asp Gln Arg Pro Tyr
 355 360 365
 Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile Val Pro Ala Ser Gln
 370 375 380
 Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val Val Val Gly
 385 390 395 400
 Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn Trp Gly Ala Asn Asp
 405 410 415
 Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro Pro Arg Gly Asn Trp
 420 425 430
 Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe Thr Lys Thr Cys Gly

435

440

445

Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys
450 455 460

Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala Thr Tyr Ala Arg Cys
465 470 475 480

Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met Val His Tyr Pro Tyr
485 490 495

Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Val
500 505 510

Arg Met Tyr Val Gly Gly Val Glu His Arg Phe Glu Ala Ala Cys Asn
515 520 525

Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp Arg Ser Glu
530 535 540

Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp Gln Ile Leu Pro Cys
545 550 555 560

Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly Leu Ile His Leu His
565 570 575

Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly Val Gly Ser Ala Val
580 585 590

Val Ser Leu Val Ile Lys Trp Glu Tyr Val Leu Leu Leu Phe Leu Leu
595 600 605

Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu Trp Met Met Leu Leu Ile
610 615 620

Ala Gln Ala Glu Ala Ala Leu Glu Asn Leu Val Val Leu Asn Ala Ala
625 630 635 640

Ala Val Ala Gly Ala His Gly Thr Leu Ser Phe Leu Val Phe Phe Cys
645 650 655

Ala Ala Trp Tyr Ile Lys Gly Arg Leu Val Pro Gly Ala Ala Tyr Ala
660 665 670

Phe Tyr Gly Val Trp Pro Leu Leu Leu Leu Leu Ala Leu Pro Pro
675 680 685

Arg Ala Tyr Ala
690

(2) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2433 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..2430

(ix) FEATURE:

(A) NAME/KEY: mat_peptide

(B) LOCATION: 1..2427

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

ATG	AGC	ACG	AAT	CCT	AAA	CCT	CAA	AGA	AAA	ACC	AAA	CGT	AAC	ACC	AAC	48
Met	Ser	Thr	Asn	Pro	Lys	Pro	Gln	Arg	Lys	Thr	Lys	Arg	Asn	Thr	Asn	
1				5					10					15		
CGC	CGC	CCA	CAG	GAC	GTC	AAG	TTC	CCG	GGC	GGT	GGT	CAG	ATC	GTT	GGT	96
Arg	Arg	Pro	Gln	Asp	Val	Lys	Phe	Pro	Gly	Gly	Gly	Gln	Ile	Val	Gly	
			20					25					30			
GGA	GTT	TAC	CTG	TTG	CCG	CGC	AGG	GGC	CCC	AGG	TTG	GGT	GTG	CGC	GCG	144
Gly	Val	Tyr	Leu	Leu	Pro	Arg	Arg	Gly	Pro	Arg	Leu	Gly	Val	Arg	Ala	
		35					40					45				
ACT	AGG	AAG	ACT	TCC	GAG	CGG	TCG	CAA	CCT	CGT	GGG	AGG	CGA	CAA	CCT	192
Thr	Arg	Lys	Thr	Ser	Glu	Arg	Ser	Gln	Pro	Arg	Gly	Arg	Arg	Gln	Pro	
	50					55					60					
ATC	CCC	AAG	GCT	CGC	CGA	CCC	GAG	GGT	AGG	GCC	TGG	GCT	CAG	CCC	GGG	240
Ile	Pro	Lys	Ala	Arg	Arg	Pro	Glu	Gly	Arg	Ala	Trp	Ala	Gln	Pro	Gly	
65					70				75					80		
TAC	CCT	TGG	CCC	CTC	TAT	GGC	AAT	GAG	GGC	ATG	GGG	TGG	GCA	GGA	TGG	288
Tyr	Pro	Trp	Pro	Leu	Tyr	Gly	Asn	Glu	Gly	Met	Gly	Trp	Ala	Gly	Trp	
				85					90					95		
CTC	CTG	TCA	CCC	CGC	GGC	TCT	CGG	CCT	AGT	TGG	GGC	CCT	ACA	GAC	CCC	336
Leu	Leu	Ser	Pro	Arg	Gly	Ser	Arg	Pro	Ser	Trp	Gly	Pro	Thr	Asp	Pro	
			100					105					110			
CGG	CGT	AGG	TCG	CGT	AAT	TTG	GGT	AAG	GTC	ATC	GAT	ACC	CTT	ACA	TGC	384
Arg	Arg	Arg	Ser	Arg	Asn	Leu	Gly	Lys	Val	Ile	Asp	Thr	Leu	Thr	Cys	
		115					120					125				
GGC	TTC	GCC	GAC	CTC	GTG	GGG	TAC	ATT	CCG	CTC	GTC	GGC	GCC	CCC	CTA	432
Gly	Phe	Ala	Asp	Leu	Val	Gly	Tyr	Ile	Pro	Leu	Val	Gly	Ala	Pro	Leu	
	130					135					140					
GGG	GGC	GCT	GCC	AGG	GCC	CTG	GCG	CAT	GGC	GTC	CGG	GTT	CTG	GAG	GAC	480
Gly	Gly	Ala	Ala	Arg	Ala	Leu	Ala	His	Gly	Val	Arg	Val	Leu	Glu	Asp	
145					150				155					160		
GGC	GTG	AAC	TAT	GCA	ACA	GGG	AAT	TTG	CCC	GGT	TGC	TCT	TTC	TCT	ATC	528
Gly	Val	Asn	Tyr	Ala	Thr	Gly	Asn	Leu	Pro	Gly	Cys	Ser	Phe	Ser	Ile	
				165				170						175		
TTC	CTC	TTG	GCT	TTG	CTG	TCC	TGT	CTG	ACC	GTT	CCA	GCT	TCC	GCT	TAT	576
Phe	Leu	Leu	Ala	Leu	Leu	Ser	Cys	Leu	Thr	Val	Pro	Ala	Ser	Ala	Tyr	

180										185										190										
GAA	GTG	CGC	AAC	GTG	TCC	GGG	ATG	TAC	CAT	GTC	ACG	AAC	GAC	TGC	TCC		624													
Glu	Val	Arg	Asn	Val	Ser	Gly	Met	Tyr	His	Val	Thr	Asn	Asp	Cys	Ser															
		195					200						205																	
AAC	TCA	AGC	ATT	GTG	TAT	GAG	GCA	GCG	GAC	ATG	ATC	ATG	CAC	ACC	CCC		672													
Asn	Ser	Ser	Ile	Val	Tyr	Glu	Ala	Ala	Asp	Met	Ile	Met	His	Thr	Pro															
	210						215					220																		
GGG	TGC	GTG	CCC	TGC	GTT	CGG	GAG	AAC	AAC	TCT	TCC	CGC	TGC	TGG	GTA		720													
Gly	Cys	Val	Pro	Cys	Val	Arg	Glu	Asn	Asn	Ser	Ser	Arg	Cys	Trp	Val															
	225				230					235					240															
GCG	CTC	ACC	CCC	ACG	CTC	GCA	GCT	AGG	AAC	GCC	AGC	GTC	CCC	ACC	ACG		768													
Ala	Leu	Thr	Pro	Thr	Leu	Ala	Ala	Arg	Asn	Ala	Ser	Val	Pro	Thr	Thr															
				245					250					255																
ACA	ATA	CGA	CGC	CAC	GTC	GAT	TTG	CTC	GTT	GGG	GCG	GCT	GCT	TTC	TGT		816													
Thr	Ile	Arg	Arg	His	Val	Asp	Leu	Leu	Val	Gly	Ala	Ala	Ala	Phe	Cys															
			260					265					270																	
TCC	GCT	ATG	TAC	GTG	GGG	GAC	CTC	TGC	GGA	TCT	GTC	TTC	CTC	GTC	TCC		864													
Ser	Ala	Met	Tyr	Val	Gly	Asp	Leu	Cys	Gly	Ser	Val	Phe	Leu	Val	Ser															
		275					280						285																	
CAG	CTG	TTC	ACC	ATC	TCG	CCT	CGC	CGG	CAT	GAG	ACG	GTG	CAG	GAC	TGC		912													
Gln	Leu	Phe	Thr	Ile	Ser	Pro	Arg	Arg	His	Glu	Thr	Val	Gln	Asp	Cys															
	290						295				300																			
AAT	TGC	TCA	ATC	TAT	CCC	GGC	CAC	ATA	ACG	GGT	CAC	CGT	ATG	GCT	TGG		960													
Asn	Cys	Ser	Ile	Tyr	Pro	Gly	His	Ile	Thr	Gly	His	Arg	Met	Ala	Trp															
	305				310					315					320															
GAT	ATG	ATG	ATG	AAC	TGG	TCG	CCT	ACA	ACG	GCC	CTG	GTG	GTA	TCG	CAG		1008													
Asp	Met	Met	Met	Asn	Trp	Ser	Pro	Thr	Thr	Ala	Leu	Val	Val	Ser	Gln															
				325				330						335																
CTG	CTC	CGG	ATC	CCA	CAA	GCT	GTC	GTG	GAC	ATG	GTG	GCG	GGG	GCC	CAT		1056													
Leu	Leu	Arg	Ile	Pro	Gln	Ala	Val	Val	Asp	Met	Val	Ala	Gly	Ala	His															
			340				345						350																	
TGG	GGA	GTC	CTG	GCG	GGC	CTC	GCC	TAC	TAT	TCC	ATG	GTG	GGG	AAC	TGG		1104													
Trp	Gly	Val	Leu	Ala	Gly	Leu	Ala	Tyr	Tyr	Ser	Met	Val	Gly	Asn	Trp															
		355					360					365																		
GCT	AAG	GTT	TTG	GTT	GTG	ATG	CTA	CTC	TTT	GCC	GGC	GTC	GAC	GGG	CAT		1152													
Ala	Lys	Val	Leu	Val	Val	Met	Leu	Leu	Phe	Ala	Gly	Val	Asp	Gly	His															
	370					375					380																			
ACC	CGC	GTG	TCA	GGA	GGG	GCA	GCA	GCC	TCC	GAT	ACC	AGG	GGC	CTT	GTG		1200													
Thr	Arg	Val	Ser	Gly	Gly	Ala	Ala	Ala	Ser	Asp	Thr	Arg	Gly	Leu	Val															
	385				390				395						400															
TCC	CTC	TTT	AGC	CCC	GGG	TCG	GCT	CAG	AAA	ATC	CAG	CTC	GTA	AAC	ACC		1248													
Ser	Leu	Phe	Ser	Pro	Gly	Ser	Ala	Gln	Lys	Ile	Gln	Leu	Val	Asn	Thr															
				405				410						415																
AAC	GGC	AGT	TGG	CAC	ATC	AAC	AGG	ACT	GCC	CTG	AAC	TGC	AAC	GAC	TCC		1296													
Asn	Gly	Ser	Trp	His	Ile	Asn	Arg	Thr	Ala	Leu	Asn	Cys	Asn	Asp	Ser															
			420				425						430																	

CTC Leu	CAA Gln	ACA Thr 435	GGG Gly	TTC Phe	TTT Phe	GCC Ala	GCA Ala 440	CTA Leu	TTC Phe	TAC Tyr	AAA Lys	CAC His 445	AAA Lys	TTC Phe	AAC Asn	1344
TCG Ser	TCT Ser 450	GGA Gly	TGC Cys	CCA Pro	GAG Glu	CGC Arg 455	TTG Leu	GCC Ala	AGC Ser	TGT Cys	CGC Arg 460	TCC Ser	ATC Ile	GAC Asp	AAG Lys	1392
TTC Phe 465	GCT Ala	CAG Gln	GGG Gly	TGG Trp	GGT Gly 470	CCC Pro	CTC Leu	ACT Thr	TAC Tyr	ACT Thr 475	GAG Glu	CCT Pro	AAC Asn	AGC Ser	TCG Ser 480	1440
GAC Asp	CAG Gln	AGG Arg	CCC Pro	TAC Tyr 485	TGC Cys	TGG Trp	CAC His	TAC Tyr	GCG Ala 490	CCT Pro	CGA Arg	CCG Pro	TGT Cys	GGT Gly 495	ATT Ile	1488
GTA Val	CCC Pro	GCG Ala	TCT Ser 500	CAG Gln	GTG Val	TGC Cys	GGT Gly 505	CCA Pro	GTG Val	TAT Tyr	TGC Cys	TTC Phe 510	ACC Thr	CCG Pro	AGC Ser	1536
CCT Pro	GTT Val 515	GTG Val	GTG Val	GGG Gly	ACG Thr	ACC Thr	GAT Asp 520	CGG Arg	TTT Phe	GGT Gly	GTC Val 525	CCC Pro	ACG Thr	TAT Tyr	AAC Asn	1584
TGG Trp	GGG Gly 530	GCG Ala	AAC Asn	GAC Asp	TCG Ser	GAT Asp 535	GTG Val	CTG Leu	ATT Ile	CTC Leu	AAC Asn 540	AAC Asn	ACG Thr	CGG Arg	CCG Pro	1632
CCG Pro 545	CGA Arg	GGC Gly	AAC Asn	TGG Trp	TTC Phe 550	GGC Gly	TGT Cys	ACA Thr	TGG Trp	ATG Met 555	AAT Asn	GGC Gly	ACT Thr	GGG Gly	TTC Phe 560	1680
ACC Thr	AAG Lys	ACG Thr	TGT Cys	GGG Gly 565	GGC Gly	CCC Pro	CCG Pro	TGC Cys	AAC Asn 570	ATC Ile	GGG Gly	GGG Gly	GCC Ala	GGC Gly 575	AAC Asn	1728
AAC Asn	ACC Thr	TTG Leu 580	ACC Thr	TGC Cys	CCC Pro	ACT Thr	GAC Asp 585	TGT Cys	TTT Phe	CGG Arg	AAG Lys	CAC His 590	CCC Pro	GAG Glu	GCC Ala	1776
ACC Thr	TAC Tyr 595	GCC Ala	AGA Arg	TGC Cys	GGT Gly	TCT Ser	GGG Gly 600	CCC Pro	TGG Trp	CTG Leu	ACA Thr	CCT Pro 605	AGG Arg	TGT Cys	ATG Met	1824
GTT Val 610	CAT His	TAC Tyr	CCA Pro	TAT Tyr	AGG Arg	CTC Leu 615	TGG Trp	CAC His	TAC Tyr	CCC Pro	TGC Cys 620	ACT Thr	GTC Val	AAC Asn	TTC Phe	1872
ACC Thr 625	ATC Ile	TTC Phe	AAG Lys	GTT Val	AGG Arg 630	ATG Met	TAC Tyr	GTG Val	GGG Gly	GGC Gly 635	GTG Val	GAG Glu	CAC His	AGG Arg	TTC Phe 640	1920
GAA Glu	GCC Ala	GCA Ala	TGC Cys	AAT Asn 645	TGG Trp	ACT Thr	CGA Arg	GGA Gly	GAG Glu 650	CGT Arg	TGT Cys	GAC Asp	TTG Leu	GAG Glu 655	GAC Asp	1968
AGG Arg	GAT Asp	AGA Arg	TCA Ser 660	GAG Glu	CTT Leu	AGC Ser	CCG Pro	CTG Leu 665	CTG Leu	CTG Leu	TCT Ser	ACA Thr 670	ACA Thr	GAG Glu	TGG Trp	2016

CAG ATA CTG CCC TGT TCC TTC ACC ACC CTG CCG GCC CTA TCC ACC GGC Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly 675 680 685	2064
CTG ATC CAC CTC CAT CAG AAC ATC GTG GAC GTG CAA TAC CTG TAC GGT Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly 690 695 700	2112
GTA GGG TCG GCG GTT GTC TCC CTT GTC ATC AAA TGG GAG TAT GTC CTG Val Gly Ser Ala Val Val Ser Leu Val Ile Lys Trp Glu Tyr Val Leu 705 710 715 720	2160
TTG CTC TTC CTT CTC CTG GCA GAC GCG CGC ATC TGC GCC TGC TTA TGG Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu Trp 725 730 735	2208
ATG ATG CTG CTG ATA GCT CAA GCT GAG GCC GCC TTA GAG AAC CTG GTG Met Met Leu Leu Ile Ala Gln Ala Glu Ala Ala Leu Glu Asn Leu Val 740 745 750	2256
GTC CTC AAT GCG GCG GCC GTG GCC GGG GCG CAT GGC ACT CTT TCC TTC Val Leu Asn Ala Ala Ala Val Ala Gly Ala His Gly Thr Leu Ser Phe 755 760 765	2304
CTT GTG TTC TTC TGT GCT GCC TGG TAC ATC AAG GGC AGG CTG GTC CCT Leu Val Phe Phe Cys Ala Ala Trp Tyr Ile Lys Gly Arg Leu Val Pro 770 775 780	2352
GGT GCG GCA TAC GCC TTC TAT GGC GTG TGG CCG CTG CTC CTG CTT CTG Gly Ala Ala Tyr Ala Phe Tyr Gly Val Trp Pro Leu Leu Leu Leu Leu 785 790 795 800	2400
CTG GCC TTA CCA CCA CGA GCT TAT GCC TAGTAA Leu Ala Leu Pro Pro Arg Ala Tyr Ala 805 810	2433

(2) INFORMATION FOR SEQ ID NO: 50:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 809 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

Met	Ser	Thr	Asn	Pro	Lys	Pro	Gln	Arg	Lys	Thr	Lys	Arg	Asn	Thr	Asn	
1				5					10					15		
Arg	Arg	Pro	Gln	Asp	Val	Lys	Phe	Pro	Gly	Gly	Gly	Gln	Ile	Val	Gly	
			20					25					30			
Gly	Val	Tyr	Leu	Leu	Pro	Arg	Arg	Gly	Pro	Arg	Leu	Gly	Val	Arg	Ala	
			35				40					45				
Thr	Arg	Lys	Thr	Ser	Glu	Arg	Ser	Gln	Pro	Arg	Gly	Arg	Arg	Gln	Pro	
			50			55					60					
Ile	Pro	Lys	Ala	Arg	Arg	Pro	Glu	Gly	Arg	Ala	Trp	Ala	Gln	Pro	Gly	
65				70				75						80		

Tyr	Pro	Trp	Pro	Leu 85	Tyr	Gly	Asn	Glu	Gly 90	Met	Gly	Trp	Ala	Gly 95	Trp
Leu	Leu	Ser	Pro 100	Arg	Gly	Ser	Arg	Pro 105	Ser	Trp	Gly	Pro	Thr 110	Asp	Pro
Arg	Arg	Arg 115	Ser	Arg	Asn	Leu	Gly 120	Lys	Val	Ile	Asp	Thr 125	Leu	Thr	Cys
Gly	Phe 130	Ala	Asp	Leu	Val	Gly 135	Tyr	Ile	Pro	Leu	Val 140	Gly	Ala	Pro	Leu
Gly 145	Gly	Ala	Ala	Arg	Ala 150	Leu	Ala	His	Gly	Val 155	Arg	Val	Leu	Glu	Asp 160
Gly	Val	Asn	Tyr	Ala 165	Thr	Gly	Asn	Leu	Pro 170	Gly	Cys	Ser	Phe	Ser 175	Ile
Phe	Leu	Leu	Ala 180	Leu	Leu	Ser	Cys	Leu 185	Thr	Val	Pro	Ala	Ser 190	Ala	Tyr
Glu	Val	Arg 195	Asn	Val	Ser	Gly	Met 200	Tyr	His	Val	Thr	Asn 205	Asp	Cys	Ser
Asn	Ser 210	Ser	Ile	Val	Tyr	Glu 215	Ala	Ala	Asp	Met	Ile 220	Met	His	Thr	Pro
Gly 225	Cys	Val	Pro	Cys	Val 230	Arg	Glu	Asn	Asn 235	Ser	Ser	Arg	Cys	Trp	Val 240
Ala	Leu	Thr	Pro	Thr 245	Leu	Ala	Ala	Arg	Asn 250	Ala	Ser	Val	Pro	Thr 255	Thr
Thr	Ile	Arg	Arg 260	His	Val	Asp	Leu	Leu 265	Val	Gly	Ala	Ala	Ala 270	Phe	Cys
Ser	Ala	Met 275	Tyr	Val	Gly	Asp	Leu 280	Cys	Gly	Ser	Val	Phe 285	Leu	Val	Ser
Gln	Leu 290	Phe	Thr	Ile	Ser	Pro 295	Arg	Arg	His	Glu	Thr 300	Val	Gln	Asp	Cys
Asn 305	Cys	Ser	Ile	Tyr	Pro 310	Gly	His	Ile	Thr	Gly 315	His	Arg	Met	Ala	Trp 320
Asp	Met	Met	Met	Asn 325	Trp	Ser	Pro	Thr	Thr 330	Ala	Leu	Val	Val	Ser 335	Gln
Leu	Leu	Arg	Ile 340	Pro	Gln	Ala	Val	Val 345	Asp	Met	Val	Ala	Gly 350	Ala	His
Trp	Gly	Val 355	Leu	Ala	Gly	Leu	Ala 360	Tyr	Tyr	Ser	Met	Val 365	Gly	Asn	Trp
Ala	Lys 370	Val	Leu	Val	Val	Met 375	Leu	Leu	Phe	Ala	Gly 380	Val	Asp	Gly	His
Thr 385	Arg	Val	Ser	Gly	Gly 390	Ala	Ala	Ala	Ser	Asp 395	Thr	Arg	Gly	Leu	Val 400

Ser Leu Phe Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr
405 410 415

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser
420 425 430

Leu Gln Thr Gly Phe Phe Ala Ala Leu Phe Tyr Lys His Lys Phe Asn
435 440 445

Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Ser Ile Asp Lys
450 455 460

Phe Ala Gln Gly Trp Gly Pro Leu Thr Tyr Thr Glu Pro Asn Ser Ser
465 470 475 480

Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile
485 490 495

Val Pro Ala Ser Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser
500 505 510

Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Asn
515 520 525

Trp Gly Ala Asn Asp Ser Asp Val Leu Ile Leu Asn Asn Thr Arg Pro
530 535 540

Pro Arg Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Gly Thr Gly Phe
545 550 555 560

Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ala Gly Asn
565 570 575

Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala
580 585 590

Thr Tyr Ala Arg Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Met
595 600 605

Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe
610 615 620

Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Phe
625 630 635 640

Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu Asp
645 650 655

Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp
660 665 670

Gln Ile Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly
675 680 685

Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr Gly
690 695 700

Val Gly Ser Ala Val Val Ser Leu Val Ile Lys Trp Glu Tyr Val Leu
705 710 715 720

Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Ile Cys Ala Cys Leu Trp

CCCTG 2626680

735

Leu Ala Leu Pro Pro Arg Ala Tyr Ala
805

Gly Gly Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp

1 5 10 15

Ser Pro Thr Thr Ala Leu
20

(2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1..37

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

Tyr Glu Val Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys
1 5 10 15
Ser Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr
20 25 30
Pro Gly Cys Gly Lys
35

(2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1..25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

Gly Gly Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Ala Thr
1 5 10 15
Gln Leu Arg Arg His Ile Asp Leu Leu
20 25

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 amino acids
- (B) TYPE: amino acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: 1..25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

Gly Gly Thr Pro Thr Leu Ala Ala Arg Asp Ala Ser Val Pro Thr Thr
1 5 10 15
Thr Ile Arg Arg His Val Asp Leu Leu
20 25

(2) INFORMATION FOR SEQ ID NO: 56:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Gln Val Arg Asn
1 5 10 15
Ser Thr Gly Leu
20

(2) INFORMATION FOR SEQ ID NO: 57:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

Gln Val Arg Asn Ser Thr Gly Leu Tyr His Val Thr Asn Asp Cys Pro
1 5 10 15
Asn Ser Ser Ile
20

(2) INFORMATION FOR SEQ ID NO: 58:

08998757.004997
262769 2928680

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

Asn Asp Cys Pro Asn Ser Ser Ile Val Tyr Glu Ala His Asp Ala Ile
1 5 10 15

Leu His Thr Pro
 20

(2) INFORMATION FOR SEQ ID NO: 59:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

Ser Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr
1 5 10 15

Pro Gly Cys Val
 20

(2) INFORMATION FOR SEQ ID NO: 60:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

His Asp Ala Ile Leu His Thr Pro Gly Val Pro Cys Val Arg Glu Gly
1 5 10 15

Asn Val Ser

(2) INFORMATION FOR SEQ ID NO: 61:

- (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

Cys Val Arg Glu Gly Asn Val Ser Arg Cys Trp Val Ala Met Thr Pro
1 5 10 15

Thr Val Ala Thr
20

(2) INFORMATION FOR SEQ ID NO: 62:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

Ala Met Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Ala Thr
1 5 10 15

Gln Leu Arg Arg
20

(2) INFORMATION FOR SEQ ID NO: 63:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

Leu Pro Ala Thr Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser
1 5 10 15

Ala Thr Leu Cys
20

(2) INFORMATION FOR SEQ ID NO: 64:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 amino acids
 - (B) TYPE: amino acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

Leu Val Gly Ser Ala Thr Leu Cys Ser Ala Leu Tyr Val Gly Asp Leu
1 5 10 15
Cys Gly Ser Val
 20

(2) INFORMATION FOR SEQ ID NO: 65:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Gly Cys
1 5 10 15
Asn Cys Ser Ile
 20

(2) INFORMATION FOR SEQ ID NO: 66:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

Thr Gln Gly Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His
1 5 10 15
Arg Met Ala Trp
 20

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp Ser Pro
1 5 10 15

Thr Ala Ala Leu
20

(2) INFORMATION FOR SEQ ID NO: 68:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

Asn Trp Ser Pro Thr Ala Ala Leu Val Met Ala Gln Leu Leu Arg Ile
1 5 10 15

Pro Gln Ala Ile
20

(2) INFORMATION FOR SEQ ID NO: 69:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

Leu Leu Arg Ile Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His
1 5 10 15

Trp Gly Val Leu
20

(2) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:

Ala Gly Ala His Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met
1 5 10 15
Val Gly Asn Met
20

(2) INFORMATION FOR SEQ ID NO: 71:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu Thr Ile Val Ser
1 5 10 15
Gly Gly Gln Ala
20

(2) INFORMATION FOR SEQ ID NO: 72:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

Ser Gly Leu Val Ser Leu Phe Thr Pro Gly Ala Lys Gln Asn Ile Gln
1 5 10 15
Leu Ile Asn Thr
20

(2) INFORMATION FOR SEQ ID NO: 73:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:

Gln Asn Ile Gln Leu Ile Asn Thr Asn Gly Gln Trp His Ile Asn Ser
1 5 10 15
Thr Ala Leu Asn
 20

(2) INFORMATION FOR SEQ ID NO: 74:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:

Leu Asn Cys Asn Glu Ser Leu Asn Thr Gly Trp Trp Leu Ala Gly Leu
1 5 10 15
Ile Tyr Gln His Lys
 20

(2) INFORMATION FOR SEQ ID NO: 75:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75:

Ala Gly Leu Ile Tyr Gln His Lys Phe Asn Ser Ser Gly Cys Pro Glu
1 5 10 15
Arg Leu Ala Ser
 20

(2) INFORMATION FOR SEQ ID NO: 76:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

20250915 15:28:58

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:

Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Pro Leu Thr Asp Phe Asp
1 5 10 15
Gln Gly Trp Gly
 20

(2) INFORMATION FOR SEQ ID NO: 77:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77:

Thr Asp Phe Asp Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser
1 5 10 15
Gly Pro Asp Gln
 20

(2) INFORMATION FOR SEQ ID NO: 78:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:

Ala Asn Gly Ser Gly Pro Asp Gln Arg Pro Tyr Cys Trp His Tyr Pro
1 5 10 15
Pro Lys Pro Cys
 20

(2) INFORMATION FOR SEQ ID NO: 79:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:

Trp His Tyr Pro Pro Lys Pro Cys Gly Ile Val Pro Ala Lys Ser Val
1 5 10 15
Cys Gly Pro Val
20

(2) INFORMATION FOR SEQ ID NO: 80:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80:

Ala Lys Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val
1 5 10 15
Val Val Gly Thr
20

(2) INFORMATION FOR SEQ ID NO: 81:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:

Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Ser Gly Ala Pro Thr
1 5 10 15
Tyr Ser Trp Gly
20

(2) INFORMATION FOR SEQ ID NO: 82:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

[illegible]

```
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82:
Gly Ala Pro Thr Tyr Ser Trp Gly Glu Asn Asp Thr Asp Val Phe Val
1          5          10          15
Leu Asn Asn Thr
          20
```

(2) INFORMATION FOR SEQ ID NO: 83:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83:

Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe Thr Lys
1 5 10 15
Val Cys Gly Ala
20

(2) INFORMATION FOR SEQ ID NO: 84:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84:

Gly Phe Thr Lys Val Cys Gly Ala Pro Pro Val Cys Ile Gly Gly Ala
1 5 10 15
Gly Asn Asn Thr
20

(2) INFORMATION FOR SEQ ID NO: 85:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85:

Ile Gly Gly Ala Gly Asn Asn Thr Leu His Cys Pro Thr Asp Cys Arg
1 5 10 15

Lys His Pro

(2) INFORMATION FOR SEQ ID NO: 86:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86:

Thr Asp Cys Phe Arg Lys His Pro Asp Ala Thr Tyr Ser Arg Cys Gly
1 5 10 15

Ser Gly Pro Trp
20

(2) INFORMATION FOR SEQ ID NO: 87:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87:

Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Leu Val Asp
1 5 10 15

Tyr Pro Tyr Arg
20

(2) INFORMATION FOR SEQ ID NO: 88:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88:

Cys Leu Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Ile

1 5 10 15
Asn Tyr Thr Ile
 20

(2) INFORMATION FOR SEQ ID NO: 89:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89:

Pro Cys Thr Ile Asn Tyr Thr Ile Phe Lys Ile Arg Met Tyr Val Gly
1 5 10 15

Gly Val Glu His
 20

(2) INFORMATION FOR SEQ ID NO: 90:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90:

Met Tyr Val Gly Gly Val Glu His Arg Leu Glu Ala Ala Cys Asn Trp
1 5 10 15

Thr Pro Gly Glu
 20

(2) INFORMATION FOR SEQ ID NO: 91:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91:

Ala Cys Asn Trp Thr Pro Gly Glu Arg Cys Asp Leu Glu Asp Arg Asp
1 5 10 15

Arg Ser Glu Leu
20

(2) INFORMATION FOR SEQ ID NO: 92:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92:

Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Thr Thr Thr
1 5 10 15

Gln Trp Gln Val
20

(2) INFORMATION FOR SEQ ID NO: 93:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93:

Tyr Gln Val Arg Asn Ser Thr Gly Leu
1 5

(2) INFORMATION FOR SEQ ID NO: 94:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94:

ACGTCCGTAC GTTCGAATTA ATTAATCGA

(2) INFORMATION FOR SEQ ID NO: 95:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 60 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95:

CCTCCGGACG TGCCTAGCT CCCGTCTGTG GTAGTGGTGG TAGTGATTAT CAATTAATTG

60

(2) INFORMATION FOR SEQ ID NO: 96:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96:

GTTTAACCAC TGCATGATG

19

(2) INFORMATION FOR SEQ ID NO: 97:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 97:

GTCCCATCGA GTGCGGCTAC

20

(2) INFORMATION FOR SEQ ID NO: 98:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 45 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 98:

CGTGACATGG TACATTCCGG ACACTTGGCG CACTTCATAA GCGGA

45

(2) INFORMATION FOR SEQ ID NO: 99:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 42 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99:

TGCCTCATAC ACAATGGAGC TCTGGGACGA GTCGTTCTGTG AC

42

(2) INFORMATION FOR SEQ ID NO: 100:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 42 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100:

TACCCAGCAG CGGGAGCTCT GTTGCTCCCG AACGCAGGGC AC

42

(2) INFORMATION FOR SEQ ID NO: 101:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 101:

TGTCGTGGTG GGGACGGAGG CCTGCCTAGC TGCGAGCGTG GG

42

(2) INFORMATION FOR SEQ ID NO: 102:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102:

CGTTATGTGG CCCGGGTAGA TTGAGCACTG GCAGTCCTGC ACCGTCTC

48

(2) INFORMATION FOR SEQ ID NO: 103:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103:

CAGGGCCGTT CTAGGCCTCC ACTGCATCAT CATATCCCAA GC

42

(2) INFORMATION FOR SEQ ID NO: 104:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104:

CCGGAATGTA CCATGTCACG AACGAC

26

(2) INFORMATION FOR SEQ ID NO: 105:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105:

GCTCCATTGT GTATGAGGCA GCGG

24

(2) INFORMATION FOR SEQ ID NO: 106:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 106:

GAGCTCCCGC TGCTGGGTAG CGC

23

(2) INFORMATION FOR SEQ ID NO: 107:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107:

CCTCCGTCCC CACCACGACA ATACG

25

(2) INFORMATION FOR SEQ ID NO: 108:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108:

CTACCCGGGC CACATAACGG GTCACCG

27

(2) INFORMATION FOR SEQ ID NO: 109:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109:

GGAGGCCTAC AACGGCCCTG GTGG

24

(2) INFORMATION FOR SEQ ID NO: 110:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 22 base pairs

[illegible]

(iii) ANTI-SENSE: NO

TTCTATCGAT TAAATAGAAT TC

22

(i) SEQUENCE CHARACTERISTICS:

(ii) MOLECULE TYPE: DNA (genomic)

(iii) ANTI-SENSE: NO

GCCATACGCT CACAGCCGAT CCC

23

PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND
THERAPEUTIC USE

5 Field of the invention

The present invention relates to the general fields of recombinant protein expression, purification of recombinant proteins, synthetic peptides, diagnosis of HCV infection, prophylactic treatment against HCV infection and to the prognosis/monitoring of the clinical efficiency of treatment of an individual with chronic hepatitis, or the prognosis/monitoring of natural disease.

More particularly, the present invention relates to purification methods for hepatitis C virus envelope proteins, the use in diagnosis, prophylaxis or therapy of HCV envelope proteins purified according to the methods described in the present invention, the use of single or specific oligomeric E1 and/or E2 and/or E1/E2 envelope proteins in assays for monitoring disease, and/or diagnosis of disease, and/or treatment of disease. The invention also relates to epitopes of the E1 and/or E2 envelope proteins and monoclonal antibodies thereto, as well their use in diagnosis, prophylaxis or treatment.

20 Background of the invention

The E2 protein purified from cell lysates according to the methods described in the present invention reacts with approximately 95% of patient sera. This reactivity is similar to the reactivity obtained with E2 secreted from CHO cells (Spaete et al., 1992). However, the intracellularly expressed form of E2 may more closely resemble the native viral envelope protein because it contains high mannose carbohydrate motifs, whereas the E2 protein secreted from CHO cells is further modified with galactose and sialic acid sugar moieties. When the aminoterminal half of E2 is expressed in the baculovirus system, only about 13 to 21% of sera from several patient groups can be detected (Inoue et al., 1992). After expression of E2 from E. coli, the reactivity of HCV sera was even lower and ranged from 14 (Yokosuka et al., 1992) to 17% (Mita et al., 1992).

About 75% of HCV sera (and 95% of chronic patients) are anti-E1 positive using the purified, vaccinia-expressed recombinant E1 protein of the present invention, in sharp contrast with the results of Kohara et al. (1992) and Hsu et al. (1993). Kohara

et al. used a vaccinia-virus expressed E1 protein and detected anti-E1 antibodies in 7 to 23% of patients, while Hsu²et al. only detected 14/50 (28%) sera using baculovirus-expressed E1.

These results show that not only a good expression system but also a good purification protocol are required to reach a high reactivity of the envelope proteins with human patient sera. This can be obtained using the proper expression system and/or purification protocols of the present invention which guarantee the conservation of the natural folding of the protein and the purification protocols of the present invention which guarantee the elimination of contaminating proteins and which preserve the conformation, and thus the reactivity of the HCV envelope proteins. The amounts of purified HCV envelope protein needed for diagnostic screening assays are in the range of grams per year. For vaccine purposes, even higher amounts of envelope protein would be needed. Therefore, the vaccinia virus system may be used for selecting the best expression constructs and for limited upscaling, and large-scale expression and purification of single or specific oligomeric envelope proteins containing high-mannose carbohydrates may be achieved when expressed from several yeast strains. In the case of hepatitis B for example, manufacturing of HBsAg from mammalian cells was much more costly compared with yeast-derived hepatitis B vaccines.

Aims of the invention

It is an aim of the present invention to provide a new purification method for recombinantly expressed E1 and/or E2 and/or E1/E2 proteins such that said recombinant proteins are directly usable for diagnostic and vaccine purposes as single or specific oligomeric recombinant proteins free from contaminants instead of aggregates.

It is another aim of the present invention to provide compositions comprising purified (single or specific oligomeric) recombinant E1 and/or E2 and/or E1/E2 glycoproteins comprising conformational epitopes from the E1 and/or E2 domains of HCV.

It is yet another aim of the present invention to provide novel recombinant vector constructs for recombinantly expressing E1 and/or E2 and/or E1/E2 proteins, as well as host cells transformed with said vector constructs.

It is also an aim of the present invention to provide a method for producing and purifying recombinant HCV E1 and/or E2 and/or E1/E2 proteins.

It is also an aim of the present invention to provide diagnostic and immunogenic uses of the recombinant HCV E1 and/or E2 and/or E1/E2 proteins of the present invention, as well as to provide kits for diagnostic use, vaccines or therapeutics comprising any of the recombinant HCV E1 and/or E2 and/or E1/E2 proteins of the present invention.

It is further an aim of the present invention to provide for a new use of E1, E2, and/or E1/E2 proteins, or suitable parts thereof, for monitoring/prognosing the response to treatment of patients (e.g. with interferon) suffering from HCV infection.

It is also an aim of the present invention to provide for the use of the recombinant E1, E2, and/or E1/E2 proteins of the present invention in HCV screening and confirmatory antibody tests.

It is also an aim of the present invention to provide E1 and/or E2 peptides which can be used for diagnosis of HCV infection and for raising antibodies. Such peptides may also be used to isolate human monoclonal antibodies.

It is also an aim of the present invention to provide monoclonal antibodies, more particularly human monoclonal antibodies or mouse monoclonal antibodies which are humanized, which react specifically with E1 and/or E2 epitopes, either comprised in peptides or conformational epitopes comprised in recombinant proteins.

It is also an aim of the present invention to provide possible uses of anti-E1 or anti-E2 monoclonal antibodies for HCV antigen detection or for therapy of chronic HCV infection.

It is also an aim of the present invention to provide kits for monitoring/prognosing the response to treatment (e.g. with interferon) of patients suffering from HCV infection or monitoring/prognosing the outcome of the disease.

All the aims of the present invention are considered to have been met by the embodiments as set out below.

Definitions

The following definitions serve to illustrate the different terms and expressions used in the present invention.

The term 'hepatitis C virus single envelope protein' refers to a polypeptide or an analogue thereof (e.g. mimotopes) comprising an amino acid sequence (and/or amino acid analogues) defining at least one HCV epitope of either the E1 or the E2 region.

These single envelope proteins in the broad sense of the word may be both monomeric or homo-oligomeric forms of recombinantly expressed envelope proteins. Typically, the sequences defining the epitope correspond to the amino acid sequence of either the E1 or the E2 region of HCV (either identically or via substitution of analogues of the native amino acid residue that do not destroy the epitope). In general, the epitope-defining sequence will be 3 or more amino acids in length, more typically, 5 or more amino acids in length, more typically 8 or more amino acids in length, and even more typically 10 or more amino acids in length. With respect to conformational epitopes, the length of the epitope-defining sequence can be subject to wide variations, since it is believed that these epitopes are formed by the three-dimensional shape of the antigen (e.g. folding). Thus, the amino acids defining the epitope can be relatively few in number, but widely dispersed along the length of the molecule being brought into the correct epitope conformation via folding. The portions of the antigen between the residues defining the epitope may not be critical to the conformational structure of the epitope. For example, deletion or substitution of these intervening sequences may not affect the conformational epitope provided sequences critical to epitope conformation are maintained (e.g. cysteines involved in disulfide bonding, glycosylation sites, etc.). A conformational epitope may also be formed by 2 or more essential regions of subunits of a homooligomer or heterooligomer.

The HCV antigens of the present invention comprise conformational epitopes from the E1 and/or E2 (envelope) domains of HCV. The E1 domain, which is believed to correspond to the viral envelope protein, is currently estimated to span amino acids 192-383 of the HCV polyprotein (Hijikata et al., 1991). Upon expression in a mammalian system (glycosylated), it is believed to have an approximate molecular weight of 35 kDa as determined via SDS-PAGE. The E2 protein, previously called NS1, is believed to span amino acids 384-809 or 384-746 (Grakoui et al., 1993) of the HCV polyprotein and to also be an envelope protein. Upon expression in a vaccinia system (glycosylated), it is believed to have an apparent gel molecular weight of about 72 kDa. It is understood that these protein endpoints are approximations (e.g. the carboxy terminal end of E2 could lie somewhere in the 730-820 amino acid region, e.g. ending at amino acid 730, 735, 740, 742, 744, 745, preferably 746, 747, 748, 750, 760, 770, 780, 790, 800, 809, 810, 820). The E2 protein may also be expressed together with the E1, P7 (aa 747-809), NS2 (aa 810-1026), NS4A (aa 1658-1711) or NS4B (aa 1712-1972). Expression together with these other HCV proteins may be important for

obtaining the correct protein folding.

It is also understood that the isolates used in the examples section of the present invention were not intended to limit the scope of the invention and that any HCV isolate from type 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or any other new genotype of HCV is a suitable source of E1 and/or E2 sequence for the practice of the present invention.

The E1 and E2 antigens used in the present invention may be full-length viral proteins, substantially full-length versions thereof, or functional fragments thereof (e.g. fragments which are not missing sequence essential to the formation or retention of an epitope). Furthermore, the HCV antigens of the present invention can also include other sequences that do not block or prevent the formation of the conformational epitope of interest. The presence or absence of a conformational epitope can be readily determined though screening the antigen of interest with an antibody (polyclonal serum or monoclonal to the conformational epitope) and comparing its reactivity to that of a denatured version of the antigen which retains only linear epitopes (if any). In such screening using polyclonal antibodies, it may be advantageous to adsorb the polyclonal serum first with the denatured antigen and see if it retains antibodies to the antigen of interest.

The HCV antigens of the present invention can be made by any recombinant method that provides the epitope of interest. For example, recombinant intracellular expression in mammalian or insect cells is a preferred method to provide glycosylated E1 and/or E2 antigens in 'native' conformation as is the case for the natural HCV antigens. Yeast cells and mutant yeast strains (e.g. mnn 9 mutant (Kniskern et al., 1994) or glycosylation mutants derived by means of vanadate resistance selection (Baillou et al., 1991)) may be ideally suited for production of secreted high-mannose-type sugars; whereas proteins secreted from mammalian cells may contain modifications including galactose or sialic acids which may be undesirable for certain diagnostic or vaccine applications. However, it may also be possible and sufficient for certain applications, as it is known for proteins, to express the antigen in other recombinant hosts (such as *E. coli*) and renature the protein after recovery.

The term 'fusion polypeptide' intends a polypeptide in which the HCV antigen(s) are part of a single continuous chain of amino acids, which chain does not occur in nature. The HCV antigens may be connected directly to each other by peptide bonds or be separated by intervening amino acid sequences. The fusion polypeptides may also contain amino acid sequences exogenous to HCV.

The term 'solid phase' intends a solid body to which the individual HCV antigens or the fusion polypeptide comprised of HCV antigens are bound covalently or by noncovalent means such as hydrophobic adsorption.

5 The term 'biological sample' intends a fluid or tissue of a mammalian individual (e.g. an anthropoid, a human) that commonly contains antibodies produced by the individual, more particularly antibodies against HCV. The fluid or tissue may also contain HCV antigen. Such components are known in the art and include, without limitation, blood, plasma, serum, urine, spinal fluid, lymph fluid, secretions of the respiratory, intestinal or genitourinary tracts, tears, saliva, milk, white blood cells and myelomas.
10 Body components include biological liquids. The term 'biological liquid' refers to a fluid obtained from an organism. Some biological fluids are used as a source of other products, such as clotting factors (e.g. Factor VIII;C), serum albumin, growth hormone and the like. In such cases, it is important that the source of biological fluid be free of contamination by virus such as HCV.

15 The term 'immunologically reactive' means that the antigen in question will react specifically with anti-HCV antibodies present in a body component from an HCV infected individual.

The term 'immune complex' intends the combination formed when an antibody binds to an epitope on an antigen.

20 'E1' as used herein refers to a protein or polypeptide expressed within the first 400 amino acids of an HCV polyprotein, sometimes referred to as the E, ENV or S protein. In its natural form it is a 35 kDa glycoprotein which is found in strong association with membranes. In most natural HCV strains, the E1 protein is encoded in the viral polyprotein following the C (core) protein. The E1 protein extends from
25 approximately amino acid (aa) 192 to about aa 383 of the full-length polyprotein.

The term 'E1' as used herein also includes analogs and truncated forms that are immunologically cross-reactive with natural E1, and includes E1 proteins of genotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or any other newly identified HCV type or subtype.

30 'E2' as used herein refers to a protein or polypeptide expressed within the first 900 amino acids of an HCV polyprotein, sometimes referred to as the NS1 protein. In its natural form it is a 72 kDa glycoprotein that is found in strong association with membranes. In most natural HCV strains, the E2 protein is encoded in the viral polyprotein following the E1 protein. The E2 protein extends from approximately amino acid position 384 to amino acid position 746, another form of E2 extends to amino acid

position 809. The term 'E2' as used herein also includes analogs and truncated forms that are immunologically cross-reactive with natural E2. For example, insertions of multiple codons between codon 383 and 384, as well as deletions of amino acids 384-387 have been reported by Kato et al. (1992).

5 'E1/E2' as used herein refers to an oligomeric form of envelope proteins containing at least one E1 component and at least one E2 component.

The term 'specific oligomeric' E1 and/or E2 and/or E1/E2 envelope proteins refers to all possible oligomeric forms of recombinantly expressed E1 and/or E2 envelope proteins which are not aggregates. E1 and/or E2 specific oligomeric envelope proteins are also referred to as homo-oligomeric E1 or E2 envelope proteins (see below).

10 The term 'single or specific oligomeric' E1 and/or E2 and/or E1/E2 envelope proteins refers to single monomeric E1 or E2 proteins (single in the strict sense of the word) as well as specific oligomeric E1 and/or E2 and/or E1/E2 recombinantly expressed proteins. These single or specific oligomeric envelope proteins according to the present invention can be further defined by the following formula $(E1)_x(E2)_y$ wherein x can be a number between 0 and 100, and y can be a number between 0 and 100, provided that x and y are not both 0. With x=1 and y=0 said envelope proteins include monomeric E1.

15 The term 'homo-oligomer' as used herein refers to a complex of E1 and/or E2 containing more than one E1 or E2 monomer, e.g. E1/E1 dimers, E1/E1/E1 trimers or E1/E1/E1/E1 tetramers and E2/E2 dimers, E2/E2/E2 trimers or E2/E2/E2/E2 tetramers, E1 pentamers and hexamers, E2 pentamers and hexamers or any higher-order homo-oligomers of E1 or E2 are all 'homo-oligomers' within the scope of this definition. The oligomers may contain one, two, or several different monomers of E1 or E2 obtained from different types or subtypes of hepatitis C virus including for example those described in an international application published under WO 94/25601 and European application No. 94870166.9 both by the present applicants. Such mixed oligomers are still homo-oligomers within the scope of this invention, and may allow more universal diagnosis, prophylaxis or treatment of HCV.

25 The term 'purified' as applied to proteins herein refers to a composition wherein the desired protein comprises at least 35% of the total protein component in the composition. The desired protein preferably comprises at least 40%, more preferably at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, even more preferably at least about 80%, even more preferably at least

about 90%, and most preferably at least about 95% of the total protein component. The composition may contain other compounds such as carbohydrates, salts, lipids, solvents, and the like, without affecting the determination of the percentage purity as used herein. An 'isolated' HCV protein intends an HCV protein composition that is at least 35% pure.

The term 'essentially purified proteins' refers to proteins purified such that they can be used for in vitro diagnostic methods and as a therapeutic compound. These proteins are substantially free from cellular proteins, vector-derived proteins or other HCV viral components. Usually these proteins are purified to homogeneity (at least 80% pure, preferably, 90%, more preferably 95%, more preferably 97%, more preferably 98%, more preferably 99%, even more preferably 99.5%, and most preferably the contaminating proteins should be undetectable by conventional methods like SDS-PAGE and silver staining.

The term 'recombinantly expressed' used within the context of the present invention refers to the fact that the proteins of the present invention are produced by recombinant expression methods be it in prokaryotes, or lower or higher eukaryotes as discussed in detail below.

The term 'lower eukaryote' refers to host cells such as yeast, fungi and the like. Lower eukaryotes are generally (but not necessarily) unicellular. Preferred lower eukaryotes are yeasts, particularly species within Saccharomyces, Schizosaccharomyces, Kluveromyces, Pichia (e.g. Pichia pastoris), Hansenula (e.g. Hansenula polymorpha), Yarrowia, Schwaniomyces, Schizosaccharomyces, Zygosaccharomyces and the like. Saccharomyces cerevisiae, S. carlsbergensis and K. lactis are the most commonly used yeast hosts, and are convenient fungal hosts.

The term 'prokaryotes' refers to hosts such as E.coli, Lactobacillus, Lactococcus, Salmonella, Streptococcus, Bacillus subtilis or Streptomyces. Also these hosts are contemplated within the present invention.

The term 'higher eukaryote' refers to host cells derived from higher animals, such as mammals, reptiles, insects, and the like. Presently preferred higher eukaryote host cells are derived from Chinese hamster (e.g. CHO), monkey (e.g. COS and Vero cells), baby hamster kidney (BHK), pig kidney (PK15), rabbit kidney 13 cells (RK13), the human osteosarcoma cell line 143 B, the human cell line HeLa and human hepatoma cell lines like Hep G2, and insect cell lines (e.g. Sitotroterus frugiperda). The host cells may be provided in suspension or flask cultures, tissue cultures, organ cultures and the like.

Alternatively the host cells may also be transgenic animals.

5 The term 'polypeptide' refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogues of an amino acid (including, for example, 10 unnatural amino acids, PNA, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

15 The term 'recombinant polynucleotide or nucleic acid' intends a polynucleotide or nucleic acid of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation : (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is linked in nature, or (3) does not occur in nature.

20 The term 'recombinant host cells', 'host cells', 'cells', 'cell lines', 'cell cultures', and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities refer to cells which can be or have been, used as recipients for a recombinant vector or other transfer polynucleotide, and include the progeny of the original cell which has been transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.

25 The term 'replicon' is any genetic element, e.g., a plasmid, a chromosome, a virus, a cosmid, etc., that behaves as an autonomous unit of polynucleotide replication within a cell; i.e., capable of replication under its own control.

The term 'vector' is a replicon further comprising sequences providing replication and/or expression of a desired open reading frame.

30 The term 'control sequence' refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and terminators; in eukaryotes, generally, such control sequences include promoters, terminators and, in some instances, enhancers. The term 'control sequences' is intended

to include, at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences which govern secretion.

5 The term 'promoter' is a nucleotide sequence which is comprised of consensus sequences which allow the binding of RNA polymerase to the DNA template in a manner such that mRNA production initiates at the normal transcription initiation site for the adjacent structural gene.

10 The expression 'operably linked' refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence 'operably linked' to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

15 An 'open reading frame' (ORF) is a region of a polynucleotide sequence which encodes a polypeptide and does not contain stop codons; this region may represent a portion of a coding sequence or a total coding sequence.

20 A 'coding sequence' is a polynucleotide sequence which is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation stop codon at the 3'-terminus. A coding sequence can include but is not limited to mRNA, DNA (including cDNA), and recombinant polynucleotide sequences.

25 As used herein, 'epitope' or 'antigenic determinant' means an amino acid sequence that is immunoreactive. Generally an epitope consists of at least 3 to 4 amino acids, and more usually, consists of at least 5 or 6 amino acids, sometimes the epitope consists of about 7 to 8, or even about 10 amino acids. As used herein, an epitope of a designated polypeptide denotes epitopes with the same amino acid sequence as the epitope in the designated polypeptide, and immunologic equivalents thereof. Such equivalents also include strain, subtype (=genotype), or type(group)-specific variants, e.g. of the currently known sequences or strains belonging to genotypes 1a, 1b, 1c, 1d,
30 1e, 1f, 2a, 2b, 2c, 2d, 2e, 2f, 2g, 2h, 2i, 3a, 3b, 3c, 3d, 3e, 3f, 3g, 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 4j, 4k, 4l, 5a, 5b, 6a, 6b, 6c, 7a, 7b, 7c, 8a, 8b, 9a, 9b, 10a, or any other newly defined HCV (sub)type. It is to be understood that the amino acids constituting the epitope need not be part of a linear sequence, but may be interspersed by any number of amino acids, thus forming a conformational epitope.

The term 'immunogenic' refers to the ability of a substance to cause a humoral and/or cellular response, whether alone or when linked to a carrier, in the presence or absence of an adjuvant. 'Neutralization' refers to an immune response that blocks the infectivity, either partially or fully, of an infectious agent. A 'vaccine' is an immunogenic composition capable of eliciting protection against HCV, whether partial or complete. A vaccine may also be useful for treatment of an individual, in which case it is called a therapeutic vaccine.

The term 'therapeutic' refers to a composition capable of treating HCV infection.

The term 'effective amount' refers to an amount of epitope-bearing polypeptide sufficient to induce an immunogenic response in the individual to which it is administered, or to otherwise detectably immunoreact in its intended system (e.g., immunoassay). Preferably, the effective amount is sufficient to effect treatment, as defined above. The exact amount necessary will vary according to the application. For vaccine applications or for the generation of polyclonal antiserum / antibodies, for example, the effective amount may vary depending on the species, age, and general condition of the individual, the severity of the condition being treated, the particular polypeptide selected and its mode of administration, etc. It is also believed that effective amounts will be found within a relatively large, non-critical range. An appropriate effective amount can be readily determined using only routine experimentation. Preferred ranges of E1 and/or E2 and/or E1/E2 single or specific oligomeric envelope proteins for prophylaxis of HCV disease are 0.01 to 100 $\mu\text{g}/\text{dose}$, preferably 0.1 to 50 $\mu\text{g}/\text{dose}$. Several doses may be needed per individual in order to achieve a sufficient immune response and subsequent protection against HCV disease.

Detailed description of the invention

More particularly, the present invention contemplates a method for isolating or purifying recombinant HCV single or specific oligomeric envelope protein selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleaving agent.

The essence of these 'single or specific oligomeric' envelope proteins of the invention is that they are free from contaminating proteins and that they are not

disulphide bond linked with contaminants.

The proteins according to the present invention are recombinantly expressed in lower or higher eukaryotic cells or in prokaryotes. The recombinant proteins of the present invention are preferably glycosylated and may contain high-mannose-type, hybrid, or complex glycosylations. Preferentially said proteins are expressed from mammalian cell lines as discussed in detail in the Examples section, or in yeast such as in mutant yeast strains also as detailed in the Examples section.

The proteins according to the present invention may be secreted or expressed within components of the cell, such as the ER or the Golgi Apparatus. Preferably, however, the proteins of the present invention bear high-mannose-type glycosylations and are retained in the ER or Golgi Apparatus of mammalian cells or are retained in or secreted from yeast cells, preferably secreted from yeast mutant strains such as the *mnn9* mutant (Kniskern et al., 1994), or from mutants that have been selected by means of vanadate resistance (Ballou et al., 1991).

Upon expression of HCV envelope proteins, the present inventors could show that some of the free thiol groups of cysteines not involved in intra- or inter-molecular disulphide bridges, react with cysteines of host or expression-system-derived (e.g. vaccinia) proteins or of other HCV envelope proteins (single or oligomeric), and form aspecific intermolecular bridges. This results in the formation of 'aggregates' of HCV envelope proteins together with contaminating proteins. It was also shown in WO 92/08734 that 'aggregates' were obtained after purification, but it was not described which protein interactions were involved. In patent application WO 92/08734, recombinant E1/E2 protein expressed with the vaccinia virus system were partially purified as aggregates and only found to be 70% pure, rendering the purified aggregates not useful for diagnostic, prophylactic or therapeutic purposes.

Therefore, a major aim of the present invention resides in the separation of single or specific-oligomeric HCV envelope proteins from contaminating proteins, and to use the purified proteins (> 95% pure) for diagnostic, prophylactic and therapeutic purposes. To those purposes, the present inventors have been able to provide evidence that aggregated protein complexes ('aggregates') are formed on the basis of disulphide bridges and non-covalent protein-protein interactions. The present invention thus provides a means for selectively cleaving the disulphide bonds under specific conditions and for separating the cleaved proteins from contaminating proteins which greatly interfere with diagnostic, prophylactic and therapeutic applications. The free thiol groups

may be blocked (reversibly or irreversibly) in order to prevent the reformation of disulphide bridges, or may be left to oxidize and oligomerize with other envelope proteins (see definition homo-oligomer). It is to be understood that such protein oligomers are essentially different from the 'aggregates' described in WO 92/08734 and
5 WO 94/01778, since the level of contaminating proteins is undetectable.

Said disulphide bond cleavage may also be achieved by:

- (1) performic acid oxidation by means of cysteic acid in which case the cysteine residues are modified into cysteic acid (Moore et al., 1963).
- (2) Sulfitolysis ($R-S-S-R \rightarrow 2 R-SO_3^-$) for example by means of sulphite (SO_3^{2-}) together
10 with a proper oxidant such as Cu^{2+} in which case the cysteine is modified into S-sulpho-cysteine (Bailey and Cole, 1959).
- (3) Reduction by means of mercaptans, such as dithiotreitol (DDT), β -mercapto-ethanol, cysteine, glutathione Red, ϵ -mercapto-ethylamine, or thioglycolic acid, of which DTT and β -mercapto-ethanol are commonly used (Cleland, 1964), is the preferred method
15 of this invention because the method can be performed in a water environment and because the cysteine remains unmodified.
- (4) Reduction by means of a phosphine (e.g. Bu_3P) (Ruegg and Rudinger, 1977).

All these compounds are thus to be regarded as agents or means for cleaving disulphide bonds according to the present invention.

20 Said disulphide bond cleavage (or reducing) step of the present invention is preferably a partial disulphide bond cleavage (reducing) step (carried out under partial cleavage or reducing conditions).

A preferred disulphide bond cleavage or reducing agent according to the present invention is dithiothreitol (DTT). Partial reduction is obtained by using a low
25 concentration of said reducing agent, i.e. for DTT for example in the concentration range of about 0.1 to about 50 mM, preferably about 0.1 to about 20 mM, preferably about 0.5 to about 10 mM, preferably more than 1 mM, more than 2 mM or more than 5 mM, more preferably about 1.5 mM, about 2.0 mM, about 2.5 mM, about 5 mM or about 7.5 mM.


30 Said disulphide bond cleavage step may also be carried out in the presence of a suitable detergent (as an example of a means for cleaving disulphide bonds or in combination with a cleaving agent) able to dissociate the expressed proteins, such as DecylPEG, EMPIGEN-BB, NP-40, sodium cholate, Triton X-100.

Said reduction or cleavage step (preferably a partial reduction or cleavage step)

5 A particularly preferred method for obtaining disulphide bond cleavage employs a combination of a classical disulphide bond cleavage agent as detailed above and a detergent (also as detailed above). As contemplated in the Examples section, the particular combination of a low concentration of DTT (1.5 to 7.5 mM) and about 3.5 % of Empigen-BB is proven to be a particularly preferred combination of reducing agent and
0 detergent for the purification of recombinantly expressed E1 and E2 proteins. Upon gelfiltration chromatography, said partial reduction is shown to result in the production of possibly dimeric E1 protein and separation of this E1 protein from contaminating proteins that cause false reactivity upon use in immunoassays.

15

20



25

disulphide bond reforming as well as disulphide bond blocking agents.

30

- Glutathion
- 5,5'-dithiobis-(2-nitrobenzoic acid) or bis-(3-carboxy-4-nitrophenyl)-disulphide (DTNB or Ellman's reagent) (Elmann, 1959)

- N-ethylmaleimide (NEM; Benesch et al., 1956)
- N-(4-dimethylamino-3,5-dinitrophenyl) maleimide or Tuppy's maleimide which provides a color to the protein
- P-chloromercuribenzoate (Grassetti et al., 1969)
- 5 - 4-vinylpyridine (Friedman and Krull, 1969) can be liberated after reaction by acid hydrolysis
- acrylonitrile, can be liberated after reaction by acid hydrolysis (Weil and Seibles, 1961)
- NEM-biotin (e.g. obtained from Sigma B1267)
- 10 - 2,2'-dithiopyridine (Grassetti and Murray, 1967)
- 4,4'-dithiopyridine (Grassetti and Murray, 1967)
- 6,6'-dithiodinicotinic acid (DTDNA; Brown and Cunningham, 1970)
- 2,2'-dithiobis-(5'-nitropyridine) (DTNP; US patent 3597160) or other dithiobis (heterocyclic derivative) compounds (Grassetti and Murray, 1969)

15 A survey of the publications cited shows that often different reagents for sulphydryl groups will react with varying numbers of thiol groups of the same protein or enzyme molecule. One may conclude that this variation in reactivity of the thiol groups is due to the steric environment of these groups, such as the shape of the molecule and the surrounding groups of atoms and their charges, as well as to the size, shape and charge of the reagent molecule or ion. Frequently the presence of adequate concentrations of denaturants such as sodium dodecylsulfate, urea or guanidine hydrochloride will cause sufficient unfolding of the protein molecule to permit equal access to all of the reagents for thiol groups. By varying the concentration of denaturant, the degree of unfolding can be controlled and in this way thiol groups with

20 different degrees of reactivity may be revealed. Although up to date most of the work reported has been done with p-chloromercuribenzoate, N-ethylmaleimide and DTNB, it is likely that the other more recently developed reagents may prove equally useful. Because of their varying structures, it seems likely, in fact, that they may respond differently to changes in the steric environment of the thiol groups.

25 30 Alternatively, conditions such as low pH (preferably lower than pH 6) for preventing free SH groups from oxidizing and thus preventing the formation of large intermolecular aggregates upon recombinant expression and purification of E1 and E2 (envelope) proteins are also within the scope of the present invention.

A preferred SH group blocking reagent according to the present invention is N-

ethylmaleimide (NEM). Said SH group blocking reagent may be administrated during lysis of the recombinant host cells and after the above-mentioned partial reduction process or after any other process for cleaving disulphide bridges. Said SH group blocking reagent may also be modified with any group capable of providing a detectable label and/or any group aiding in the immobilization of said recombinant protein to a solid substrate, e.g. biotinylated NEM.

Methods for cleaving cysteine bridges and blocking free cysteines have also been described in Darbre (1987), Means and Feeney (1971), and by Wong (1993).

A method to purify single or specific oligomeric recombinant E1 and/or E2 and/or E1/E2 proteins according to the present invention as defined above is further characterized as comprising the following steps:

- lysing recombinant E1 and/or E2 and/or E1/E2 expressing host cells, preferably in the presence of an SH group blocking agent, such as N-ethylmaleimide (NEM), and possibly a suitable detergent, preferably Empigen-BB,
- recovering said HCV envelope protein by affinity purification for instance by means lectin-chromatography, such as lentil-lectin chromatography, or immunoaffinity chromatography using anti-E1 and/or anti-E2 specific monoclonal antibodies, followed by,
- reduction or cleavage of disulphide bonds with a disulphide bond cleaving agent, such as DTT, preferably also in the presence of an SH group blocking agent, such as NEM or Biotin-NEM, and,
- recovering the reduced HCV E1 and/or E2 and/or E1/E2 envelope proteins for instance by gelfiltration (size exclusion chromatography or molecular sieving) and possibly also by an additional Ni^{2+} -IMAC chromatography and desalting step.

It is to be understood that the above-mentioned recovery steps may also be carried out using any other suitable technique known by the person skilled in the art.

Preferred lectin-chromatography systems include Galanthus nivalis agglutinin (GNA) - chromatography, or Lens culinaris agglutinin (LCA) (lentil) lectin chromatography as illustrated in the Examples section. Other useful lectins include those recognizing high-mannose type sugars, such as Narcissus pseudonarcissus agglutinin (NPA), Pisum sativum agglutinin (PSA), or Allium ursinum agglutinin (AUA).

Preferably said method is usable to purify single or specific oligomeric HCV envelope protein produced intracellularly as detailed above.

For secreted E1 or E2 or E1/E2 oligomers, lectins binding complex sugars such

as Ricinus communis agglutinin I (RCA I), are preferred lectins.

5 The present invention more particularly contemplates essentially purified recombinant HCV single or specific oligomeric envelope proteins, selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized as being isolated or purified by a method as defined above.

The present invention more particularly relates to the purification or isolation of recombinant envelope proteins which are expressed from recombinant mammalian cells such as vaccinia.

10 The present invention also relates to the purification or isolation of recombinant envelope proteins which are expressed from recombinant yeast cells.

The present invention equally relates to the purification or isolation of recombinant envelope proteins which are expressed from recombinant bacterial (prokaryotic) cells.

15 The present invention also contemplates a recombinant vector comprising a vector sequence, an appropriate prokaryotic, eukaryotic or viral or synthetic promoter sequence followed by a nucleotide sequence allowing the expression of the single or specific oligomeric E1 and/or E2 and/or E1/E2 of the invention.

20 Particularly, the present invention contemplates a recombinant vector comprising a vector sequence, an appropriate prokaryotic, eukaryotic or viral or synthetic promoter sequence followed by a nucleotide sequence allowing the expression of the single E1 or E1 of the invention.

25 Particularly, the present invention contemplates a recombinant vector comprising a vector sequence, an appropriate prokaryotic, eukaryotic or viral or synthetic promoter sequence followed by a nucleotide sequence allowing the expression of the single E1 or E2 of the invention.

30 The segment of the HCV cDNA encoding the desired E1 and/or E2 sequence inserted into the vector sequence may be attached to a signal sequence. Said signal sequence may be that from a non-HCV source, e.g. the IgG or tissue plasminogen activator (tpa) leader sequence for expression in mammalian cells, or the α -mating factor sequence for expression into yeast cells, but particularly preferred constructs according to the present invention contain signal sequences appearing in the HCV genome before the respective start points of the E1 and E2 proteins. The segment of the HCV cDNA encoding the desired E1 and/or E2 sequence inserted into the vector may also include deletions e.g. of the hydrophobic domain(s) as illustrated in the examples section, or of

the E2 hypervariable region I.

More particularly, the recombinant vectors according to the present invention encompass a nucleic acid having an HCV cDNA segment encoding the polyprotein starting in the region between amino acid positions 1 and 192 and ending in the region between positions 250 and 400 of the HCV polyprotein, more preferably ending in the region between positions 250 and 341, even more preferably ending in the region between positions 290 and 341 for expression of the HCV single E1 protein. Most preferably, the present recombinant vector encompasses a recombinant nucleic acid having a HCV cDNA segment encoding part of the HCV polyprotein starting in the region between positions 117 and 192, and ending at any position in the region between positions 263 and 326, for expression of HCV single E1 protein. Also within the scope of the present invention are forms that have the first hydrophobic domain deleted (positions 264 to 293 plus or minus 8 amino acids), or forms to which a 5'-terminal ATG codon and a 3'-terminal stop codon has been added, or forms which have a factor Xa cleavage site and/or 3 to 10, preferably 6 Histidine codons have been added.

More particularly, the recombinant vectors according to the present invention encompass a nucleic acid having an HCV cDNA segment encoding the polyprotein starting in the region between amino acid positions 290 and 406 and ending in the region between positions 600 and 820 of the HCV polyprotein, more preferably starting in the region between positions 322 and 406, even more preferably starting in the region between positions 347 and 406, even still more preferably starting in the region between positions 364 and 406 for expression of the HCV single E2 protein. Most preferably, the present recombinant vector encompasses a recombinant nucleic acid having a HCV cDNA segment encoding the polyprotein starting in the region between positions 290 and 406, and ending at any position of positions 623, 650, 661, 673, 710, 715, 720, 746 or 809, for expression of HCV single E2 protein. Also within the scope of the present invention are forms to which a 5'-terminal ATG codon and a 3'-terminal stop codon has been added, or forms which have a factor Xa cleavage site and/or 3 to 10, preferably 6 Histidine codons have been added.

A variety of vectors may be used to obtain recombinant expression of HCV single or specific oligomeric envelope proteins of the present invention. Lower eukaryotes such as yeasts and glycosylation mutant strains are typically transformed with plasmids, or are transformed with a recombinant virus. The vectors may replicate within the host

independently, or may integrate into the host cell genome.

Higher eukaryotes may be transformed with vectors, or may be infected with a recombinant virus, for example a recombinant vaccinia virus. Techniques and vectors for the insertion of foreign DNA into vaccinia virus are well known in the art, and utilize, for example homologous recombination. A wide variety of viral promoter sequences, possibly terminator sequences and poly(A)-addition sequences, possibly enhancer sequences and possibly amplification sequences, all required for the mammalian expression, are available in the art. Vaccinia is particularly preferred since vaccinia halts the expression of host cell proteins. Vaccinia is also very much preferred since it allows the expression of E1 and E2 proteins of HCV in cells or individuals which are immunized with the live recombinant vaccinia virus. For vaccination of humans the avipox and Ankara Modified Virus (AMV) are particularly useful vectors.

Also known are insect expression transfer vectors derived from baculovirus Autographa californica nuclear polyhedrosis virus (AcNPV), which is a helper-independent viral expression vector. Expression vectors derived from this system usually use the strong viral polyhedrin gene promoter to drive the expression of heterologous genes. Different vectors as well as methods for the introduction of heterologous DNA into the desired site of baculovirus are available to the man skilled in the art for baculovirus expression. Also different signals for posttranslational modification recognized by insect cells are known in the art.

Also included within the scope of the present invention is a method for producing purified recombinant single or specific oligomeric HCV E1 or E2 or E1/E2 proteins, wherein the cysteine residues involved in aggregates formation are replaced at the level of the nucleic acid sequence by other residues such that aggregate formation is prevented. The recombinant proteins expressed by recombinant vectors carrying such a mutated E1 and/or E2 protein encoding nucleic acid are also within the scope of the present invention.

The present invention also relates to recombinant E1 and/or E2 and/or E1/E2 proteins characterized in that at least one of their glycosylation sites has been removed and are consequently termed glycosylation mutants. As explained in the Examples section, different glycosylation mutants may be desired to diagnose (screening, confirmation, prognosis, etc.) and prevent HCV disease according to the patient in question. An E2 protein glycosylation mutant lacking the GLY4 has for instance been found to improve the reactivity of certain sera in diagnosis. These glycosylation mutants

are preferably purified according to the method disclosed in the present invention. Also contemplated within the present invention are recombinant vectors carrying the nucleic acid insert encoding such a E1 and/or E2 and/or E1/E2 glycosylation mutant as well as host cells transformed with such a recombinant vector.

5 The present invention also relates to recombinant vectors including a polynucleotide which also forms part of the present invention. The present invention relates more particularly to the recombinant nucleic acids as represented in SEQ ID NO 3, 5, 7, 9, 11, 13, 21, 23, 25, 27, 29, 31, 35, 37, 39, 41, 43, 45, 47 and 49, or parts thereof.

10 The present invention also contemplates host cells transformed with a recombinant vector as defined above, wherein said vector comprises a nucleotide sequence encoding HCV E1 and/or E2 and/or E1/E2 protein as defined above in addition to a regulatory sequence operably linked to said HCV E1 and/or E2 and/or E1/E2 sequence and capable of regulating the expression of said HCV E1 and/or E2 and/or
15 E1/E2 protein.

Eukaryotic hosts include lower and higher eukaryotic hosts as described in the definitions section. Lower eukaryotic hosts include yeast cells well known in the art. Higher eukaryotic hosts mainly include mammalian cell lines known in the art and include many immortalized cell lines available from the ATCC, including HeLa cells,
20 Chinese hamster ovary (CHO) cells, Baby hamster kidney (BHK) cells, PK15, RK13 and a number of other cell lines.

The present invention relates particularly to a recombinant E1 and/or E2 and/or E1/E2 protein expressed by a host cell as defined above containing a recombinant vector as defined above. These recombinant proteins are particularly purified according
25 to the method of the present invention.

A preferred method for isolating or purifying HCV envelope proteins as defined above is further characterized as comprising at least the following steps:

- growing a host cell as defined above transformed with a recombinant vector according to the present invention or with a known recombinant vector
30 expressing E1 and/or E2 and/or E1/E2 HCV envelope proteins in a suitable culture medium,
- causing expression of said vector sequence as defined above under suitable conditions, and,
- lysing said transformed host cells, preferably in the presence of a SH group

blocking agent, such as N-ethylmaleimide (NEM), and possibly a suitable detergent, preferably Empigen-BE.

- recovering said HCV envelope protein by affinity purification such as by means of lectin-chromatography or immunoaffinity chromatography using anti-E1 and/or anti-E2 specific monoclonal antibodies, with said lectin being preferably lentil-lectin or GNA, followed by,
- incubation of the eluate of the previous step with a disulphide bond cleavage means, such as DTT, preferably followed by incubation with an SH group blocking agent, such as NEM or Biotin-NEM, and,
- isolating the HCV single or specific oligomeric E1 and/or E2 and/or E1/E2 proteins such as by means of gelfiltration and possibly also by a subsequent Ni^{2+} -IMAC chromatography followed by a desalting step.

As a result of the above-mentioned process, E1 and/or E2 and/or E1/E2 proteins may be produced in a form which elute differently from the large aggregates containing vector-derived components and/or cell components in the void volume of the gelfiltration column or the IMAC column as illustrated in the Examples section. The disulphide bridge cleavage step advantageously also eliminates the false reactivity due to the presence of host and/or expression-system-derived proteins. The presence of NEM and a suitable detergent during lysis of the cells may already partly or even completely prevent the aggregation between the HCV envelope proteins and contaminants.

Ni^{2+} -IMAC chromatography followed by a desalting step is preferably used for constructs bearing a $(\text{His})_6$ as described by Janknecht et al., 1991, and Hochuli et al., 1988.

The present invention also relates to a method for producing monoclonal antibodies in small animals such as mice or rats, as well as a method for screening and isolating human B-cells that recognize anti-HCV antibodies, using the HCV single or specific oligomeric envelope proteins of the present invention.

The present invention further relates to a composition comprising at least one of the following E1 peptides as listed in Table 3:

- E1-31 (SEQ ID NO 56) spanning amino acids 181 to 200 of the Core/E1 V1 region,
- E1-33 (SEQ ID NO 57) spanning amino acids 193 to 212 of the E1 region,
- E1-35 (SEQ ID NO 58) spanning amino acids 205 to 224 of the E1 V2 region (epitope B),

E1-35A (SEQ ID NO 59) spanning amino acids 208 to 227 of the E1 V2 region (epitope B).

1bE1 (SEQ ID NO 53) spanning amino acids 192 to 228 of E1 regions (V1, C1, and V2 regions (containing epitope B)).

5 E1-51 (SEQ ID NO 66) spanning amino acids 301 to 320 of the E1 region,

E1-53 (SEQ ID NO 67) spanning amino acids 313 to 332 of the E1 C4 region (epitope A).

E1-55 (SEQ ID NO 68) spanning amino acids 325 to 344 of the E1 region.

10 The present invention also relates to a composition comprising at least one of the following E2 peptides as listed in Table 3:

Env 67 or E2-67 (SEQ ID NO 72) spanning amino acid positions 397 to 416 of the E2 region (epitope A, recognized by monoclonal antibody 2F10H10, see Figure 19).

15 Env 69 or E2-69 (SEQ ID NO 73) spanning amino acid positions 409 to 428 of the E2 region (epitope A).

Env 23 or E2-23 (SEQ ID NO 86) spanning positions 583 to 602 of the E2 region (epitope E).

Env 25 or E2-25 (SEQ ID NO 87) spanning positions 595 to 614 of the E2 region (epitope E).

20 Env 27 or E2-27 (SEQ ID NO 88) spanning positions 607 to 626 of the E2 region (epitope E).

Env 17B or E2-17B (SEQ ID NO 83) spanning positions 547 to 566 of the E2 region (epitope D).

25 Env 13B or E2-13B (SEQ ID NO 82) spanning positions 523 to 542 of the E2 region (epitope C; recognized by monoclonal antibody 16A6E7, see Figure 19).

The present invention also relates to a composition comprising at least one of the following E2 conformational epitopes:

epitope F recognized by monoclonal antibodies 15C8C1, 12D11F1 and 8G10D1H9,

30 epitope G recognized by monoclonal antibody 9G3E6,

epitope H (or C) recognized by monoclonal antibody 10D3C4 and 4H6B2, or,

epitope I recognized by monoclonal antibody 17F2C2.

The present invention also relates to an E1 or E2 specific antibody raised upon immunization with a peptide or protein composition, with said antibody being specifically

0092337.001297
252160 25282580

reactive with any of the polypeptides or peptides as defined above, and with said antibody being preferably a monoclonal antibody.

5 The present invention also relates to an E1 or E2 specific antibody screened from a variable chain library in plasmids or phages or from a population of human B-cells by means of a process known in the art, with said antibody being reactive with any of the polypeptides or peptides as defined above, and with said antibody being preferably a monoclonal antibody.

10 The E1 or E2 specific monoclonal antibodies of the invention can be produced by any hybridoma liable to be formed according to classical methods from splenic cells of an animal, particularly from a mouse or rat, immunized against the HCV polypeptides or peptides according to the invention, as defined above on the one hand, and of cells of a myeloma cell line on the other hand, and to be selected by the ability of the hybridoma to produce the monoclonal antibodies recognizing the polypeptides which has been initially used for the immunization of the animals.

15 The antibodies involved in the invention can be labelled by an appropriate label of the enzymatic, fluorescent, or radioactive type.

20 The monoclonal antibodies according to this preferred embodiment of the invention may be humanized versions of mouse monoclonal antibodies made by means of recombinant DNA technology, departing from parts of mouse and/or human genomic DNA sequences coding for H and L chains from cDNA or genomic clones coding for H and L chains.

25 Alternatively the monoclonal antibodies according to this preferred embodiment of the invention may be human monoclonal antibodies. These antibodies according to the present embodiment of the invention can also be derived from human peripheral blood lymphocytes of patients infected with HCV, or vaccinated against HCV. Such human monoclonal antibodies are prepared, for instance, by means of human peripheral blood lymphocytes (PBL) repopulation of severe combined immune deficiency (SCID) mice (for recent review, see Duchosal et al., 1992).

30 The invention also relates to the use of the proteins or peptides of the invention, for the selection of recombinant antibodies by the process of repertoire cloning (Persson et al., 1991).

Antibodies directed to peptides or single or specific oligomeric envelope proteins derived from a certain genotype may be used as a medicament, more particularly for incorporation into an immunoassay for the detection of HCV genotypes (for detecting

the presence of HCV E1 or E2 antigen), for prognosing/monitoring of HCV disease, or as therapeutic agents.

Alternatively, the present invention also relates to the use of any of the above-specified E1 or E2 specific monoclonal antibodies for the preparation of an immunoassay kit for detecting the presence of E1 or E2 antigen in a biological sample, for the
5 preparation of a kit for prognosing/monitoring of HCV disease or for the preparation of a HCV medicament.

The present invention also relates to the a method for *in vitro* diagnosis or detection of HCV antigen present in a biological sample, comprising at least the
10 following steps :

- (i) contacting said biological sample with any of the E1 and/or E2 specific monoclonal antibodies as defined above, preferably in an immobilized form under appropriate conditions which allow the formation of an immune complex,
- 15 (ii) removing unbound components,
- (iii) incubating the immune complexes formed with heterologous antibodies, which specifically bind to the antibodies present in the sample to be analyzed, with said heterologous antibodies having conjugated to a detectable label under appropriate conditions,
- 20 (iv) detecting the presence of said immune complexes visually or mechanically (e.g. by means of densitometry, fluorimetry, colorimetry).

The present invention also relates to a kit for *in vitro* diagnosis of HCV antigen present in a biological sample, comprising:

- 25 - at least one monoclonal antibody as defined above, with said antibody being preferentially immobilized on a solid substrate,
- a buffer or components necessary for producing the buffer enabling binding reaction between these antibodies and the HCV antigens present in the biological sample,
- a means for detecting the immune complexes formed in the preceding
30 binding reaction,
- possibly also including an automated scanning and interpretation device for inferring the HCV antigens present in the sample from the observed binding pattern.

The present invention also relates to a composition comprising E1 and/or E2

and/or E1, E2 recombinant HCV proteins purified according to the method of the present invention or a composition comprising at least one peptides as specified above for use as a medicament.

5 The present invention more particularly relates to a composition comprising at least one of the above-specified envelope peptides or a recombinant envelope protein composition as defined above, for use as a vaccine for immunizing a mammal, preferably humans, against HCV, comprising administering a sufficient amount of the composition possibly accompanied by pharmaceutically acceptable adjuvant(s), to produce an immune response.

10 More particularly, the present invention relates to the use of any of the compositions as described here above for the preparation of a vaccine as described above.

Also, the present invention relates to a vaccine composition for immunizing a mammal, preferably humans, against HCV, comprising HCV single or specific oligomeric proteins or peptides derived from the E1 and/or the E2 region as described above.

15 Immunogenic compositions can be prepared according to methods known in the art. The present compositions comprise an immunogenic amount of a recombinant E1 and/or E2 and/or E1/E2 single or specific oligomeric proteins as defined above or E1 or E2 peptides as defined above, usually combined with a pharmaceutically acceptable carrier, preferably further comprising an adjuvant.

20 The single or specific oligomeric envelope proteins of the present invention, either E1 and/or E2 and/or E1/E2, are expected to provide a particularly useful vaccine antigen, since the formation of antibodies to either E1 or E2 may be more desirable than to the other envelope protein, and since the E2 protein is cross-reactive between HCV types and the E1 protein is type-specific. Cocktails including type 1 E2 protein and E1 proteins derived from several genotypes may be particularly advantageous. Cocktails containing a molar excess of E1 versus E2 or E2 versus E1 may also be particularly useful.

25 Immunogenic compositions may be administered to animals to induce production of antibodies, either to provide a source of antibodies or to induce protective immunity in the animal.

30

Pharmaceutically acceptable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids,

amino acid copolymers; and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.

Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to : aluminim hydroxide (alum), N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP) as found in U.S. Patent No. 4,606,918, N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE) and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate, and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene:Tween 80 emulsion. Any of the 3 components MPL, TDM or CWS may also be used alone or combined 2 by 2. Additionally, adjuvants such as Stimulon (Cambridge Bioscience, Worcester, MA) or SAF-1 (Syntex) may be used. Further, Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA) may be used for non-human applications and research purposes.

The immunogenic compositions typically will contain pharmaceutically acceptable vehicles, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, preservatives, and the like, may be included in such vehicles.

Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect. The E1 and E2 proteins may also be incorporated into Immune Stimulating Complexes together with saponins, for example Quil A (ISCOMS).

Immunogenic compositions used as vaccines comprise a 'sufficient amount' or 'an immunologically effective amount' of the envelope proteins of the present invention, as well as any other of the above mentioned components, as needed. 'Immunologically effective amount', means that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment, as defined above. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (e.g. nonhuman primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, the strain of infecting HCV, and other relevant

factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. Usually, the amount will vary from 0.01 to 1000 $\mu\text{g}/\text{dose}$, more particularly from 0.1 to 100 $\mu\text{g}/\text{dose}$.

5 The single or specific oligomeric envelope proteins may also serve as vaccine carriers to present homologous (e.g. T cell epitopes or B cell epitopes from the core, NS2, NS3, NS4 or NS5 regions) or heterologous (non-HCV) haptens, in the same manner as Hepatitis B surface antigen (see European Patent Application 174,444). In this use, envelope proteins provide an immunogenic carrier capable of stimulating an immune response to haptens or antigens conjugated to the aggregate. The antigen may
10 be conjugated either by conventional chemical methods, or may be cloned into the gene encoding E1 and/or E2 at a location corresponding to a hydrophilic region of the protein. Such hydrophilic regions include the V1 region (encompassing amino acid positions 191 to 202), the V2 region (encompassing amino acid positions 213 to 223), the V3 region (encompassing amino acid positions 230 to 242), the V4 region (encompassing amino acid positions 230 to 242), the V5 region (encompassing amino acid positions 294 to 303) and the V6 region (encompassing amino acid positions 329 to 336). Another
15 useful location for insertion of haptens is the hydrophobic region (encompassing approximately amino acid positions 264 to 293). It is shown in the present invention that this region can be deleted without affecting the reactivity of the deleted E1 protein with antisera. Therefore, haptens may be inserted at the site of the deletion.
20

The immunogenic compositions are conventionally administered parenterally, typically by injection, for example, subcutaneously or intramuscularly. Additional formulations suitable for other methods of administration include oral formulations and suppositories. Dosage treatment may be a single dose schedule or a multiple dose
25 schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.

The present invention also relates to a composition comprising peptides or polypeptides as described above, for *in vitro* detection of HCV antibodies present in a biological sample.

30 The present invention also relates to the use of a composition as described above for the preparation of an immunoassay kit for detecting HCV antibodies present in a biological sample.

The present invention also relates to a method for *in vitro* diagnosis of HCV antibodies present in a biological sample, comprising at least the following steps :

- 5 (i) contacting said biological sample with a composition comprising any of the envelope peptide or proteins as defined above, preferably in an immobilized form under appropriate conditions which allow the formation of an immune complex, wherein said peptide or protein can be a biotinylated peptide or protein which is covalently bound to a solid substrate by means of streptavidin or avidin complexes.
- (ii) removing unbound components,
- 10 (iii) incubating the immune complexes formed with heterologous antibodies, with said heterologous antibodies having conjugated to a detectable label under appropriate conditions,
- (iv) detecting the presence of said immune complexes visually or mechanically (e.g. by means of densitometry, fluorimetry, colorimetry).

Alternatively, the present invention also relates to competition immunoassay formats in which recombinantly produced purified single or specific oligomeric protein
15 E1 and/or E2 and/or E1/E2 proteins as disclosed above are used in combination with E1 and/or E2 peptides in order to compete for HCV antibodies present in a biological sample.

The present invention also relates to a kit for determining the presence of HCV antibodies, in a biological sample, comprising :

- 20 - at least one peptide or protein composition as defined above, possibly in combination with other polypeptides or peptides from HCV or other types of HCV, with said peptides or proteins being preferentially immobilized on a solid substrate, more preferably on different microwells of the same ELISA plate, and even more preferentially on one and the same membrane strip,
- 25 - a buffer or components necessary for producing the buffer enabling binding reaction between these polypeptides or peptides and the antibodies against HCV present in the biological sample,
- means for detecting the immune complexes formed in the preceding
30 binding reaction,
- possibly also including an automated scanning and interpretation device for inferring the HCV genotypes present in the sample from the observed binding pattern.

The immunoassay methods according to the present invention utilize single or

specific oligomeric antigens from the E1 and/or E2 domains that maintain linear (in case of peptides) and conformational epitopes (single or specific oligomeric proteins) recognized by antibodies in the sera from individuals infected with HCV. It is within the scope of the invention to use for instance single or specific oligomeric antigens, dimeric antigens, as well as combinations of single or specific oligomeric antigens. The HCV E1 and E2 antigens of the present invention may be employed in virtually any assay format that employs a known antigen to detect antibodies. Of course, a format that denatures the HCV conformational epitope should be avoided or adapted. A common feature of all of these assays is that the antigen is contacted with the body component suspected of containing HCV antibodies under conditions that permit the antigen to bind to any such antibody present in the component. Such conditions will typically be physiologic temperature, pH and ionic strength using an excess of antigen. The incubation of the antigen with the specimen is followed by detection of immune complexes comprised of the antigen.

Design of the immunoassays is subject to a great deal of variation, and many formats are known in the art. Protocols may, for example, use solid supports, or immunoprecipitation. Most assays involve the use of labeled antibody or polypeptide; the labels may be, for example, enzymatic, fluorescent, chemiluminescent, radioactive, or dye molecules. Assays which amplify the signals from the immune complex are also known; examples of which are assays which utilize biotin and avidin or streptavidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays.

The immunoassay may be, without limitation, in a heterogeneous or in a homogeneous format, and of a standard or competitive type. In a heterogeneous format, the polypeptide is typically bound to a solid matrix or support to facilitate separation of the sample from the polypeptide after incubation. Examples of solid supports that can be used are nitrocellulose (e.g., in membrane or microtiter well form), polyvinyl chloride (e.g., in sheets or microtiter wells), polystyrene latex (e.g., in beads or microtiter plates), polyvinylidene fluoride (known as Immulon™), diazotized paper, nylon membranes, activated beads, and Protein A beads. For example, Dynatech Immulon™ 1 or Immulon™ 2 microtiter plates or 0.25 inch polystyrene beads (Precision Plastic Ball) can be used in the heterogeneous format. The solid support containing the antigenic polypeptides is typically washed after separating it from the test sample, and prior to detection of bound antibodies. Both standard and competitive formats are known in the art.

In a homogeneous format, the test sample is incubated with the combination of antigens in solution. For example, it may be under conditions that will precipitate any antigen-antibody complexes which are formed. Both standard and competitive formats for these assays are known in the art.

5 In a standard format, the amount of HCV antibodies in the antibody-antigen complexes is directly monitored. This may be accomplished by determining whether labeled anti-xenogeneic (e.g. anti-human) antibodies which recognize an epitope on anti-HCV antibodies will bind due to complex formation. In a competitive format, the amount of HCV antibodies in the sample is deduced by monitoring the competitive effect on the
10 binding of a known amount of labeled antibody (or other competing ligand) in the complex.

 Complexes formed comprising anti-HCV antibody (or in the case of competitive assays, the amount of competing antibody) are detected by any of a number of known techniques, depending on the format. For example, unlabeled HCV antibodies in the
15 complex may be detected using a conjugate of anti-xenogeneic Ig complexed with a label (e.g. an enzyme label).

 In an immunoprecipitation or agglutination assay format the reaction between the HCV antigens and the antibody forms a network that precipitates from the solution or suspension and forms a visible layer or film of precipitate. If no anti-HCV antibody is
20 present in the test specimen, no visible precipitate is formed.

 There currently exist three specific types of particle agglutination (PA) assays. These assays are used for the detection of antibodies to various antigens when coated to a support. One type of this assay is the hemagglutination assay using red blood cells (RBCs) that are sensitized by passively adsorbing antigen (or antibody) to the RBC. The
25 addition of specific antigen antibodies present in the body component, if any, causes the RBCs coated with the purified antigen to agglutinate.

 To eliminate potential non-specific reactions in the hemagglutination assay, two artificial carriers may be used instead of RBC in the PA. The most common of these are latex particles. However, gelatin particles may also be used. The assays utilizing either
30 of these carriers are based on passive agglutination of the particles coated with purified antigens.

 The HCV single or specific oligomeric E1 and/or E2 and/or E1/E2 antigens of the present invention comprised of conformational epitopes will typically be packaged in the form of a kit for use in these immunoassays. The kit will normally contain in separate

containers the native HCV antigen, control antibody formulations (positive and/or negative), labeled antibody when the assay format requires the same and signal generating reagents (e.g. enzyme substrate) if the label does not generate a signal directly. The native HCV antigen may be already bound to a solid matrix or separate
5 with reagents for binding it to the matrix. Instructions (e.g. written, tape, CD-ROM, etc.) for carrying out the assay usually will be included in the kit.

Immunoassays that utilize the native HCV antigen are useful in screening blood for the preparation of a supply from which potentially infective HCV is lacking. The method for the preparation of the blood supply comprises the following steps. Reacting
10 a body component, preferably blood or a blood component, from the individual donating blood with HCV E1 and/or E2 proteins of the present invention to allow an immunological reaction between HCV antibodies, if any, and the HCV antigen. Detecting whether anti-HCV antibody - HCV antigen complexes are formed as a result of the reacting. Blood contributed to the blood supply is from donors that do not exhibit
15 antibodies to the native HCV antigens, E1 or E2.

In cases of a positive reactivity to the HCV antigen, it is preferable to repeat the immunoassay to lessen the possibility of false positives. For example, in the large scale screening of blood for the production of blood products (e.g. blood transfusion, plasma, Factor VIII, immunoglobulin, etc.) 'screening' tests are typically formatted to increase
20 sensitivity (to insure no contaminated blood passes) at the expense of specificity; i.e. the false-positive rate is increased. Thus, it is typical to only defer for further testing those donors who are 'repeatedly reactive'; i.e. positive in two or more runs of the immunoassay on the donated sample. However, for confirmation of HCV-positivity, the 'confirmation' tests are typically formatted to increase specificity (to insure that no
25 false-positive samples are confirmed) at the expense of sensitivity. Therefore the purification method described in the present invention for E1 and E2 will be very advantageous for including single or specific oligomeric envelope proteins into HCV diagnostic assays.

The solid phase selected can include polymeric or glass beads, nitrocellulose,
30 microparticles, microwells of a reaction tray, test tubes and magnetic beads. The signal generating compound can include an enzyme, a luminescent compound, a chromogen, a radioactive element and a chemiluminescent compound. Examples of enzymes include alkaline phosphatase, horseradish peroxidase and beta-galactosidase. Examples of enhancer compounds include biotin, anti-biotin and avidin. Examples of enhancer

5 compounds binding members include biotin, anti-biotin and avidin. In order to block the effects of rheumatoid factor-like substances, the test sample is subjected to conditions sufficient to block the effect of rheumatoid factor-like substances. These conditions comprise contacting the test sample with a quantity of anti-human IgG to form a mixture, and incubating the mixture for a time and under conditions sufficient to form a reaction mixture product substantially free of rheumatoid factor-like substance.

10 The present invention further contemplates the use of E1 proteins, or parts thereof, more particularly HCV single or specific oligomeric E1 proteins as defined above, for *in vitro* monitoring HCV disease or prognosing the response to treatment (for instance with Interferon) of patients suffering from HCV infection comprising:

- incubating a biological sample from a patient with hepatitis C infection with an E1 protein or a suitable part thereof under conditions allowing the formation of an immunological complex,
 - removing unbound components,
 - 15 - calculating the anti-E1 titers present in said sample (for example at the start of and/or during the course of (interferon) therapy),
 - monitoring the natural course of HCV disease, or prognosing the response to treatment of said patient on the basis of the amount anti-E1 titers found in said sample at the start of treatment and/or during the course of treatment.
- 20

Patients who show a decrease of 2, 3, 4, 5, 7, 10, 15, or preferably more than 20 times of the initial anti-E1 titers could be concluded to be long-term, sustained responders to HCV therapy, more particularly to interferon therapy. It is illustrated in the Examples section, that an anti-E1 assay may be very useful for prognosing long-term response to IFN treatment, or to treatment of Hepatitis C virus disease in general.

25

More particularly the following E1 peptides as listed in Table 3 were found to be useful for *in vitro* monitoring HCV disease or prognosing the response to interferon treatment of patients suffering from HCV infection:

- 30 E1-31 (SEQ ID NO 56) spanning amino acids 181 to 200 of the Core/E1 V1 region,
- E1-33 (SEQ ID NO 57) spanning amino acids 193 to 212 of the E1 region,
- E1-35 (SEQ ID NO 58) spanning amino acids 205 to 224 of the E1 V2 region (epitope B),
- E1-35A (SEQ ID NO 59) spanning amino acids 208 to 227 of the E1 V2 region

(epitope B),

1bE1 (SEQ ID NO 53) spanning amino acids 192 to 228 of E1 regions (V1, C1, and V2 regions (containing epitope B)),

E1-51 (SEQ ID NO 66) spanning amino acids 301 to 320 of the E1 region,

5 E1-53 (SEQ ID NO 67) spanning amino acids 313 to 332 of the E1 C4 region (epitope A),

E1-55 (SEQ ID NO 68) spanning amino acids 325 to 344 of the E1 region.

10 It is to be understood that smaller fragments of the above-mentioned peptides also fall within the scope of the present invention. Said smaller fragments can be easily prepared by chemical synthesis and can be tested for their ability to be used in an assay as detailed above and in the Examples section.

The present invention also relates to a kit for monitoring HCV disease or prognosing the response to treatment (for instance to interferon) of patients suffering from HCV infection comprising:

- 15
- at least one E1 protein or E1 peptide, more particularly an E1 protein or E1 peptide as defined above,
 - a buffer or components necessary for producing the buffer enabling the binding reaction between these proteins or peptides and the anti-E1 antibodies present in a biological sample,

20

 - means for detecting the immune complexes formed in the preceding binding reaction,
 - possibly also an automated scanning and interpretation device for inferring a decrease of anti-E1 titers during the progression of treatment.

25 It is to be understood that also E2 protein and peptides according to the present invention can be used to a certain degree to monitor/prognose HCV treatment as indicated above for the E1 proteins or peptides because also the anti-E2 levels decrease in comparison to antibodies to the other HCV antigens. It is to be understood, however, that it might be possible to determine certain epitopes in the E2 region which would also be suited for use in an test for monitoring/prognosing HCV disease.

30 The present invention also relates to a serotyping assay for detecting one or more serological types of HCV present in a biological sample, more particularly for detecting antibodies of the different types of HCV to be detected combined in one assay format, comprising at least the following steps :

- (i) contacting the biological sample to be analyzed for the presence of HCV

5 antibodies of one or more serological types, with at least one of the E1 and/or E2 and/or E1/E2 protein compositions or at least one of the E1 or E2 peptide compositions as defined above, preferentially in an immobilized form under appropriate conditions which allow the formation of an immune complex,

- (ii) removing unbound components,
- (iii) incubating the immune complexes formed with heterologous antibodies, with said heterologous antibodies being conjugated to a detectable label under appropriate conditions,
- 10 (iv) detecting the presence of said immune complexes visually or mechanically (e.g. by means of densitometry, fluorimetry, colorimetry) and inferring the presence of one or more HCV serological types present from the observed binding pattern.

15 It is to be understood that the compositions of proteins or peptides used in this method are recombinantly expressed type-specific envelope proteins or type-specific peptides.

The present invention further relates to a kit for serotyping one or more serological types of HCV present in a biological sample, more particularly for detecting the antibodies to these serological types of HCV comprising:

- 20 - at least one E1 and/or E2 and/or E1/E2 protein or E1 or E2 peptide, as defined above,
- a buffer or components necessary for producing the buffer enabling the binding reaction between these proteins or peptides and the anti-E1 antibodies present in a biological sample,
- 25 - means for detecting the immune complexes formed in the preceding binding reaction,
- possibly also an automated scanning and interpretation device for detecting the presence of one or more serological types present from the observed binding pattern.

30 The present invention also relates to the use of a peptide or protein composition as defined above, for immobilization on a solid substrate and incorporation into a reversed phase hybridization assay, preferably for immobilization as parallel lines onto a solid support such as a membrane strip, for determining the presence or the genotype of HCV according to a method as defined above. Combination with other type-specific

antigens from other HCV polyprotein regions also lies within the scope of the present invention.

3.

Table 1. Demographic characteristics of the study population	
Age (years)	65.8 ± 1.2
Gender (male/female)	10/10
Education (years)	12.5 ± 0.5
Marital status (married/divorced/widowed)	10/0/0
Occupation (retired/employed)	10/0
Income (USD/month)	1,200 ± 100
Smoking status (smoker/nonsmoker)	0/10
Alcohol consumption (yes/no)	0/10
Comorbidities (hypertension/diabetes/cholesterol)	5/2/3
Medication (antihypertensive/antidiabetic/anticholesterol)	5/2/3
Physical activity (sedentary/active)	0/10
Stress level (low/moderate/high)	0/5/5
Family history (heart disease/stroke)	0/0
Previous surgery (bypass/stent)	0/0
Current symptoms (chest pain/shortness of breath)	0/0
Quality of life (SF-36 score)	45.2 ± 2.1
Healthcare utilization (hospitalizations/visits)	0/10
Health insurance (private/public)	0/10
Health literacy (low/moderate/high)	0/5/5
Health beliefs (fatalistic/health conscious)	0/10
Health behaviors (diet/exercise)	0/10
Health status (stable/unstable)	0/10
Health outcomes (mortality/morbidity)	0/0
Healthcare costs (inpatient/outpatient)	0/10
Healthcare access (distance/availability)	0/10
Healthcare quality (patient satisfaction)	0/10
Healthcare equity (disparities)	0/10
Healthcare sustainability (long-term care)	0/10
Healthcare innovation (new technologies)	0/10
Healthcare research (clinical trials)	0/10
Healthcare policy (regulations)	0/10
Healthcare system (public/private)	0/10
Healthcare financing (insurance/payers)	0/10
Healthcare delivery (primary care/specialty)	0/10
Healthcare workforce (nurses/doctors)	0/10
Healthcare infrastructure (hospitals/clinics)	0/10
Healthcare information (data management)	0/10
Healthcare communication (patient education)	0/10
Healthcare collaboration (multisectoral)	0/10
Healthcare leadership (management)	0/10
Healthcare governance (oversight)	0/10
Healthcare accountability (transparency)	0/10
Healthcare integrity (ethics)	0/10
Healthcare justice (fairness)	0/10
Healthcare respect (dignity)	0/10
Healthcare beneficence (well-being)	0/10
Healthcare non-maleficence (harm avoidance)	0/10
Healthcare autonomy (self-determination)	0/10
Healthcare information (knowledge)	0/10
Healthcare communication (skills)	0/10
Healthcare collaboration (networks)	0/10
Healthcare leadership (vision)	0/10
Healthcare governance (structure)	0/10
Healthcare accountability (mechanisms)	0/10
Healthcare integrity (standards)	0/10
Healthcare justice (equity)	0/10
Healthcare respect (rights)	0/10
Healthcare beneficence (benefits)	0/10
Healthcare non-maleficence (risks)	0/10
Healthcare autonomy (choices)	0/10
Healthcare information (resources)	0/10
Healthcare communication (tools)	0/10
Healthcare collaboration (partnerships)	0/10
Healthcare leadership (strategies)	0/10
Healthcare governance (policies)	0/10
Healthcare accountability (reports)	0/10
Healthcare integrity (protocols)	0/10
Healthcare justice (access)	0/10
Healthcare respect (privacy)	0/10
Healthcare beneficence (evidence)	0/10
Healthcare non-maleficence (safety)	0/10
Healthcare autonomy (empowerment)	0/10
Healthcare information (literacy)	0/10
Healthcare communication (counseling)	0/10
Healthcare collaboration (coalitions)	0/10
Healthcare leadership (commitment)	0/10
Healthcare governance (oversight)	0/10
Healthcare accountability (transparency)	0/10
Healthcare integrity (ethics)	0/10
Healthcare justice (equity)	0/10
Healthcare respect (dignity)	0/10
Healthcare beneficence (well-being)	0/10
Healthcare non-maleficence (harm avoidance)	0/10
Healthcare autonomy (self-determination)	0/10
Healthcare information (knowledge)	0/10
Healthcare communication (skills)	0/10
Healthcare collaboration (networks)	0/10
Healthcare leadership (vision)	0/10
Healthcare governance (structure)	0/10
Healthcare accountability (mechanisms)	0/10
Healthcare integrity (standards)	0/10
Healthcare justice (equity)	0/10
Healthcare respect (rights)	0/10
Healthcare beneficence (benefits)	0/10
Healthcare non-maleficence (risks)	0/10
Healthcare autonomy (choices)	0/10
Healthcare information (resources)	0/10
Healthcare communication (tools)	0/10
Healthcare collaboration (partnerships)	0/10
Healthcare leadership (strategies)	0/10
Healthcare governance (policies)	0/10
Healthcare accountability (reports)	0/10
Healthcare integrity (protocols)	0/10
Healthcare justice (access)	0/10
Healthcare respect (privacy)	0/10
Healthcare beneficence (evidence)	0/10
Healthcare non-maleficence (safety)	0/10
Healthcare autonomy (empowerment)	0/10
Healthcare information (literacy)	0/10
Healthcare communication (counseling)	0/10
Healthcare collaboration (coalitions)	0/10
Healthcare leadership (commitment)	0/10
Healthcare governance (oversight)	0/10
Healthcare accountability (transparency)	0/10
Healthcare integrity (ethics)	0/10
Healthcare justice (equity)	0/10
Healthcare respect (dignity)	0/10
Healthcare beneficence (well-being)	0/10
Healthcare non-maleficence (harm avoidance)	0/10
Healthcare autonomy (self-determination)	0/10
Healthcare information (knowledge)	0/10
Healthcare communication (skills)	0/10
Healthcare collaboration (networks)	0/10
Healthcare leadership (vision)	0/10
Healthcare governance (structure)	0/10
Healthcare accountability (mechanisms)	0/10
Healthcare integrity (standards)	0/10
Healthcare justice (equity)	0/10
Healthcare respect (rights)	0/10
Healthcare beneficence (benefits)	0/10
Healthcare non-maleficence (risks)	0/10
Healthcare autonomy (choices)	0/10
Healthcare information (resources)	0/10
Healthcare communication (tools)	0/10
Healthcare collaboration (partnerships)	0/10
Healthcare leadership (strategies)	0/10
Healthcare governance	

Figure and Table legends

- Figure 1 : Restriction map of plasmid pgpt ATA 18
- Figure 2 : Restriction map of plasmid pgs ATA 18
- 5 Figure 3 : Restriction map of plasmid pMS 66
- Figure 4 : Restriction map of plasmid pv HCV-11A
- Figure 5 : Anti-E1 levels in non-responders to IFN treatment
- Figure 6 : Anti-E1 levels in responders to IFN treatment
- Figure 7 : Anti-E1 levels in patients with complete response to IFN treatment
- 10 Figure 8 : Anti-E1 levels in incomplete responders to IFN treatment
- Figure 9 : Anti-E2 levels in non-responders to IFN treatment
- Figure 10 : Anti-E2 levels in responders to IFN treatment
- Figure 11 : Anti-E2 levels in incomplete responders to IFN treatment
- Figure 12 : Anti-E2 levels in complete responders to IFN treatment
- 15 Figure 13 : Human anti-E1 reactivity competed with peptides
- Figure 14 : Competition of reactivity of anti-E1 monoclonal antibodies with peptides
- Figure 15 : Anti-E1 (epitope 1) levels in non-responders to IFN treatment
- Figure 16 : Anti-E1 (epitope 1) levels in responders to IFN treatment
- Figure 17 : Anti-E1 (epitope 2) levels in non-responders to IFN treatment
- 20 Figure 18 : Anti-E1 (epitope 2) levels in responders to IFN treatment
- Figure 19 : Competition of reactivity of anti-E2 monoclonal antibodies with peptides
- Figure 20: Human anti-E2 reactivity competed with peptides
- Figure 21: Nucleic acid sequences of the present invention. The nucleic acid sequences encoding an E1 or E2 protein according to the present invention may be translated (SEQ ID NO 3 to 13, 21-31, 35 and 41-49 are translated in a reading frame starting from residue number 1, SEQ ID NO 37-39 are translated in a reading frame starting from residue number 2), into the amino acid sequences of the respective E1 or E2 proteins as shown in the sequence listing.
- 25
- 30 Figure 22: ELISA results obtained from lentil lectin chromatography eluate fractions of 4 different E1 purifications of cell lysates infected with vvHCV39 (type 1b), vvHCV40 (type 1b), vvHCV62 (type 3a), and vvHCV63 (type 5a).
- Figure 23: Elution profiles obtained from the lentil lectin chromatography of the 4 different E1 constructs on the basis of the values as shown in Figure 22.

0092037-091297
25250-252500

- Figure 24: ELISA results obtained from fractions obtained after gelfiltration chromatography of 4 different E1 purifications of cell lysates infected with vvHCV39 (type 1b), vvHCV40 (type 1b), vvHCV62 (type 3a), and vvHCV63 (type 5a).
- 5 Figure 25: Profiles obtained from purifications of E1 proteins of type 1b (1), type 3a (2), and type 5a (3) (from RK13 cells infected with vvHCV39, vvHCV62, and vvHCV63, respectively; purified on lentil lectin and reduced as in example 5.2 - 5.3) and a standard (4). The peaks indicated with '1', '2', and '3', represent pure E1 protein peaks (see Figure 24, E1 reactivity mainly in fractions 26 to 30).
- 10 Figure 26: Silver staining of an SDS-PAGE as described in example 4 of a raw lysate of E1 vvHCV40 (type 1b) (lane 1), pool 1 of the gelfiltration of vvHCV40 representing fractions 10 to 17 as shown in Figure 25 (lane 2), pool 2 of the gelfiltration of vvHCV40 representing fractions 18 to 25 as shown in Figure 25 (lane 3), and E1 pool (fractions 26 to 30) (lane 4).
- 15 Figure 27: Streptavidine-alkaline phosphatase blot of the fractions of the gelfiltration of E1 constructs 39 (type 1b) and 62 (type 3a). The proteins were labelled with NEM-biotin. Lane 1: start gelfiltration construct 39, lane 2: fraction 26 construct 39, lane 3: fraction 27 construct 39, lane 4: fraction 28 construct 39, lane 5: fraction 29 construct 39, lane 6: fraction 30 construct 39, lane 7 fraction 31 construct 39, lane 8: molecular weight marker, lane 9: start gelfiltration construct 62, lane 10: fraction 26 construct 62, lane 11: fraction 27 construct 62, lane 12: fraction 28 construct 62, lane 13: fraction 29 construct 62, lane 14: fraction 30 construct 62, lane 15: fraction 31 construct 62.
- 20 Figure 28: Silver staining of an SDS-PAGE gel of the gelfiltration fractions of vvHCV-39 (E1s, type 1b) and vvHCV-62 (E1s, type 3a) run under identical conditions as Figure 26. Lane 1: start gelfiltration construct 39, lane 2: fraction 26 construct 39, lane 3: fraction 27 construct 39, lane 4: fraction 28 construct 39, lane 5: fraction 29 construct 39, lane 6: fraction 30 construct 39, lane 7 fraction 31 construct 39, lane 8: molecular weight marker, lane 9: start gelfiltration construct 62, lane 10: fraction 26 construct 62, lane 11: fraction 27 construct 62, lane 12: fraction 28 construct 62, lane 13: fraction 29 construct 62, lane 14:
- 25 Figure 29: Silver staining of an SDS-PAGE gel of the gelfiltration fractions of vvHCV-39 (E1s, type 1b) and vvHCV-62 (E1s, type 3a) run under identical conditions as Figure 26. Lane 1: start gelfiltration construct 39, lane 2: fraction 26 construct 39, lane 3: fraction 27 construct 39, lane 4: fraction 28 construct 39, lane 5: fraction 29 construct 39, lane 6: fraction 30 construct 39, lane 7 fraction 31 construct 39, lane 8: molecular weight marker, lane 9: start gelfiltration construct 62, lane 10: fraction 26 construct 62, lane 11: fraction 27 construct 62, lane 12: fraction 28 construct 62, lane 13: fraction 29 construct 62, lane 14:
- 30 Figure 30: Silver staining of an SDS-PAGE gel of the gelfiltration fractions of vvHCV-39 (E1s, type 1b) and vvHCV-62 (E1s, type 3a) run under identical conditions as Figure 26. Lane 1: start gelfiltration construct 39, lane 2: fraction 26 construct 39, lane 3: fraction 27 construct 39, lane 4: fraction 28 construct 39, lane 5: fraction 29 construct 39, lane 6: fraction 30 construct 39, lane 7 fraction 31 construct 39, lane 8: molecular weight marker, lane 9: start gelfiltration construct 62, lane 10: fraction 26 construct 62, lane 11: fraction 27 construct 62, lane 12: fraction 28 construct 62, lane 13: fraction 29 construct 62, lane 14:

fraction 30 construct 62, lane 15: fraction 31 construct 62.

- 5 Figure 29: Western Blot analysis with anti-E1 mouse monoclonal antibody 5E1A10 giving a complete overview of the purification procedure. Lane 1: crude lysate, Lane 2: flow through of lentil chromatography, Lane 3: wash with Empigen BB after lentil chromatography, Lane 4: Eluate of lentil chromatography, Lane 5: Flow through during concentration of the lentil eluate, Lane 6: Pool of E1 after Size Exclusion Chromatography (gelfiltration).
- 10 Figure 30: OD₂₈₀ profile (continuous line) of the lentil lectin chromatography of E2 protein from RK13 cells infected with vvHCV44. The dotted line represents the E2 reactivity as detected by ELISA (as in example 6).
- 15 Figure 31A: OD₂₈₀ profile (continuous line) of the lentil-lectin gelfiltration chromatography E2 protein pool from RK13 cells infected with vvHCV44 in which the E2 pool is applied immediately on the gelfiltration column (non-reduced conditions). The dotted line represents the E2 reactivity as detected by ELISA (as in example 6).
- 20 Figure 31B: OD₂₈₀ profile (continuous line) of the lentil-lectin gelfiltration chromatography E2 protein pool from RK13 cells infected with vvHCV44 in which the E2 pool was reduced and blocked according to Example 5.3 (reduced conditions). The dotted line represents the E2 reactivity as detected by ELISA (as in example 6).
- 25 Figure 32: Ni²⁺-IMAC chromatography and ELISA reactivity of the E2 protein as expressed from vvHCV44 after gelfiltration under reducing conditions as shown in Figure 31B.
- Figure 33: Silver staining of an SDS-PAGE of 0.5 µg of purified E2 protein recovered by a 200 mM imidazole elution step (lane 2) and a 30mM imidazole wash (lane 1) of the Ni²⁺-IMAC chromatography as shown in Figure 32.
- 30 Figure 34: OD profiles of a desalting step of the purified E2 protein recovered by 200 mM imidazole as shown in Figure 33, intended to remove imidazole.
- Figure 35A: Antibody levels to the different HCV antigens (Core 1, Core 2, E2HCVR, NS3) for NR and LTR followed during treatment and over a period of 6 to 12 months after treatment determined by means of the LIAScan method. The average values are indicated by the curves with the open squares.

Figure 35B: Antibody levels to the different HCV antigens (NS4, NS5, E1 and E2) for NR and LTR followed during treatment and over a period of 6 to 12 months after treatment determined by means of the LIAscan method. The average values are indicated by the curve with the open squares.

5

Figure 36: Average E1 antibody (E1Ab) and E2 antibody (E2Ab) levels in the LTR and NR groups.

Figure 37: Averages E1 antibody (E1Ab) levels for non-responders (NR) and long term responders (LTR) for type 1b and type 3a.

10 Figure 38: Relative map positions of the anti-E2 monoclonal antibodies.

Figure 39: Partial deglycosylation of HCV E1 envelope protein. The lysate of vvHCV10A-infected RK13 cells were incubated with different concentrations of glycosidases according to the manufacturer's instructions. Right panel: Glycopeptidase F (PNGase F). Left panel: Endoglycosidase H (Endo H).

15

Figure 40: Partial deglycosylation of HCV E2 envelope proteins. The lysate of vvHCV64-infected (E2) and vvHCV41-infected (E2s) RK13 cells were incubated with different concentrations of Glycopeptidase F (PNGase F) according to the manufacturer's instructions.

20 Figure 41: In vitro mutagenesis of HCV E1 glycoproteins. Map of the mutated sequences and the creation of new restriction sites.

Figure 42A: In vitro mutagenesis of HCV E1 glycoprotein (part 1). First step of PCR amplification.

Figure 42B: In vitro mutagenesis of HCV E1 glycoprotein (part 2). Overlap extension and nested PCR.

25

Figure 43: In vitro mutagenesis of HCV E1 glycoproteins. Map of the PCR mutated fragments (GLY-# and OVR-#) synthesized during the first step of amplification.

Figure 44A: Analysis of E1 glycoprotein mutants by Western blot expressed in HeLa (left) and RK13 (right) cells. Lane 1: wild type VV (vaccinia virus), Lane 2: original E1 protein (vvHCV-10A), Lane 3: E1 mutant Gly-1 (vvHCV-81), Lane 4: E1 mutant Gly-2 (vvHCV-82), Lane 5: E1 mutant Gly-3 (vvHCV-83), Lane 6: E1 mutant Gly-4 (vvHCV-84), Lane 7: E1 mutant Gly-5 (vvHCV-85), Lane 8: E1 mutant Gly-6 (vvHCV-86).

30

00920757-001007

- Figure 44B: Analysis of E1 glycosylation mutant vaccinia viruses by PCR amplification/restriction. Lane 1: E1 (vvHCV-10A), *BspE* I, Lane 2: E1.GLY-1 (vvHCV-81), *BspE* I, Lane 4: E1 (vvHCV-10A), *Sac* I, Lane 5: E1.GLY-2 (vvHCV-82), *Sac* I, Lane 7: E1 (vvHCV-10A), *Sac* I, Lane 8: E1.GLY-3 (vvHCV-83), *Sac* I, Lane 10: E1 (vvHCV-10A), *Stu* I, Lane 11: E1.GLY-4 (vvHCV-84), *Stu* I, Lane 13: E1 (vvHCV-10A), *Sma* I, Lane 14: E1.GLY-5 (vvHCV-85), *Sma* I, Lane 16: E1 (vvHCV-10A), *Stu* I, Lane 17: E1.GLY-6 (vvHCV-86), *Stu* I, Lane 3 - 6 - 9 - 12 - 15 : Low Molecular Weight Marker, pBluescript SK+, *Msp* I.
- Figure 45: SDS polyacrylamide gel electrophoresis of recombinant E2 expressed in *S. cerevisiae*. Inoculates were grown in leucine selective medium for 72 hrs. and diluted 1/15 in complete medium. After 10 days of culture at 28°C, medium samples were taken. The equivalent of 200 µl of culture supernatant concentrated by speedvac was loaded on the gel. Two independent transformants were analysed.
- Figure 46: SDS polyacrylamide gel electrophoresis of recombinant E2 expressed in a glycosylation deficient *S. cerevisiae* mutant. Inoculae were grown in leucine selective medium for 72 hrs. and diluted 1/15 in complete medium. After 10 days of culture at 28°C, medium samples were taken. The equivalent of 350 µl of culture supernatant, concentrated by ion exchange chromatography, was loaded on the gel.
- Table 1 : Features of the respective clones and primers used for amplification for constructing the different forms of the E1 protein as despected in Example 1.
- Table 2 : Summary of Anti-E1 tests
- Table 3 : Synthetic peptides for competition studies
- Table 4: Changes of envelope antibody levels over time.
- Table 5: Difference between LTR and NR
- Table 6: Competition experiments between murine E2 monoclonal antibodies
- Table 7: Primers for construction of E1 glycosylation mutants
- Table 8: Analysis of E1 glycosylation mutants by ELISA

Example 1: Cloning and expression of the hepatitis C virus E1 protein

1. Construction of vaccinia virus recombination vectors

5 The pgptATA18 vaccinia recombination plasmid is a modified version of pATA18
(Stunnenberg et al, 1988) with an additional insertion containing the E. coli xanthine
guanine phosphoribosyl transferase gene under the control of the vaccinia virus 13
intermediate promoter (Figure 1). The plasmid pgsATA18 was constructed by inserting
an oligonucleotide linker with SEQ ID NO 1/94, containing stop codons in the three
10 reading frames, into the Pst I and HindIII-cut pATA18 vector. This created an extra Pac
I restriction site (Figure 2). The original HindIII site was not restored.

Oligonucleotide linker with SEQ ID NO 1794:

15 5' G GCATGC AAGCTT AATTAAAT 3'
 3' ACGTC CGTACG TTCGAA TTAATTAA TCGA 5'

PstI SphI HindIII Pac I (HindIII)

In order to facilitate rapid and efficient purification by means of Ni^{2+} chelation of engineered histidine stretches fused to the recombinant proteins, the vaccinia recombination vector pMS66 was designed to express secreted proteins with an additional carboxy-terminal histidine tag. An oligonucleotide linker with SEQ ID NO 2/95, containing unique sites for 3 restriction enzymes generating blunt ends (Sma I, Stu I and Pml I/Bbr PI) was synthesized in such a way that the carboxy-terminal end of any cDNA could be inserted in frame with a sequence encoding the protease factor Xa cleavage site followed by a nucleotide sequence encoding 6 histidines and 2 stop codons (a new Pac I restriction site was also created downstream the 3' end). This oligonucleotide with SEQ ID NO 2/95 was introduced between the Xma I and Pst I sites of pgptATA18 (Figure 3).

30 Oligonucleotide linker with SEQ ID NO 2/95:

5' CCGGG GAGGCCTGCACGTGATCGAGGGGCAGACACCATCACCACCATCACTAATAGTTAATTA CTGCA3
3' C CTCCGGACGTGCACTAGCTCCCGTCTGTGGTAGTGGTGGTAGTGATTATCAATTAAT G

XmaI PsrI

35

Example 2. Construction of HCV recombinant plasmids

i.

2.1. Constructs encoding different forms of the E1 protein

5 Polymerase Chain Reaction (PCR) products were derived from the serum samples by RNA preparation and subsequent reverse-transcription and PCR as described previously (Stuyver et al., 1993b). Table 1 shows the features of the respective clones and the primers used for amplification. The PCR fragments were cloned into the Sma I-cut pSP72 (Promega) plasmids. The following clones were selected for insertion into
10 vaccinia recombination vectors: HCCI9A (SEQ ID NO 3), HCCI10A (SEQ ID NO 5), HCCI11A (SEQ ID NO 7), HCCI12A (SEQ ID NO 9), HCCI13A (SEQ ID NO 11), and HCCI17A (SEQ ID NO 13) as depicted in Figure 21. cDNA fragments containing the E1-coding regions were cleaved by EcoRI and HindIII restriction from the respective pSP72 plasmids and inserted into the EcoRI/HindIII-cut pgptATA-18 vaccinia recombination
15 vector (described in example 1), downstream of the 11K vaccinia virus late promoter. The respective plasmids were designated pvHCV-9A, pvHCV-10A, pvHCV-11A, pvHCV-12A, pvHCV-13A and pvHCV-17A, of which pvHCV-11A is shown in Figure 4.

2.2. Hydrophobic region E1 deletion mutants

20 Clone HCCI37, containing a deletion of codons Asp264 to Val287 (nucleotides 790 to 861, region encoding hydrophobic domain I) was generated as follows: 2 PCR fragments were generated from clone HCCI10A with primer sets HCPPr52 (SEQ ID NO 16)/HCPPr107 (SEQ ID NO 19) and HCPPr108 (SEQ ID NO 20)/HCPPr54 (SEQ ID NO 18).
25 These primers are shown in Figure 21. The two PCR fragments were purified from agarose gel after electrophoresis and 1 ng of each fragment was used together as template for PCR by means of primers HCPPr52 (SEQ ID NO 16) and HCPPr54 (SEQ ID NO 18). The resulting fragment was cloned into the Sma I-cut pSP72 vector and clones containing the deletion were readily identified because of the deletion of 24 codons (72
30 base pairs). Plasmid pSP72HCCI37 containing clone HCCI37 (SEQ ID 15) was selected. A recombinant vaccinia plasmid containing the full-length E1 cDNA lacking hydrophobic domain I was constructed by inserting the HCV sequence surrounding the deletion (fragment cleaved by Xma I and BamH I from the vector pSP72-HCCI37) into the Xma I-Bam H I sites of the vaccinia plasmid pvHCV-10A. The resulting plasmid was named

pvHCV-37. After confirmatory sequencing, the amino-terminal region containing the internal deletion was isolated from this vector pvHCV-37 (cleavage by EcoR I and BstE II) and reinserted into the Eco R I and Bst EII-cut pvHCV-11A plasmid. This construct was expected to express an E1 protein with both hydrophobic domains deleted and was named pvHCV-38. The E1-coding region of clone HCCI38 is represented by SEQ ID NO 23.

As the hydrophilic region at the E1 carboxyterminus (theoretically extending to around amino acids 337-340) was not completely included in construct pvHCV-38, a larger E1 region lacking hydrophobic domain I was isolated from the pvHCV-37 plasmid by EcoR I/Bam HI cleavage and cloned into an EcoRI/BamHI-cut pgsATA-18 vector. The resulting plasmid was named pvHCV-39 and contained clone HCCI39 (SEQ ID NO 25). The same fragment was cleaved from the pvHCV-37 vector by BamH I (of which the sticky ends were filled with Klenow DNA Polymerase I (Boehringer)) and subsequently by EcoR I (5' cohesive end). This sequence was inserted into the EcoRI and Bbr PI-cut vector pMS-66. This resulted in clone HCCI40 (SEQ ID NO 27) in plasmid pvHCV-40, containing a 6 histidine tail at its carboxy-terminal end.

2.3. E1 of other genotypes

Clone HCCI62 (SEQ ID NO 29) was derived from a type 3a-infected patient with chronic hepatitis C (serum BR36, clone BR36-9-13, SEQ ID NO 19 in WO 94/25601, and see also Stuyver et al. 1993a) and HCCI63 (SEQ ID NO 31) was derived from a type 5a-infected child with post-transfusion hepatitis (serum BE95, clone PC-4-1, SEQ ID NO 45 in WO 94/25601).

2.4. E2 constructs

The HCV E2 PCR fragment 22 was obtained from serum BE11 (genotype 1b) by means of primers HCP109 (SEQ ID NO 33) and HCP72 (SEQ ID NO 34) using techniques of RNA preparation, reverse-transcription and PCR, as described in Stuyver et al., 1993b, and the fragment was cloned into the Sma I-cut pSP72 vector. Clone HCCI22A (SEQ ID NO 35) was cut with NcoI/AlwNI or by BamHI/AlwNI and the sticky ends of the fragments were blunted (NcoI and BamHI sites with Klenow DNA Polymerase I (Boehringer), and AlwNI with T4 DNA polymerase (Boehringer)). The

BamHI/AIwNI cDNA fragment was then inserted into the vaccinia pgsATA-18 vector that had been linearized by EcoR I and Hind III cleavage and of which the cohesive ends had been filled with Klenow DNA Polymerase (Boehringer). The resulting plasmid was named pvHCV-41 and encoded the E2 region from amino acids Met347 to Gln673, including 37 amino acids (from Met347 to Gly383) of the E1 protein that can serve as signal sequence. The same HCV cDNA was inserted into the EcoR I and Bbr PI-cut vector pMS66, that had subsequently been blunt ended with Klenow DNA Polymerase. The resulting plasmid was named pvHCV-42 and also encoded amino acids 347 to 683. The NcoI/AIwNI fragment was inserted in a similar way into the same sites of pgsATA-18 (pvHCV-43) or pMS-66 vaccinia vectors (pvHCV-44). pvHCV-43 and pvHCV-44 encoded amino acids 364 to 673 of the HCV polyprotein, of which amino acids 364 to 383 were derived from the natural carboxyterminal region of the E1 protein encoding the signal sequence for E2, and amino acids 384 to 673 of the mature E2 protein.

2.5. Generation of recombinant HCV-vaccinia viruses

Rabbit kidney RK13 cells (ATCC CCL 37), human osteosarcoma 143B thymidine kinase deficient (TK⁻) (ATCC CRL 8303), HeLa (ATCC CCL 2), and Hep G2 (ATCC HB 8065) cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, Md, USA). The cells were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10 % foetal calf serum, and with Earle's salts (EMEM) for RK13 and 143 B (TK⁻), and with glucose (4 g/l) for Hep G2. The vaccinia virus WR strain (Western Reserve, ATCC VR119) was routinely propagated in either 143B or RK13 cells, as described previously (Panicali & Paoletti, 1982; Piccini et al., 1987; Mackett et al., 1982, 1984, and 1986). A confluent monolayer of 143B cells was infected with wild type vaccinia virus at a multiplicity of infection (m.o.i.) of 0.1 (= 0.1 plaque forming unit (PFU) per cell). Two hours later, the vaccinia recombination plasmid was transfected into the infected cells in the form of a calcium phosphate coprecipitate containing 500 ng of the plasmid DNA to allow homologous recombination (Graham & van der Eb, 1973; Mackett et al., 1985). Recombinant viruses expressing the *Escherichia coli* xanthine-guanine phosphoribosyl transferase (gpt) protein were selected on rabbit kidney RK13 cells incubated in selection medium (EMEM containing 25 µg/ml mycophenolic acid (MPA), 250 µg/ml xanthine, and 15 µg/ml hypoxanthine; Falkner and Moss, 1988; Janknecht et al, 1991). Single recombinant viruses were purified on fresh

monolayers of RK13 cells under a 0.9% agarose overlay in selection medium. Thymidine kinase deficient (TK⁻) recombinant viruses were selected and then plaque purified on fresh monolayers of human 143B cells (TK⁻) in the presence of 25 µg/ml 5-bromo-2'-deoxyuridine. Stocks of purified recombinant HCV-vaccinia viruses were prepared by
5 infecting either human 143 B or rabbit RK13 cells at an m.o.i. of 0.05 (Mackett et al, 1988). The insertion of the HCV cDNA fragment in the recombinant vaccinia viruses was confirmed on an aliquot (50 µl) of the cell lysate after the MPA selection by means of PCR with the primers used to clone the respective HCV fragments (see Table 1). The recombinant vaccinia-HCV viruses were named according to the vaccinia recombination
10 plasmid number, e.g. the recombinant vaccinia virus vvHCV-10A was derived from recombining the wild type WR strain with the pvHCV-10A plasmid.

Example 3: infection of cells with recombinant vaccinia viruses

15 A confluent monolayer of RK13 cells was infected at a m.o.i. of 3 with the recombinant HCV-vaccinia viruses as described in example 2. For infection, the cell monolayer was washed twice with phosphate-buffered saline pH 7.4 (PBS) and the recombinant vaccinia virus stock was diluted in MEM medium. Two hundred µl of the virus solution was added per 10⁶ cells such that the m.o.i. was 3, and incubated for 45
20 min at 24°C. The virus solution was aspirated and 2 ml of complete growth medium (see example 2) was added per 10⁵ cells. The cells were incubated for 24 hr at 37°C during which expression of the HCV proteins took place.

Example 4: Analysis of recombinant proteins by means of western blotting

25 The infected cells were washed two times with PBS, directly lysed with lysis buffer (50 mM Tris.HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 5 mM MgCl₂, 1 µg/ml aprotinin (Sigma, Bornem, Belgium)) or detached from the flasks by incubation in 50 mM Tris.HCL pH 7.5/ 10 mM EDTA/ 150 mM NaCl for 5 min, and collected by
30 centrifugation (5 min at 1000g). The cell pellet was then resuspended in 200 µl lysis buffer (50 mM Tris.HCL pH 8.0, 2 mM EDTA, 150 mM NaCl, 5 mM MgCl₂, aprotinin, 1% Triton X-100) per 10⁵ cells. The cell lysates were cleared for 5 min at 14,000 rpm in an Eppendorf centrifuge to remove the insoluble debris. Proteins of 20 µl lysate were separated by means of sodium dodecyl sulphate-polyacrylamide gel electrophoresis

(SDS-PAGE). The proteins were then electro-transferred from the gel to a nitrocellulose sheet (Amersham) using a Hoëfer HSI transfer unit cooled to 4°C for 2 hr at 100 V constant voltage, in transfer buffer (25 mM Tris.HCl pH 8.0, 192 mM glycine, 20% (v/v) methanol). Nitrocellulose filters were blocked with Blotto (5 % (w/v) fat-free instant milk powder in PBS; Johnson et al., 1981) and incubated with primary antibodies diluted in Blotto/0.1 % Tween 20. Usually, a human negative control serum or serum of a patient infected with HCV were 200 times diluted and preincubated for 1 hour at room temperature with 200 times diluted wild type vaccinia virus-infected cell lysate in order to decrease the non-specific binding. After washing with Blotto/0.1 % Tween 20, the nitrocellulose filters were incubated with alkaline phosphatase substrate solution diluted in Blotto/0.1 % Tween 20. After washing with 0.1 % Tween 20 in PBS, the filters were incubated with alkaline phosphatase substrate solution (100 mM Tris.HCl pH 9.5, 100 mM NaCl, 5 mM MgCl₂, 0.38 µg/ml nitroblue tetrazolium, 0.165 µg/ml 5-bromo-4-chloro-3-indolylphosphate). All steps, except the electrotransfer, were performed at room temperature.

Example 5: Purification of recombinant E1 or E2 protein

5.1. Lysis

Infected RK13 cells (carrying E1 or E2 constructs) were washed 2 times with phosphate-buffered saline (PBS) and detached from the culture recipients by incubation in PBS containing 10 mM EDTA. The detached cells were washed twice with PBS and 1 ml of lysis buffer (50 mM Tris.HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 5 mM MgCl₂, 1 µg/ml aprotinin (Sigma, Bornem, Belgium) containing 2 mM biotinylated N-ethylmaleimide (biotin-NEM) (Sigma) was added per 10⁵ cells at 4°C. This lysate was homogenized with a type B douncer and left at room temperature for 0.5 hours. Another 5 volumes of lysis buffer containing 10 mM N-ethylmaleimide (NEM, Aldrich, Bornem, Belgium) was added to the primary lysate and the mixture was left at room temperature for 15 min. Insoluble cell debris was cleared from the solution by centrifugation in a Beckman JA-14 rotor at 14,000 rpm (30100 g at r_{max}) for 1 hour at 4°C.

5.2. Lectin Chromatography

The cleared cell lysate was loaded at a rate of 1 ml/min on a 0.8 by 10 cm Lentil-
lectin Sepharose 4B column (Pharmacia) that had been equilibrated with 5 column
5 volumes of lysis buffer at a rate of 1 ml/min. The lentil-lectin column was washed with
5 to 10 column volumes of buffer 1 (0.1M potassium phosphate pH 7.3, 500 mM KCl,
5% glycerol, 1 mM 6-NH₂-hexanoic acid, 1 mM MgCl₂, and 1% DecylPEG (KWANT,
Bedum, The Netherlands). In some experiments, the column was subsequently washed
with 10 column volumes of buffer 1 containing 0.5% Empigen-BB (Calbiochem, San
10 Diego, CA, USA) instead of 1% DecylPEG. The bound material was eluted by applying
elution buffer (10 mM potassium phosphate pH 7.3, 5% glycerol, 1 mM hexanoic acid,
1mM MgCl₂, 0.5% Empigen-BB, and 0.5 M α -methyl-mannopyranoside). The eluted
material was fractionated and fractions were screened for the presence of E1 or E2
protein by means of ELISA as described in example 6. Figure 22 shows ELISA results
15 obtained from lentil lectin eluate fractions of 4 different E1 purifications of cell lysates
infected with vvHCV39 (type 1b), vvHCV40 (type 1b), vvHCV62 (type 3a), and
vvHCV63 (type 5a). Figure 23 shows the profiles obtained from the values shown in
Figure 22. These results show that the lectin affinity column can be employed for
envelope proteins of the different types of HCV.

5.3. Concentration and partial reduction

The E1- or E2-positive fractions were pooled and concentrated on a Centricon
25 30 kDa (Amicon) by centrifugation for 3 hours at 5,000 rpm in a Beckman JA-20 rotor
at 4°C. In some experiments the E1- or E2-positive fractions were pooled and
concentrated by nitrogen evaporation. An equivalent of $3 \cdot 10^8$ cells was concentrated
to approximately 200 μ l. For partial reduction, 30% Empigen-BB (Calbiochem, San
Diego, CA, USA) was added to this 200 μ l to a final concentration of 3.5 %, and 1M
30 DTT in H₂O was subsequently added to a final concentration of 1.5 to 7.5 mM and
incubated for 30 min at 37 °C. NEM (1M in dimethylsulphoxide) was subsequently
added to a final concentration of 50 mM and left to react for another 30 min at 37 °C
to block the free sulphydryl groups.

5.4. Gel filtration chromatography

i.

A Superdex-200 HR 10/20 column (Pharmacia) was equilibrated with 3 column volumes PBS/3% Empigen-BB. The reduced mixture was injected in a 500 μ l sample
5 loop of the Smart System (Pharmacia) and PBS/3% Empigen-BB buffer was added for gelfiltration. Fractions of 250 μ l were collected from V_0 to V_r . The fractions were screened for the presence of E1 or E2 protein as described in example 6.

Figure 24 shows ELISA results obtained from fractions obtained after gelfiltration chromatography of 4 different E1 purifications of cell lysates infected with vvHCV39
10 (type 1b), vvHCV40 (type 1b), vvHCV62 (type 3a), and vvHCV63 (type 5a). Figure 25 shows the profiles obtained from purifications of E1 proteins of types 1b, 3a, and 5a (from RK13 cells infected with vvHCV39, vvHCV62, and vvHCV63, respectively; purified on lentil lectin and reduced as in the previous examples). The peaks indicated with '1', '2', and '3', represent pure E1 protein peaks (E1 reactivity mainly in fractions
15 26 to 30). These peaks show very similar molecular weights of approximately 70 kDa, corresponding to dimeric E1 protein. Other peaks in the three profiles represent vaccinia virus and/or cellular proteins which could be separated from E1 only because of the reduction step as outlined in example 5.3. and because of the subsequent gelfiltration step in the presence of the proper detergent. As shown in Figure 26 pool 1
20 (representing fractions 10 to 17) and pool 2 (representing fractions 18 to 25) contain contaminating proteins not present in the E1 pool (fractions 26 to 30). The E1 peak fractions were ran on SDS/PAGE and blotted as described in example 4. Proteins labelled with NEM-biotin were detected by streptavidin-alkaline phosphatase as shown in Figure 27. It can be readily observed that, amongst others, the 29 kDa and 45kDa
25 contaminating proteins present before the gelfiltration chromatography (lane 1) are only present at very low levels in the fractions 26 to 30. The band at approximately 65kDa represents the E1 dimeric form that could not be entirely disrupted into the monomeric E1 form. Similar results were obtained for the type 3a E1 protein (lanes 10 to 15), which shows a faster mobility on SDS/PAGE because of the presence of only 5
30 carbohydrates instead of 6. Figure 28 shows a silver stain of an SDS/PAGE gel run in identical conditions as in Figure 26. A complete overview of the purification procedure is given in Figure 29.

The presence of purified E1 protein was further confirmed by means of western blotting as described in example 4. The dimeric E1 protein appeared to be non-

aggregated and free of contaminants. The subtype 1b E1 protein purified from vvHCV40-infected cells according to the above scheme was aminoterminally sequenced on an 477 Perkins-Elmer sequencer and appeared to contain a tyrosine as first residue. This confirmed that the E1 protein had been cleaved by the signal peptidase at the correct position (between A191 and Y192) from its signal sequence. This confirms the finding of Hijikata et al. (1991) that the aminotermminus of the mature E1 protein starts at amino acid position 192.

5.5. Purification of the E2 protein

The E2 protein (amino acids 384 to 673) was purified from RK13 cells infected with vvHCV44 as indicated in Examples 5.1 to 5.4. Figure 30 shows the OD₂₈₀ profile (continuous line) of the lentil lectin chromatography. The dotted line represents the E2 reactivity as detected by ELISA (see example 6). Figure 31 shows the same profiles obtained from gelfiltration chromatography of the lentil-lectin E2 pool (see Figure 30), part of which was reduced and blocked according to the methods as set out in example 5.3., and part of which was immediately applied to the column. Both parts of the E2 pool were run on separate gelfiltration columns. It could be demonstrated that E2 forms covalently-linked aggregates with contaminating proteins if no reduction has been performed. After reduction and blocking, the majority of contaminating proteins segregated into the V₀ fraction. Other contaminating proteins copurified with the E2 protein, were not covalently linked to the E2 protein any more because these contaminants could be removed in a subsequent step. Figure 32 shows an additional Ni²⁺-IMAC purification step carried out for the E2 protein purification. This affinity purification step employs the 6 histidine residues added to the E2 protein as expressed from vvHCV44. Contaminating proteins either run through the column or can be removed by a 30 mM imidazole wash. Figure 33 shows a silver-stained SDS/PAGE of 0.5 µg of purified E2 protein and a 30 mM imidazole wash. The pure E2 protein could be easily recovered by a 200 mM imidazole elution step. Figure 34 shows an additional desalting step intended to remove imidazole and to be able to switch to the desired buffer, e.g. PBS, carbonate buffer, saline.

Starting from about 50,000 cm² of RK13 cells infected with vvHCV11A (or vvHCV40) for the production of E1 or vvHCV41, vvHCV42, vvHCV43, or vvHCV44 for production of E2 protein, the procedures described in examples 5.1 to 5.5 allow the

purification of approximately 1.3 mg of E1 protein and 0.6 mg of E2 protein.

It should also be remarked that secreted E2 protein (constituting approximately 30-40%, 60-70% being in the intracellular form) is characterized by aggregate formation (contrary to expectations). The same problem is thus posed to purify secreted E2. The
5 secreted E2 can be purified as disclosed above.

Example 6: ELISA for the detection of anti-E1 or anti-E2 antibodies or for the detection of E1 or E2 proteins

10

Maxisorb microwell plates (Nunc, Roskilde, Denmark) were coated with 1 volume (e.g. 50 μ l or 100 μ l or 200 μ l) per well of a 5 μ g/ml solution of Streptavidin (Boehringer Mannheim) in PBS for 16 hours at 4°C or for 1 hour at 37°C. Alternatively, the wells were coated with 1 volume of 5 μ g/ml of Galanthus nivalis agglutinin (GNA) in 50 mM
15 sodium carbonate buffer pH 9.6 for 16 hours at 4°C or for 1 hour at 37°C. In the case of coating with GNA, the plates were washed 2 times with 400 μ l of Washing Solution of the Innatest HCV Ab III kit (Innogenetics, Zwijndrecht, Belgium). Unbound coating surfaces were blocked with 1.5 to 2 volumes of blocking solution (0.1% casein and 0:1% NaN_3 in PBS) for 1 hour at 37°C or for 16 hours at 4°C. Blocking solution was
20 aspirated. Purified E1 or E2 was diluted to 100-1000 ng/ml (concentration measured at $A = 280$ nm) or column fractions to be screened for E1 or E2 (see example 5), or E1 or E2 in non-purified cell lysates (example 5.1.) were diluted 20 times in blocking solution, and 1 volume of the E1 or E2 solution was added to each well and incubated for 1 hour at 37°C on the Streptavidin- or GNA-coated plates. The microwells were
25 washed 3 times with 1 volume of Washing Solution of the Innatest HCV Ab III kit (Innogenetics, Zwijndrecht, Belgium). Serum samples were diluted 20 times or monoclonal anti-E1 or anti-E2 antibodies were diluted to a concentration of 20 ng/ml in Sample Diluent of the Innatest HCV Ab III kit and 1 volume of the solution was left to react with the E1 or E2 protein for 1 hour at 37°C. The microwells were washed 5
30 times with 400 μ l of Washing Solution of the Innatest HCV Ab III kit (Innogenetics, Zwijndrecht, Belgium). The bound antibodies were detected by incubating each well for 1 hour at 37°C with a goat anti-human or anti-mouse IgG, peroxidase-conjugated secondary antibody (DAKO, Glostrup, Denmark) diluted 1/80,000 in 1 volume of Conjugate Diluent of the Innatest HCV Ab III kit (Innogenetics, Zwijndrecht, Belgium).

and color development was obtained by addition of substrate of the Innostest HCV Ab III kit (Innogenetics, Zwijndrecht, Belgium) diluted 100 times in 1 volume of Substrate Solution of the Innostest HCV Ab III kit (Innogenetics, Zwijndrecht, Belgium) for 30 min at 24°C after washing of the plates 3 times with 400 µl of Washing Solution of the Innostest HCV Ab III kit (Innogenetics, Zwijndrecht, Belgium).

Example 7: Follow up of patient groups with different clinical profiles

7.1. Monitoring of anti-E1 and anti-E2 antibodies

The current hepatitis C virus (HCV) diagnostic assays have been developed for screening and confirmation of the presence of HCV antibodies. Such assays do not seem to provide information useful for monitoring of treatment or for prognosis of the outcome of disease. However, as is the case for hepatitis B, detection and quantification of anti-envelope antibodies may prove more useful in a clinical setting. To investigate the possibility of the use of anti-E1 antibody titer and anti-E2 antibody titer as prognostic markers for outcome of hepatitis C disease, a series of IFN-α treated patients with long-term sustained response (defined as patients with normal transaminase levels and negative HCV-RNA test (PCR in the 5' non-coding region) in the blood for a period of at least 1 year after treatment) was compared with patients showing no response or showing biochemical response with relapse at the end of treatment.

A group of 8 IFN-α treated patients with long-term sustained response (LTR, follow up 1 to 3.5 years, 3 type 3a and 5 type 1b) was compared with 9 patients showing non-complete responses to treatment (NR, follow up 1 to 4 years, 6 type 1b and 3 type 3a). Type 1b (vvHCV-39, see example 2.5.) and 3a E1 (vvHCV-62, see example 2.5.) proteins were expressed by the vaccinia virus system (see examples 3 and 4) and purified to homogeneity (example 5). The samples derived from patients infected with a type 1b hepatitis C virus were tested for reactivity with purified type 1b E1 protein, while samples of a type 3a infection were tested for reactivity of anti-type 3a E1 antibodies in an ELISA as described in example 6. The genotypes of hepatitis C viruses infecting the different patients were determined by means of the Inno-LiPA genotyping assay (Innogenetics, Zwijndrecht, Belgium). Figure 5 shows the anti-E1 signal-to-noise ratios of these patients followed during the course of interferon

08928757-0911997
treatment and during the follow-up period after treatment. LTR cases consistently showed rapidly declining anti-E1 levels (with complete negativation in 3 cases), while anti-E1 levels of NR cases remained approximately constant. Some of the obtained anti-E1 data are shown in Table 2 as average S/N ratios \pm SD (mean anti-E1 titer). The anti-E1 titer could be deduced from the signal to noise ratio as show in Figures 5, 6, 7, and 8.

Already at the end of treatment, marked differences could be observed between the 2 groups. Anti-E1 antibody titers had decreased 6.9 times in LTR but only 1.5 times in NR. At the end of follow up, the anti-E1 titers had declined by a factor of 22.5 in the patients with sustained response and even slightly increased in NR. Therefore, based on these data, decrease of anti-E1 antibody levels during monitoring of IFN- α therapy correlates with long-term, sustained response to treatment. The anti-E1 assay may be very useful for prognosis of long-term response to IFN treatment, or to treatment of the hepatitis C disease in general.

This finding was not expected. On the contrary, the inventors had expected the anti-E1 antibody levels to increase during the course of IFN treatment in patients with long term response. As is the case for hepatitis B, the virus is cleared as a consequence of the seroconversion for anti-HBsAg antibodies. Also in many other virus infections, the virus is eliminated when anti-envelope antibodies are raised. However, in the experiments of the present invention, anti-E1 antibodies clearly decreased in patients with a long-term response to treatment, while the antibody-level remained approximately at the same level in non-responding patients. Although the outcome of these experiments was not expected, this non-obvious finding may be very important and useful for clinical diagnosis of HCV infections. As shown in Figures 9, 10, 11, and 12, anti-E2 levels behaved very differently in the same patients studied and no obvious decline in titers was observed as for anti-E1 antibodies. Figure 35 gives a complete overview of the pilot study.

As can be deduced from Table 2, the anti-E1 titers were on average at least 2 times higher at the start of treatment in long term responders compared with incomplete responders to treatment. Therefore, measuring the titer of anti-E1 antibodies at the start of treatment, or monitoring the patient during the course of infection and measuring the anti-E1 titer, may become a useful marker for clinical diagnosis of hepatitis C. Furthermore, the use of more defined regions of the E1 or E2 proteins may become desirable, as shown in example 7.3.

7.2. Analysis of E1 and E2 antibodies in a larger patient cohort

The pilot study lead the inventors to conclude that, in case infection was completely cleared, antibodies to the HCV envelope proteins changed more rapidly than antibodies to the more conventionally studied HCV antigens, with E1 antibodies changing most vigorously. We therefore included more type 1b and 3a-infected LTR and further supplemented the cohort with a matched series of NR, such that both groups included 14 patients each. Some partial responders (PR) and responders with relapse (RR) were also analyzed.

Figure 36 depicts average E1 antibody (E1Ab) and E2 antibody (E2Ab) levels in the LTR and NR groups and Tables 4 and 5 show the statistical analyses. In this larger cohort, higher E1 antibody levels before IFN- α therapy were associated with LTR ($P < 0.03$). Since much higher E1 antibody levels were observed in type 3a-infected patients compared with type 1b-infected patients (Figure 37), the genotype was taken into account (Table 4). Within the type 1b-infected group, LTR also had higher E1 antibody levels than NR at the initiation of treatment [$P < 0.05$]; the limited number of type 3a-infected NR did not allow statistical analysis.

Of antibody levels monitored in LTR during the 1.5-year follow up period, only E1 antibodies cleared rapidly compared with levels measured at initiation of treatment [$P = 0.0058$, end of therapy; $P = 0.0047$ and $P = 0.0051$ at 6 and 12 months after therapy, respectively]. This clearance remained significant within type 1- or type 3-infected LTR (average P values < 0.05). These data confirmed the initial finding that E1Ab levels decrease rapidly in the early phase of resolvment. This feature seems to be independent of viral genotype. In NR, PR, or RR, no changes in any of the antibodies measured were observed throughout the follow up period. In patients who responded favourably to treatment with normalization of ALT levels and HCV-RNA negative during treatment, there was a marked difference between sustained responders (LTR) and responders with a relapse (RR). In contrast to LTR, RR did not show any decreasing E1 antibody levels, indicating the presence of occult HCV infection that could neither be demonstrated by PCR or other classical techniques for detection of HCV-RNA, nor by raised ALT levels. The minute quantities of viral RNA, still present in the RR group during treatment, seemed to be capable of anti-E1 B cell stimulation. Anti-E1 monitoring may therefore not only be able to discriminate LTR from NR, but also from RR.

7.3. Monitoring of antibodies of defined regions of the E1 protein

i.

Although the molecular biological approach of identifying HCV antigens resulted in unprecedented breakthrough in the development of viral diagnostics, the method of immune screening of λ gt11 libraries predominantly yielded linear epitopes dispersed throughout the core and non-structural regions, and analysis of the envelope regions had to await cloning and expression of the E1/E2 region in mammalian cells. This approach sharply contrasts with many other viral infections of which epitopes to the envelope regions had already been mapped long before the deciphering of the genomic structure. Such epitopes and corresponding antibodies often had neutralizing activity useful for vaccine development and/or allowed the development of diagnostic assays with clinical or prognostic significance (e.g. antibodies to hepatitis B surface antigen).

As no HCV vaccines or tests allowing clinical diagnosis and prognosis of hepatitis C disease are available today, the characterization of viral envelope regions exposed to immune surveillance may significantly contribute to new directions in HCV diagnosis and prophylaxis.

Several 20-mer peptides (Table 3) that overlapped each other by 8 amino acids, were synthesized according to a previously described method (EP-A-O 489 968) based on the HC-J1 sequence (Okamoto et al., 1990). None of these, except peptide env35 (also referred to as E1-35), was able to detect antibodies in sera of approximately 200 HCV cases. Only 2 sera reacted slightly with the env35 peptide. However, by means of the anti-E1 ELISA as described in example 6, it was possible to discover additional epitopes as follows: The anti-E1 ELISA as described in example 6 was modified by mixing 50 μ g/ml of E1 peptide with the 1/20 diluted human serum in sample diluent. Figure 13 shows the results of reactivity of human sera to the recombinant E1 (expressed from vvHCV-40) protein, in the presence of single or of a mixture of E1 peptides. While only 2% of the sera could be detected by means of E1 peptides coated on strips in a Line Immunoassay format, over half of the sera contained anti-E1 antibodies which could be competed by means of the same peptides, when tested on the recombinant E1 protein. Some of the murine monoclonal antibodies obtained from Balb/C mice after injection with purified E1 protein were subsequently competed for reactivity to E1 with the single peptides (Figure 14). Clearly, the region of env53 contained the predominant epitope, as the addition of env53 could substantially compete reactivity of several sera with E1, and antibodies to the env31 region were also

detected. This finding was surprising, since the env53 and env31 peptides had not shown any reactivity when coated directly to the solid phase.

Therefore peptides were synthesized using technology described by applicant previously (in WO 93/18054). The following peptides were synthesized:

5 peptide env35A-biotin

NH₂-SNSSEAADMIMHTPGCV-GKbiotin (SEQ ID NO 51)

spanning amino acids 208 to 227 of the HCV polyprotein in the E1 region

peptide biotin-env53 ('epitope A')

biotin-GG-ITGHRMAWDMMMNSPTTAL-COOH (SEQ ID NO 52)

10 spanning amino acids to 313 of 332 of the HCV polyprotein in the E1 region

peptide 1bE1 ('epitope B')

H₂N-YEVRNVSGIYHVTNDCSNSSIVYEAADMIMHTPGCGK -biotin (SEQ ID NO 53)

15 spanning amino acids 192 to 228 of the HCV polyprotein in the E1 region and compared with the reactivities of peptides E1a-BB (biotin-GG-TPTVATRDGKLPATQLRRHIDLL, SEQ ID NO 54) and E1b-BB (biotin-GG-TPTLAARDASVPTTTIRRHVDLL, SEQ ID NO 55) which are derived from the same region of sequences of genotype 1a and 1b respectively and which have been described at the

20 IXth international virology meeting in Glasgow, 1993 ('epitope C'). Reactivity of a panel of HCV sera was tested on epitopes A, B and C and epitope B was also compared with env35A (of 47 HCV-positive sera, 8 were positive on epitope B and none reacted with env35A). Reactivity towards epitopes A, B, and C was tested directly to the biotinylated peptides (50 µg/ml) bound to streptavidin-coated plates as described in example 6.

25 Clearly, epitopes A and B were most reactive while epitopes C and env35A-biotin were much less reactive. The same series of patients that had been monitored for their reactivity towards the complete E1 protein (example 7.1.) was tested for reactivity towards epitopes A, B, and C. Little reactivity was seen to epitope C, while as shown in Figures 15, 16, 17, and 18, epitopes A and B reacted with the majority of sera.

30 However, antibodies to the most reactive epitope (epitope A) did not seem to predict remission of disease, while the anti-1bE1 antibodies (epitope B) were present almost exclusively in long term responders at the start of IFN treatment. Therefore, anti-1bE1 (epitope B) antibodies and anti-env53 (epitope A) antibodies could be shown to be useful markers for prognosis of hepatitis C disease. The env53 epitope may be

advantageously used for the detection of cross-reactive antibodies (antibodies that cross-react between major genotypes) and antibodies to the env53 region may be very useful for universal E1 antigen detection in serum or liver tissue. Monoclonal antibodies that recognized the env53 region were reacted with a random epitope library. In 4 clones that reacted upon immunoscreening with the monoclonal antibody 5E1A10, the sequence -GWD- was present. Because of its analogy with the universal HCV sequence present in all HCV variants in the env53 region, the sequence AWD is thought to contain the essential sequence of the env53 cross-reactive murine epitope. The env31 clearly also contains a variable region which may contain an epitope in the amino terminal sequence -YQVRNSTGL- (SEQ ID NO 93) and may be useful for diagnosis. Env31 or E1-31 as shown in Table 3, is a part of the peptide 1bE1. Peptides E1-33 and E1-51 also reacted to some extent with the murine antibodies, and peptide E1-55 (containing the variable region 6 (V6); spanning amino acid positions 329-336) also reacted with some of the patient sera.

Anti-E2 antibodies clearly followed a different pattern than the anti-E1 antibodies, especially in patients with a long-term response to treatment. Therefore, it is clear that the decrease in anti-envelope antibodies could not be measured as efficiently with an assay employing a recombinant E1/E2 protein as with a single anti-E1 or anti-E2 protein. The anti-E2 response would clearly blur the anti-E1 response in an assay measuring both kinds of antibodies at the same time. Therefore, the ability to test anti-envelope antibodies to the single E1 and E2 proteins, was shown to be useful.

7.4. Mapping of anti-E2 antibodies

Of the 24 anti-E2 Mabs only three could be competed for reactivity to recombinant E2 by peptides, two of which reacted with the HVRI region (peptides E2-67 and E2-69, designated as epitope A) and one which recognized an epitope competed by peptide E2-13B (epitope C). The majority of murine antibodies recognized conformational anti-E2 epitopes (Figure 19). A human response to HVRI (epitope A), and to a lesser extent HVRII (epitope B) and a third linear epitope region (competed by peptides E2-23, E2-25 or E2-27, designated epitope E) and a fourth linear epitope region (competed by peptide E2-17B, epitope D) could also frequently be observed, but the majority of sera reacted with conformational epitopes (Figure 20). These conformational epitopes could be grouped according to their relative positions as follows: the IgG

antibodies in the supernatant of hybridomas 15C8C1, 12D11F1, 9G3E6, 8G10D1H9, 10D3C4, 4H6B2, 17F2C2, 5H6A7, 15B7A2 recognizing conformational epitopes were purified by means of protein A affinity chromatography and 1 mg/ml of the resulting IgG's were biotinylated in borate buffer in the presence of biotin. Biotinylated antibodies were separated from free biotin by means of gelfiltration chromatography. Pooled biotinylated antibody fractions were diluted 100 to 10,000 times. E2 protein bound to the solid phase was detected by the biotinylated IgG in the presence of 100 times the amount of non-biotinylated competing antibody and subsequently detected by alkaline phosphatase labeled streptavidin.

Percentages of competition are given in Table 6. Based on these results, 4 conformational anti-E2 epitope regions (epitopes F, G, H and I) could be delineated (Figure 38). Alternatively, these Mabs may recognize mutant linear epitopes not represented by the peptides used in this study. Mabs 4H6B2 and 10D3C4 competed reactivity of 16A6E7, but unlike 16A6E7, they did not recognize peptide E2-13B. These Mabs may recognize variants of the same linear epitope (epitope C) or recognize a conformational epitope which is sterically hindered or changes conformation after binding of 16A6E7 to the E2-13B region (epitope H).

Example 8: E1 glycosylation mutants

8.1. Introduction

The E1 protein encoded by vvHCV10A, and the E2 protein encoded by vvHCV41 to 44 expressed from mammalian cells contain 6 and 11 carbohydrate moieties, respectively. This could be shown by incubating the lysate of vvHCV10A-infected or vvHCV44-infected RK13 cells with decreasing concentrations of glycosidases (PNGase F or Endoglycosidase H, (Boehringer Mannheim Biochemica) according to the manufacturer's instructions), such that the proteins in the lysate (including E1) are partially deglycosylated (Fig. 39 and 40, respectively).

5 Mutants devoid of some of their glycosylation sites could allow the selection of envelope proteins with improved immunological reactivity. For HIV for example, gp120 proteins lacking certain selected sugar-addition motifs, have been found to be particularly useful for diagnostic or vaccine purpose. The addition of a new oligosaccharide side chain in the hemagglutinin protein of an escape mutant of the A/Hong Kong/3/68 (H3N2) influenza virus prevents reactivity with a neutralizing monoclonal antibody (Skehel et al., 1984). When novel glycosylation sites were introduced into the influenza hemagglutinin protein by site-specific mutagenesis, dramatic antigenic changes were observed, suggesting that the carbohydrates serve as a modulator of antigenicity (Gallagher et al., 1988). In another analysis, the 8 carbohydrate-addition motifs of the surface protein gp70 of the Friend Murine Leukemia Virus were deleted. Although seven of the mutations did not affect virus infectivity, mutation of the fourth glycosylation signal with respect to the amino terminus resulted in a non-infectious phenotype (Kayman et al., 1991). Furthermore, it is known in the art that addition of N-linked carbohydrate chains is important for stabilization of folding intermediates and thus for efficient folding, prevention of malfolding and degradation in the endoplasmic reticulum, oligomerization, biological activity, and transport of glycoproteins (see reviews by Rose et al., 1988; Doms et al., 1993; Helenius, 1994).

15 After alignment of the different envelope protein sequences of HCV genotypes, it may be inferred that not all 6 glycosylation sites on the HCV subtype 1b E1 protein are required for proper folding and reactivity, since some are absent in certain (sub)types. The fourth carbohydrate motif (on Asn251), present in types 1b, 6a, 7, 8, and 9, is absent in all other types known today. This sugar-addition motif may be mutated to yield a type 1b E1 protein with improved reactivity. Also the type 2b sequences show an extra glycosylation site in the V5 region (on Asn299). The isolate S83, belonging to genotype 2c, even lacks the first carbohydrate motif in the V1 region (on Asn), while it is present on all other isolates (Stuyver et al., 1994). However, even among the completely conserved sugar-addition motifs, the presence of the carbohydrate may not be required for folding, but may have a role in evasion of immune surveillance. Therefore, identification of the carbohydrate addition motifs which are not required for proper folding (and reactivity) is not obvious, and each mutant has to be analyzed and tested for reactivity. Mutagenesis of a glycosylation motif (NXS or NXT sequences) can be achieved by either mutating the codons for N, S, or T, in such a way that these codons encode amino acids different from N in the case of N, and/or amino

acids different from S or T in the case of S and in the case of T. Alternatively, the X position may be mutated into P; since it is known that NPS or NPT are not frequently modified with carbohydrates. After establishing which carbohydrate-addition motifs are required for folding and/or reactivity and which are not, combinations of such mutations may be made.

8.2. Mutagenesis of the E1 protein

All mutations were performed on the E1 sequence of clone HCCI10A (SEQ ID NO. 5). The first round of PCR was performed using sense primer 'GPT' (see Table 7) targetting the GPT sequence located upstream of the vaccinia 11K late promoter, and an antisense primer (designated GLY#, with # representing the number of the glycosylation site, see Fig. 41) containing the desired base change to obtain the mutagenesis. The six GLY# primers (each specific for a given glycosylation site) were designed such that:

- Modification of the codon encoding for the N-glycosylated Asn (AAC or AAT) to a Gln codon (CAA or CAG). Glutamine was chosen because it is very similar to asparagine (both amino acids are neutral and contain non-polar residues, glutamine has a longer side chain (one more -CH₂- group).
- The introduction of silent mutations in one or several of the codons downstream of the glycosylation site, in order to create a new unique or rare (e.g. a second SmaI site for E1Gly5) restriction enzyme site. Without modifying the amino acid sequence, this mutation will provide a way to distinguish the mutated sequences from the original E1 sequence (pvHCV-10A) or from each other (Figure 41). This additional restriction site may also be useful for the construction of new hybrid (double, triple, etc.) glycosylation mutants.
- 18 nucleotides extend 5' of the first mismatched nucleotide and 12 to 16 nucleotides extend to the 3' end. Table 7 depicts the sequences of the six GLY# primers overlapping the sequence of N-linked glycosylation sites.

For site-directed mutagenesis, the 'mispriming' or 'overlap extension' (Horton, 1993) was used. The concept is illustrated in Figures 42 and 43. First, two separate fragments were amplified from the target gene for each mutated site. The PCR product obtained from the 5' end (product GLY#) was amplified with the 5' sense GPT primer (see Table 7) and with the respective 3' antisense GLY# primers. The second fragment

(product OVR#) was amplified with the 3' antisense TK_R primer and the respective 5' sense primers (OVR# primers, see Table 7, Figure 43).

5 The OVR# primers target part of the GLY# primer sequence. Therefore, the two groups of PCR products share an overlap region of identical sequence. When these intermediate products are mixed (GLY-1 with OVR-1, GLY-2 with OVR-2, etc.), melted at high temperature, and reannealed, the top sense strand of product GLY# can anneal to the antisense strand of product OVR# (and vice versa) in such a way that the two strands act as primers for one another (see Fig. 42.B.). Extension of the annealed overlap by Taq polymerase during two PCR cycles created the full-length mutant molecule E1GLY#, which carries the mutation destroying the glycosylation site number #. Sufficient quantities of the E1GLY# products for cloning were generated in a third PCR by means of a common set of two internal nested primers. These two new primers are respectively overlapping the 3' end of the vaccinia 11K promoter (sense GPT-2 primer) and the 5' end of the vaccinia thymidine kinase locus (antisense TK_R-2 primer, see Table 7). All PCR conditions were performed as described in Stuyver et al. (1993).

15 Each of these PCR products was cloned by EcoRI/BamHI cleavage into the EcoRI/BamHI-cut vaccinia vector containing the original E1 sequence (pvHCV-10A).

The selected clones were analyzed for length of insert by EcoRI/BamHI cleavage and for the presence of each new restriction site. The sequences overlapping the mutated sites were confirmed by double-stranded sequencing.

8.3. Analysis of E1 glycosylation mutants

25 Starting from the 6 plasmids containing the mutant E1 sequences as described in example 8.2, recombinant vaccinia viruses were generated by recombination with wt vaccinia virus as described in example 2.5. Briefly, 175 cm²-flasks of subconfluent RK13 cells were infected with the 6 recombinant vaccinia viruses carrying the mutant E1 sequences, as well as with the vvHCV-10A (carrying the non-mutated E1 sequence) and wt vaccinia viruses. Cells were lysed after 24 hours of infection and analyzed on western blot as described in example 4 (see Figure 44A). All mutants showed a faster mobility (corresponding to a smaller molecular weight of approximately 2 to 3 kDa) on SDS-PAGE than the original E1 protein; confirming that one carbohydrate moiety was not added. Recombinant viruses were also analyzed by PCR and restriction enzyme analysis to confirm the identity of the different mutants. Figure 44B shows that all

mutants (as shown in Figure 41) contained the expected additional restriction sites. Another part of the cell lysate was used to test the reactivity of the different mutant by ELISA. The lysates were diluted 20 times and added to microwell plates coated with the lectin GNA as described in example 6. Captured (mutant) E1 glycoproteins were left to
5 react with 20-times diluted sera of 24 HCV-infected patients as described in example 6. Signal to noise (S/N) values (OD of GLY#/OD of wt) for the six mutants and E1 are shown in Table 8. The table also shows the ratios between S/N values of GLY# and E1 proteins. It should be understood that the approach to use cell lysates of the different mutants for comparison of reactivity with patient sera may result in observations that
10 are the consequence of different expression levels rather than reactivity levels. Such difficulties can be overcome by purification of the different mutants as described in example 5, and by testing identical quantities of all the different E1 proteins. However, the results shown in table 5 already indicate that removal of the 1st (GLY1), 3rd (GLY3), and 6th (GLY6) glycosylation motifs reduces reactivity of some sera, while
15 removal of the 2nd and 5th site does not. Removal of GLY4 seems to improve the reactivity of certain sera. These data indicate that different patients react differently to the glycosylation mutants of the present invention. Thus, such mutant E1 proteins may be useful for the diagnosis (screening, confirmation, prognosis, etc.) and prevention of HCV disease.

20

Example 9: Expression of HCV E2 protein in glycosylation-deficient yeasts

The E2 sequence corresponding to clone HCCL41 was provided with the α -
25 mating factor pre/pro signal sequence, inserted in a yeast expression vector and S. cerevisiae cells transformed with this construct secreted E2 protein into the growth medium. It was observed that most glycosylation sites were modified with high-mannose type glycosylations upon expression of such a construct in S. cerevisiae strains (Figure 45). This resulted in a too high level of heterogeneity and in shielding of
30 reactivity, which is not desirable for either vaccine or diagnostic purposes. To overcome this problem, S. cerevisiae mutants with modified glycosylation pathways were generated by means of selection of vanadate-resistant clones. Such clones were analyzed for modified glycosylation pathways by analysis of the molecular weight and heterogeneity of the glycoprotein invertase. This allowed us to identify different

glycosylation deficient *S. cerevisiae* mutants. The E2 protein was subsequently expressed in some of the selected mutants and left to react with a monoclonal antibody as described in example 7, on western blot as described in example 4 (Figure 46).

5

Example 10. General utility

10 The present results show that not only a good expression system but also a good purification protocol are required to reach a high reactivity of the HCV envelope proteins with human patient sera. This can be obtained using the proper HCV envelope protein expression system and/or purification protocols of the present invention which guarantee the conservation of the natural folding of the protein and the purification protocols of the present invention which guarantee the elimination of contaminating
15 proteins and which preserve the conformation, and thus the reactivity of the HCV envelope proteins. The amounts of purified HCV envelope protein needed for diagnostic screening assays are in the range of grams per year. For vaccine purposes, even higher amounts of envelope protein would be needed. Therefore, the vaccinia virus system may be used for selecting the best expression constructs and for limited upscaling, and
20 large-scale expression and purification of single or specific oligomeric envelope proteins containing high-mannose carbohydrates may be achieved when expressed from several yeast strains. In the case of hepatitis B for example, manufacturing of HBsAg from mammalian cells was much more costly compared with yeast-derived hepatitis B vaccines.

25 The purification method disclosed in the present invention may also be used for 'viral envelope proteins' in general. Examples are those derived from Flaviviruses, the newly discovered GB-A, GB-B and GB-C Hepatitis viruses, Pestiviruses (such as Bovine viral Diarrhoea Virus (BVDV), Hog Cholera Virus (HCV), Border Disease Virus (BDV)), but also less related viruses such as Hepatitis B Virus (mainly for the purification of
30 HBsAg).

The envelope protein purification method of the present invention may be used for intra- as well as extracellularly expressed proteins in lower or higher eukaryotic cells or in prokaryotes as set out in the detailed description section.

Table 1: Recombinant vaccinia plasmids and viruses

Plasmid name	Name	cDNA subclone construction	Length (nt/aa)	Vector used for insertion
pvHCV-13A	E1s	EcoR I - Hind III	472/157	pgptATA-18
pvHCV-12A	E1s	EcoR I - Hind III	472/158	pgptATA-18
pvHCV-9A	E1	EcoR I - Hind III	631/211	pgptATA-18
pvHCV-11A	E1s	EcoR I - Hind III	625/207	pgptATA-18
pvHCV-17A	E1s	EcoR I - Hind III	625/208	pgptATA-18
pvHCV-10A	E1	EcoR I - Hind III	783/262	pgptATA-18
pvHCV-18A	COREs	Acc I (KI) - EcoR I (KI)	403/130	pgptATA-18
pvHCV-34	CORE	Acc I (KI) - Fsp I	595/197	pgptATA-18
pvHCV-33	CORE-E1	Acc I (KI)	1150/380	pgptATA-18
pvHCV-35	CORE-E1b.his	EcoR I - BamH I (KI)	1032/352	pMS-66
pvHCV-36	CORE-E1n.his	EcoR I - Nco I (KI)	1106/376	pMS-66
pvHCV-37	E1Δ	Xma I - BamH I	711/239	pvHCV-10A
pvHCV-38	E1Δs	EcoR I - BstE II	553/183	pvHCV-11A
pvHCV-39	E1Δb	EcoR I - BamH I	960/313	pgsATA-18
pvHCV-40	E1Δb.his	EcoR I - BamH I (KI)	960/323	pMS-66
pvHCV-41	E2bs	BamH I (KI)-AlwN I (T4)	1005/331	pgsATA-18
pvHCV-42	E2bs.his	BamH I (KI)-AlwN I (T4)	1005/341	pMS-66
pvHCV-43	E2ns	Nco I (KI) - AlwN I (T4)	932/314	pgsATA-18
pvHCV-44	E2ns.his	Nco I (KI) - AlwN I (T4)	932/321	pMS-66
pvHCV-62	E1s (type 3a)	EcoR I - Hind III	625/207	pgsATA-18
pvHCV-63	E1s (type 5)	EcoR I - Hind III	625/207	pgsATA-18
pvHCV-64	E2	BamH I - Hind III	1410/463	pgsATA-18
pvHCV-65	E1-E2	BamH I - Hind III	2072/691	pvHCV-10A
pvHCV-66	CORE-E1-E2	BamH I - Hind III	2427/809	pvHCV-33

nt: nucleotide aa: aminoacid

KI: Klenow DNA Pol filling

T4: T4 DNA Pol filling

Position: aminoacid position in the HCV polyprotein sequence

2526680

Table 1 - continued: Recombinant vaccinia plasmids and viruses

Plasmid Name	HCV cDNA subclone			Vector used for insertion
	Name	Construction	Length (nt/aa)	
pvHCV-81	E1*-GLY 1	EcoRI - BamH I	783/262	pvHCV-10A
pvHCV-82	E1*-GLY 2	EcoRI - BamH I	783/262	pvHCV-10A
pvHCV-83	E1*-GLY 3	EcoRI - BamH I	783/262	pvHCV-10A
pvHCV-84	E1*-GLY 4	EcoRI - BamH I	783/262	pvHCV-10A
pvHCV-85	E1*-GLY 5	EcoRI - BamH I	783/262	pvHCV-10A
pvHCV-86	E1*-GLY 6	EcoRI - BamH I	783/262	pvHCV-10A

nt: nucleotide aa: aminoacid

KI: Klenow DNA Pol filling

T4: T4 DNA Pol filling

Position: aminoacid position in the HCV polyprotein sequence

262150 29236680

Table 2 : Summary of anti-E1 tests

i.

S/N \pm SD (mean anti-E1 titer)

	Start of treatment	End of treatment	Follow-up
LTR	6.94 \pm 2.29 (1:3946)	4.48 \pm 2.69 (1:568)	2.99 \pm 2.69 (1:175)
NR	5.77 \pm 3.77 (1:1607)	5.29 \pm 3.99 (1:1060)	6.08 \pm 3.73 (1:1978)

LTR : Long-term, sustained response for more than 1 year

NR : No response, response with relapse, or partial response

2025-09-19 14:50:00

Table 3**Synthetic peptides for competition studies**

PROTEIN	PEPTIDE	AMINO ACID SEQUENCE	POSITION	SEQ ID NO
E1	E1-31	LLSCLTVPASAYQVRNSTGL	181-200	56
	E1-33	QVRNSTGLYHVTNDCPNSSI	193-212	57
	E1-35	NDCPNSSIVYEAHDAILHTP	205-224	58
	E1-35A	SNSSIVYEAADMIMHTPGCV	208-227	59
	E1-37	HDAILHTPGCVPCVREGNVS	217-236	60
	E1-39	CVREGNVSRCWVAMTPTVAT	229-248	61
	E1-41	AMTPTVATRDGKLPATQLRR	241-260	62
	E1-43	LPATQLRRHIDLLVGSATLC	253-272	63
	E1-45	LVGSATLCSALYVGDLGGSV	265-284	64
	E1-49	QLFTFSPRRHWTTQGCNCSI	289-308	65
	E1-51	TQGCNCSIYPGHITGHRMAW	301-320	66
	E1-53	ITGHRMAWDMMMWNWSPTAAL	313-332	67
	E1-55	NWSPTAALVMAQLLRIPQAI	325-344	68
	E1-57	LLRIPQAILDMIAGAHWGV	337-356	69
	E1-59	AGAHWGVLAGIAYFSMVGNM	349-368	70
	E1-63	VVLLLFAGVDAETIVSGGQA	373-392	71

E2	E2-67	SGLVSLFTPGAKQNIQLINT	397-416	72
	E2-69	QNIQLINTNGSWHINSTALN	409-428	73
	E2-38	LNCNESLNTGWWLAGLIYQHK	427-446	74
	E2-51B	AGLIYQHKFNSSGCPERLAS	439-458	75
	E2-1B	GCPERLASCRPLTDFDQGWG	451-470	76
	E2-3B	TDFDQGWGPISYANGSGPDQ	463-482	77
	E2-5B	ANGSGPDQRPYCWHYPPKPC	475-494	78
	E2-7B	WHYPPKPCGIVPAKSVCGPV	487-506	79
	E2-9B	AKSVCGPVYCFTSPVVGVT	499-518	80
	E2-11B	PSPVVGVTDDRSGAPTYSWG	511-530	81
	E2-13B	GAPTYSWGENDTDVFLNNT	523-542	82
	E2-17B	GNWFGCTWMNSTGFTKVCGA	547-566	83
	E2-19B	GFTKVCGAPPVCIGGAGNNT	559-578	84
	E2-21	IGGAGNNTLHCPTDCFRKHP	571-590	85
	E2-23	TDCFRKHPPATYSRCGSGPW	583-602	86
	E2-25	SRCGSGPWITPRCLVDYPYR	595-614	87
	E2-27	CLVDYPYRLWHYPCTINYTI	607-626	88
	E2-29	PCTINYTIFKIRMYVGGVEH	619-638	89
	E2-31	MYVGGVEHRLEAACNWTGPE	631-650	90
	E2-33	ACNWTGGERCDLEDRDRSEL	643-662	91
	E2-35	EDRDRSELSPLLLTTTQWQV	655-674	92

00928757 091297

Table 4. Change of Envelope Antibody levels over time (complete study, 28 patients)

Coxon Signed rank test (P values)	E1Ab NR		E1Ab NR		E1Ab LTR		E1Ab LTR		E2Ab NR		E1Ab LTR	
	All	type 1b	type 3a	All	type 1b	type 3a	All	type 1b	All	type 3a	All	type 3a
1 of therapy*	0.1167	0.2604	0.285	0.0058**	0.043**	0.0499**	0.0186**	0.043**	0.0186**	0.0499**	0.0640**	0.0640**
months follow up*	0.86	0.7213	0.5930	0.0047**	0.043**	0.063**	0.04326	0.043**	0.04326	0.063**	0.0464**	0.0464**
months follow up*	0.7989	0.3105	1	0.0051**	0.0679	0.0277**	0.0869	0.0679	0.0869	0.0277**	0.0058**	0.0058**

*Data were compared with values obtained at initiation of therapy
 values < 0.05

Table 5. Difference between LTR and NR (complete study)

Mann-Whitney U test (P values)	E1Ab S/N All	E1Ab (liters All	E1Ab S/N type 1b	E1Ab S/N type 3a	E2Ab S/N All
Initiation of therapy	0.0257*		0.05*	0.68	0.1078
End of therapy	0.1742				0.1295
6 months follow up	1		0.6099	0.425	0.3081
12 months follow up	0.67		0.23	0.4386	0.6629

* P values < 0.05

20250728 14:32:50

Table 6. Competition experiments between murine E2 monoclonal antibodies

Decrease (%) of anti-E2 reactivity of biotinylated anti-E2 mabs

competitor	17H10F4D10	2F10H10	16A6E7	10D3C4	4H6B2	17C2F2	9G3E6	12D11F1	15C8C1	8G10D1H9
7H10F4D10	62	10	ND	ND	11	ND	5	6	30	ND
2F10H10	90	1	ND	ND	30	ND	0	4	12	ND
3A6E7	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
10D3C4	11	92	ND	ND	94	26	28	43	53	30
4H6B2	ND	82	ND	ND	ND	ND	ND	ND	ND	ND
17C2F2	2	75	ND	ND	56	ND	11	10	0	0
9G3E6	ND	68	ND	ND	11	ND	ND	60	76	ND
12D11F1	ND	26	ND	ND	13	ND	ND	ND	88	ND
15C8C1	ND	18	ND	ND	10	ND	ND	ND	ND	ND
8G10D1H9	2	11	ND	ND	15	ND	67	082	81	ND
competitor controls										
17H10F4D10	0	9	15	10	9	0	0	0	0	5
2F10H10	0	0	12	8	0	0	0	4	0	0
3A6E7	ND	2	12	ND	4	ND	ND	ND	ND	2

ND, not done

Table 7. Primers

SEQ ID NO. 96	GPT	5'-GTTTAACTGATGATG-3'
SEQ ID NO. 97	TK _n	5'-GTCCCATCGAGTGGGCTAC-3'
SEQ ID NO. 98	GLY1	5'-CGTGACATGGTACATTCGGGACACTTGGCGCACTTCATAAGCGGA-3'
SEQ ID NO. 99	GLY2	5'-TGCCCTCATACACAATGGAGCTCTGGGACGAGTCGTTCTGTGAC-3'
SEQ ID NO. 100	GLY3	5'-TACCCAGCAGCGGGAGCTCTGTTGCTCTCCCGAACGACGGGCAC-3'
SEQ ID NO. 101	GLY4	5'-TGTCGTGGTGGGACGGAGGCCCTGCTAGCTGCGAGCGTGGG-3'
SEQ ID NO. 102	GLY5	5'-CGTTATGTGGCCCGGTTAGATTGAGCACTGGCAGTCTGCACTGCTC-3'
SEQ ID NO. 103	GLY6	5'-CAGGGCCGTTGTAGGCCCTCCACTGCATCATATCCCAAGC-3'
SEQ ID NO. 104	OVR1	5'-CCGGAATGTACCATGTACGAAACGAC-3'
SEQ ID NO. 105	OVR2	5'-GCTCCATTGTGTATGAGGCAGCGG-3'
SEQ ID NO. 106	OVR3	5'-GAGCTCCCGCTGCTGGGTAGCGC-3'
SEQ ID NO. 107	OVR4	5'-CCCTCCCGTCCCGACACGACAAATACG-3'
SEQ ID NO. 108	OVR5	5'-CTACCCGGGCGCCACATACGGGTCACCG-3'
SEQ ID NO. 109	OVR6	5'-GGAGGCCCTACAAACGGCCCTGGTGG-3'
SEQ ID NO. 110	GPT-2	5'-TTCTATCGATTAAATAGAAATC-3'
SEQ ID NO. 111	TK _n -2	5'-GCCATACGCTCACAGCCGATCCC-3'

nucleotides underlined represent additional restriction site

nucleotides in bold represent mutations with respect to the original HCC10A sequence

Table 8_Analysis of E1 glycosylation mutants by ELISA

SERUM		1	2	3	4	5	6	7	8	9	10	11	12	Sum		Average	
		13	14	15	16	17	18	19	20	21	22	23	24	Sum	S/N	Average	S/N
Y1	1.002462	2.120971	1.403871	1.205597	2.120191	2.866913	1.950345	1.866183	1.730193	2.468162	1.220654	1.629403					
Y2	2.400795	1.76818	2.325495	2.639308	2.459019	5.043993	2.146302	1.595477	1.608973	2.482212	1.467582	2.070524					
Y3	1.642718	1.715477	2.261646	2.354748	1.591818	4.833742	1.96692	1.482099	1.602222	2.191558	1.464216	1.721164					
Y4	2.570154	3.824038	3.874605	1.499387	3.15	4.71302	4.198751	3.959542	3.710507	5.170841	4.250784	3.955153					
Y5	2.482051	1.793761	2.409344	2.627358	1.715311	4.964765	2.13912	1.576336	1.708937	3.021807	1.562092	2.07278					
Y6	2.031487	1.495737	2.131613	2.527925	2.494833	4.784027	2.02069	1.496489	1.704976	2.677757	1.529608	1.744221					
	2.828205	2.227036	2.512792	2.790881	3.131579	4.869128	2.287753	1.954198	1.805556	2.616822	1.55719	2.593886					
Y1	5.085561	3.233604	3.763498	1.985105	2.317721	6.675179	1.93476	2.47171	4.378633	1.180748	2.150889	1.706992	59.88534	2.495223			
Y2	7.556682	2.567613	3.621928	3.055649	2.933792	7.65433	2.127712	2.921288	4.680101	1.150781	1.661914	1.632785	69.65243	2.902185			
Y3	7.930538	2.763055	3.016099	2.945628	2.515305	5.775357	1.980185	2.557384	4.268633	0.97767	1.336775	1.20376	62.09072	2.507447			
Y4	8.176816	6.561122	5.707668	5.684498	5.604813	6.4125	3.813321	3.002535	4.293038	2.393011	3.68213	2.481585	102.6978	4.279076			
Y5	8.083408	2.940334	3.125561	3.338912	2.654224	5.424107	2.442804	3.126761	4.64557	1.153656	1.817901	1.638211	69.26511	2.886046			
Y6	8.005561	2.499952	2.621704	2.572385	2.363301	5.194107	1.506716	2.665433	2.781063	1.280743	1.475062	1.716423	61.32181	2.555075			
	8.025112	3.183771	3.067265	3.280335	2.980354	7.191964	2.771218	3.678068	5.35443	1.167286	2.083333	1.78252	76.54068	3.189195			
SERUM		1	2	3	4	5	6	7	8	9	10	11	12				
E1	0.637316	0.952374	0.55869	0.431977	0.677036	0.508794	0.852516	0.954961	0.958261	0.94319	0.783882	0.628171					
E1	0.848076	0.793961	0.925463	0.94569	0.785233	1.035913	0.93817	0.816436	0.935431	0.94856	0.942455	0.798232					
E1	0.580834	0.770296	0.900053	0.84373	0.508312	0.992733	0.859761	0.758418	0.887385	0.837488	0.940294	0.663547					
E1	0.911587	1.717097	1.541952	0.537245	1.005882	0.967939	1.835317	2.026172	2.05505	1.976	2.72978	1.524798					
E1	0.877607	0.805447	0.958831	0.941408	0.547746	1.019642	0.935031	0.806641	0.946488	1.154762	1.003148	0.799102					
E1	0.718296	0.671626	0.848305	0.90578	0.796669	0.982522	0.883264	0.765781	0.944294	1.023286	0.982288	0.672435					
		13	14	15	16	17	18	19	20	21	22	23	24	Sum	E1/GLY#	Average	E1/GLY#
E1	0.644248	1.015652	1.226988	0.605153	0.777666	0.928144	0.698162	0.672013	0.817759	1.018386	1.036267	0.957628	19.36524	0.806885			
E1	0.85627	0.806469	1.180833	0.931505	0.984377	1.064289	0.76779	0.794245	0.874061	0.90586	0.797719	0.915998	21.67384	0.903077			
E1	0.898633	0.867856	0.983319	0.897966	0.843962	0.803029	0.714554	0.695306	0.797215	0.837558	0.641652	0.675314	19.19921	0.799967			
E1	0.92654	2.060802	1.060833	1.732902	1.880587	0.89162	1.376045	0.816335	0.801773	2.050064	1.767422	1.392178	36.38592	1.51608			
E1	1.006606	0.923538	1.019006	1.017857	0.890574	0.75419	0.881491	0.850109	0.867612	0.988323	0.872593	0.919042	21.78679	0.907783			
E1	0.907134	0.785217	0.854737	0.784184	0.79296	0.72221	0.543702	0.724683	0.519395	1.097197	0.70803	0.962919	19.59691	0.816538			

REFERENCES

- Bailey, J. and Cole, R. (1959) J. Biol. Chem. 234, 1733-1739.
- Ballou, L., Hitzeman, R., Lewis, M. & Ballou, C. (1991) PNAS 88, 3209-3212.
- Benesch, R., Benesch, R.E., Gutcho, M. & Lanfer, L. (1956) Science 123, 981.
- 5 Cavins, J. & Friedman. (1970) Anal. Biochem. 35, 489.
- Cleland, W. (1964) Biochemistry 3, 480
- Creighton, E. (1988) BioEssays 8, 57
- Darbre, A., John Wiley & Sons Ltd. (1987) Practical Protein Chemistry - A Handbook.
- 10 Darbre, A., John Wiley & Sons Ltd. (1987) Practical Proteinchemistry p.69-79.
- Doms et al, (1993), Virology 193, 545-562.
- Ellman, G. (1959) Arch. Biochem. Biohys. 82, 70.
- Falkner, F. & Moss, B. (1988) J. Virol. 62, 1849-1854.
- Friedman, M. & Krull. (1969) Biochem. Biophys. Res. Commun. 37, 630.
- 15 Gallagher J. (1988) J. Cell Biol. 107, 2059-2073.
- Glazer, A., Delange, R., Sigman, D. (1975) North Holland publishing company, Elsevier, Biomedical. Part : Modification of protein (p. 116).
- Graham, F. & van der Eb, A. (1973) Virology 52, 456-467.
- Grakoui et al. (1993) Journal of Virology 67:1385-1395.

20250729 15:09:29

- Grasseti, D. & Murray, J. (1969) *Analyt. Chim. Acta.* 46. 139.
- i.
- Grasseti, D. & Murray, J. (1967) *Arch. Biochem Biophys.* 119, 41.
- Helenius, Mol. Biol. Cell (1994), 5: 253-265.
- Hijkata, M., Kato, N., Ootsuyama, Y., Nakagawa, M. & Shimotohno, K. (1991) *Proc. Natl. Acad. Sci. U.S.A.* 88(13):5547-51.
- 5
- Hochuli, E., Bannwarth, W., Döbeli, H., Gentz, R., Stüber, D. (1988) *Biochemistry* 88, 8976.
- Hsu, H., Donets, M., Greenberg, H. & Feinstone, S. (1993) *Hepatology* 17:763-771.
- Inoue, Y., Suzuki, R., Matsuura, Y., Harada, S., Chiba, J., Watanabe, Y., Saito, I. & Miyamura, T. (1992) *J. Gen. Virol.* 73:2151-2154.
- 10
- Janknecht, R., de Martynoff, G. *et al.*, (1991) *Proc. Natl. Acad. Sci. USA* 88, 8972-8976.
- Kayman (1991) *J. Virology* 65, 5323-5332.
- Kato, N., Oostuyama, Y., Tanaka, T., Nakagawa, M., Muraiso, K., Ohkoshi, S., Hijkata, M., Shimitohno, K. (1992) *Virus Res.* 22:107-123.
- 15
- Kniskern, P., Hagopian, A., Burke, P., Schultz, L., Montgomery, D., Hurni, W., Yu Ip, C., Schulman, C., Maigetter, R., Wampler, D., Kubek, D., Sitrin, R., West, D., Ellis, R., Miller, W. (1994) *Vaccine* 12:1021-1025.
- Kohara, M., Tsukiyama-Kohara, K., Maki, N., Asano, K., Yoshizawa, K., Miki, K., Tanaka, S., Hattori, N., Matsuura, Y., Saito, I., Miyamura, T. & Nomoto, A. (1992) *J. Gen. Virol.* 73:2313-2318.
- 20
- Mackett, M., Smith, G. & Moss, B. (1985) In: 'DNA cloning: a practical approach' (Ed. Glover, D.) IRL Press, Oxford.

- Mackett, M., & Smith, G. (1986) *J. Gen. Virol.* 67, 2067-2082.
- Mackett, M., Smith, G. & Moss, E. (1984) *J. Virol.* 49, 857-864.
- Mackett, M., Smith, G. & Moss, B. (1984) *Proc. Natl. Acad. Sci. USA* 79, 7415-7419.
- 5 Means, G. (1971) Holden Day, Inc.
- Means, G. & Feeney, R. (1971) Holden Day p.105 & p. 217.
- Mita, E., Hayashi, N., Ueda, K., Kasahara, A., Fusamoto, H., Takamizawa, A., Matsubara, K., Okayama, H. & Kamada T. (1992) *Biochem. Biophys. Res. Comm.* 183:925-930.
- 10 Moore, S. (1963) *J. Biol. Chem.* 238, 235-237.
- Okamoto, H., Okada, S., Sugiyama, Y., Yotsumoto, S., Tanaka, T., Yoshizawa, H., Tsuda, F., Miyakawa, Y. & Mayumi, M. (1990) *Jpn. J. Exp. Med.* 60:167-177.
- Panicali & Paoletti (1982) *Proc. Natl. Acad. Sci. USA* 79, 4927-4931.
- Piccini, A., Perkus, M. & Paoletti, E. (1987) *Meth. Enzymol.* 153, 545-563.
- 15 Rose (1988) *Annu. Rev. Cell Biol.* 1988, 4: 257-288;
- Ruegg, V. and Rudinger, J. (1977) *Methods Enzymol.* 47, 111-116.
- Shan, S. & Wong (1993) CRC-press p. 30-33.
- Spaete, R., Alexander, D., Rugroden, M., Choo, C., Berger, K., Crawford, K., Kuo, C., Leng, S., Lee, C., Ralston, R., et al. (1992) *Virology* 188(2):819-30.
- 20 Skehel, J., (1984) *Proc. Natl. Acad. Sci. USA* 81, 1179-1783.

2025-09-19 15:00:00

Stunnenberg, H., Lange, H., Philipson, L., Miltenburg, R. & van der Vliet, R. (1988) Nucl. Acids Res. 16, 2431-2444.

Stuyver, L., Van Arnhem, W., Wyseur, A., DeLeys, R. & Maertens, G. (1993a) Biochem. Biophys. Res. Commun. 192, 635-641.

- 5 Stuyver, L., Rossau, R., Wyseur, A., Duhamel, M., Vanderborght, B., Van Heuverswyn, H., & Maertens, G. (1993b) J. Gen. Virol. 74, 1093-1102.

Stuyver, L., Van Arnhem, W., Wyseur, A., Hernandez, F., Delaporte, E., Maertens, G. (1994), Proc. Natl. Acad. Sci. USA 91:10134-10138.

Weil, L. & Seibler, S. (1961) Arch. Biochem. Biophys. 95, 470.

- 10 Yokosuka, O., Ito, Y., Imazeki, F., Ohto, M. & Omata, M. (1992) Biochem. Biophys. Res. Commun. 189:565-571.

Miller P, Yano J, Yano E, Carroll C, Jayaram K, Ts'o P (1979) Biochemistry 18:5134-43.

Nielsen P, Egholm M, Berg R, Buchardt O (1991) Science 254:1497-500.

- 15 Nielsen P, Egholm M, Berg R, Buchardt O (1993) Nucleic-Acids-Res. 21:197-200.

Asseline U, Delarue M, Lancelot G, Toulme F, Thuong N (1984) Proc. Natl. Acad. Sci. USA 81:3297-301.

Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen J, Broder S (1987) Proc. Natl. Acad. Sci. USA 84:7706-10.

2522680 2522680

CLAIMS

1. Method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recombina
- 5 nantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent.
2. Method according to claim 1, wherein said disulphide cleavage or reduction step is carried out under partial cleavage or reducing conditions.
- 10 3. Method according to claim 1 or 2, wherein said disulphide bond cleavage agent is dithiothreitol (DTT), preferably in a concentration range of 0.1 to 50 mM, preferably 0.1 to 20 mM, more preferably 0.5 to 10 mM.
4. Method according to claim 1, wherein said disulphide bond cleavage agent is a detergent.
- 15 5. Method according to claim 4, wherein said detergent is Empigen-BB, preferably at a concentration of 1 to 10%, more preferably at a concentration of 3.5%.
6. Method according to claim 1 or 2, wherein said disulphide bond cleaving agent comprises a combination of a classical disulphide bond cleavage agent, such as DTT, and a detergent, such as Empigen-BB.
- 20 7. Method according to any of claims 1 to 6, further comprising the step of blocking disulphide bond reformation with an SH group blocking agent.
8. Method according to claim 7, wherein said SH group blocking agent is N-ethylmaleimide (NEM) or a derivative thereof.
- 25 9. Method according to claim 7, wherein said step of blocking the disulphide bond reformation is brought about by low pH conditions.

10. Method according to any of claims 1 to 9, further characterized by at least the following steps:

- lysing recombinant E1 and/or E2 and/or E1/E2 expressing host cells, possibly in the presence of an SH blocking agent such as N-ethylmaleimide (NEM),
- recovering said HCV envelope proteins by affinity purification such as by means of lectin-chromatography, such as lentil-lectin chromatography, or by means of immunoaffinity using anti-E1 and/or anti-E2 specific monoclonal antibodies,
- reduction or cleavage of the disulfide bonds with a disulphide bond cleaving agent, such as DTT, preferably also in the presence of an SH blocking agent, such as NEM or Biotin-NEM, and,
- recovering the reduced E1 and/or E2 and/or E1/E2 envelope proteins by gel-filtration and possibly also by a subsequent Ni-IMAC chromatography and desalting step.

11. Composition comprising essentially purified recombinant HCV single or specific oligomeric recombinant envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized as being isolated by a method according to any of claims 1 to 10.

12. Composition according to claim 11, further characterized in that said recombinant HCV envelope proteins are expressed from recombinant mammalian cells such as vaccinia.

13. Composition according to claim 11, further characterized in that said recombinant HCV envelope proteins are expressed from recombinant yeast cells.

14. Composition according to claim 11, further characterized in that said recombinant HCV envelope proteins are the expression product of at least one of the recombinant vectors according to any of claims 15 to 24.

15. Recombinant vector comprising a vector sequence, an appropriate prokaryotic, eukaryotic or viral promoter sequence followed by a nucleotide sequence allowing the expression of a single or specific oligomeric E1 and/or E2 and/or E1/E2 protein.

16. Recombinant vector according to claim 15, with said nucleotide sequence being characterized further in that it encodes a single HCV E1 protein starting in the region between amino acid positions 1 and 192 and ending in the region between amino acid positions 250 and 400, more particularly ending in the region between positions 250 and 341, even more preferably ending in the region between position 290 and 341.

17. Recombinant vector according to claim 16, with said nucleotide sequence being characterized further in that it encodes a single HCV E1 protein starting in the region between amino acid positions 117 and 192 and ending in the region between amino acid positions 263 and 400, more particularly ending in the region between positions 250 and 326.

18. Recombinant vector according to any of claims 16 or 17, with said nucleotide sequence being characterized further in that it encodes a single HCV E1 protein bearing a deletion of the first hydrophobic domain between positions 264 to 293, plus or minus 8 amino acids.

19. Recombinant vector according to claim 15, with said nucleotide sequence being characterized further in that it encodes a single HCV E2 protein starting in the region between amino acid positions 290 and 406 and ending in the region between amino acid positions 600 and 820, more particularly starting in the region between positions 322 and 406, even more preferably starting in the region between position 347 and 406 and most preferably starting in the region between positions 364 and 406.

20. Recombinant vector according to claim 19, with said nucleotide sequence being characterized further in that it ends at any of amino acid positions 623, 650, 661, 673, 710, 715, 720, 746 or 809.

21. Recombinant vector according to any of claims 16 to 20, with said nucleotide sequence being characterized further in that a 5'-terminal ATG codon and a 3'-terminal stop codon have been added to it.

22. Recombinant vector according to any of claims 16 to 21, with said nucleotide

sequence being characterized further in that a factor Xa cleavage site and/or 3 to 10, preferably 6, histidine codons have been added 3'-terminally to the coding region.

23. Nucleic acid comprising any of the sequences as represented in SEQ ID NO 3, 5, 7, 9, 11, 13, 21, 23, 25, 27, 29, 31, 35, 37, 39, 41, 43, 45, 47 and 49, or parts thereof.

24. Recombinant vector carrying a recombinant nucleic acid according to claim 23.

25. Recombinant vector according to any of claims 15 to 24, further characterized in that at least one of the glycosylation sites present in said E1 or E2 protein has been removed at the nucleic acid level.

26. A host cell transformed with at least one recombinant vector according to any of claims 15 to 26, wherein said vector comprises a nucleotide sequence encoding HCV E1 and/or E2 and/or E1/E2 protein as defined in any of claims 15 to 23 in addition to a regulatory sequence operable in said host cell and capable of regulating expression of said HCV E1 and/or E2 and/or E1/E2 protein.

27. A recombinant E1 and/or E2 and/or E1/E2 protein expressed by a host cell according to claim 26.

28. Method according to any of claims 1 to 10, further characterized as comprising at least the following steps:

- growing a host cell as defined in claim 26 transformed with a recombinant vector according to any of claims 15 to 25 in a suitable culture medium,
- causing expression of said vector sequence as defined in any of claims 16 to 25 under suitable conditions, and,
- lysing said transformed host cells, preferably in the presence of an SH group blocking agent, such as N-ethylmaleimide (NEM),
- recovering said HCV envelope protein by affinity purification by means of for instance lectin-chromatography or immunoaffinity chromatography using anti-E1 and/or anti-E2 specific monoclonal antibodies, with said lectin being preferably lentil-lectin, followed by,
- incubation of the eluate of the previous step with a disulphide bond cleavage

agent, such as DTT, preferably also in the presence of an SH group blocking agent, such as NEM or Biotin-NEM, and,

- isolating the HCV single or specific oligomeric E1 and/or E2 and/or E1/E2 proteins by means of gelfiltration and possibly also by means of an additional Ni^{2+} -IMAC chromatography and desalting step.

29. A composition comprising at least one of the following E1 and/or E2 peptides:

E1-31 (SEQ ID NO 56) spanning amino acids 181 to 200 of the Core E1 V1 region,

E1-33 (SEQ ID NO 57) spanning amino acids 193 to 212 of the E1 region,

E1-35 (SEQ ID NO 58) spanning amino acids 205 to 224 of the E1 V2 region (epitope B),

E1-35A (SEQ ID NO 59) spanning amino acids 208 to 227 of the E1 V2 region (epitope B),

1bE1 (SEQ ID NO 53) spanning amino acids 192 to 228 of E1 regions (V1, C1, and V2 regions (containing epitope B),

E1-51 (SEQ ID NO 66) spanning amino acids 301 to 320 of the E1 region,

E1-53 (SEQ ID NO 67) spanning amino acids 313 to 332 of the E1 C4 region (epitope A),

E1-55 (SEQ ID NO 68) spanning amino acids 325 to 344 of the E1 region.

Env 67 or E2-67 (SEQ ID NO 72) spanning amino acid positions 397 to 416 of the E2 region (epitope A),

Env 69 or E2-69 (SEQ ID NO 73) spanning amino acid positions 409 to 428 of the E2 region (epitope A),

Env 23 or E2-23 (SEQ ID NO 86) spanning positions 583 to 602 of the E2 region (epitope E),

Env 25 or E2-25 (SEQ ID NO 87) spanning positions 595 to 614 of the E2 region (epitope E),

Env 27 or E2-27 (SEQ ID NO 88) spanning positions 607 to 626 of the E2 region (epitope E),

Env 17B or E2-17B (SEQ ID NO 83) spanning positions 547 to 566 of the E2 region (epitope D),

Env 13B or E2-13B (SEQ ID NO 82) spanning positions 523 to 542 of the E2 region (epitope C).

30. A composition comprising at least one of the following E2 conformational epitopes:

epitope F recognized by monoclonal antibodies 15C8C1, 12D11F1, and 8G10D1H9,

epitope G recognized by monoclonal antibody 9G3E6,

epitope H (or C) recognized by monoclonal antibodies 10D3C4 and 4H6B2,

epitope I recognized by monoclonal antibody 17F2C2.

31. An E1 and/or E2 specific monoclonal antibody raised upon immunization with a composition according to any of claims 11 to 14 or 29 to 30.

32. An E1 and/or E2 specific monoclonal antibody according to claim 31 for use as a medicament, more particularly for incorporation into an immunoassay kit for detecting the presence of HCV E1 or E2 antigen, for prognosis/monitoring of disease or for HCV therapy.

33. Use of an E1 and/or E2 specific monoclonal antibody according to claim 31 for the preparation of an immunoassay kit for detecting HCV E1 or E2 antigens, for the preparation of a kit for prognosing/monitoring of HCV disease or for the preparation of a HCV medicament.

34. Method for in vitro diagnosis of HCV antigen present in a biological sample, comprising at least the following steps:

- (i) contacting said biological sample with an E1 and/or E2 specific monoclonal antibody according to claim 31, preferably in an immobilized form under appropriate conditions which allow the formation of an immune complex,
- (ii) removing unbound components,
- (iii) incubating the immune complexes formed with heterologous antibodies, with said heterologous antibodies being conjugated to a detectable label under appropriate conditions,
- (iv) detecting the presence of said immune complexes visually or mechanically.

35. Kit for determining the presence of HCV antigens present in a biological sample, comprising:

- at least one E1 and/or E2 specific monoclonal antibody according to claim 31, preferably in an immobilized form on a solid substrate,
- 5 - a buffer or components necessary for producing the buffer enabling binding reaction between these antibodies and the HCV antigens present in said biological sample,
- a means for detecting the immune complexes formed in the preceding binding reaction.

10 - 36. A composition according to any of claims 11 to 14 or 29 to 30 for use as a medicament.

37. A composition according to any of claims 11 to 14 or 29 to 30 for use as a vaccine for immunizing a mammal, preferably humans, against HCV, comprising administering an effective amount of said composition possibly accompanied by
15 pharmaceutically acceptable adjuvants, to produce an immune response.

38. Use of a composition according to any of claims 11 to 14 or 29 to 30, for the preparation of a vaccine for immunizing a mammal, preferably humans, against HCV, comprising administering an effective amount of said composition possibly accompanied by pharmaceutically acceptable adjuvants, to produce an immune
20 response.

39. Vaccine composition for immunizing a mammal, preferably humans, against HCV, comprising an effective amount of a composition according to any of claims 11 to 14 or 29 to 30 possibly accompanied by pharmaceutically acceptable adjuvants.

40. A composition according to any of claims 11 to 14 or 29 to 30, for *in vitro* detection of HCV antibodies present in a biological sample.
25

41. Use of a composition according to claims 11 to 14 or 29 to 30, for the preparation of an immunoassay kit for detecting HCV antibodies present in a biological sample.

42. Method for *in vitro* diagnosis of HCV antibodies present in a biological sample, comprising at least the following steps:

- 5 (i) contacting said biological sample with a composition according to any of claims 11 to 14 or 29 to 30, preferably in an immobilized form under appropriate conditions which allow the formation of an immune complex,
- (ii) removing unbound components,
- 10 (iii) incubating the immune complexes formed with heterologous antibodies, with said heterologous antibodies being conjugated to a detectable label under appropriate conditions,
- (iv) 15 detecting the presence of said immune complexes visually or mechanically.

43. Kit for determining the presence of HCV antibodies present in a biological sample, comprising:

- at least one peptide or protein composition according to any of claims 11 to 14 or 29 to 30, preferably in an immobilized form on a solid substrate,
- 20 - a buffer or components necessary for producing the buffer enabling binding reaction between these proteins or peptides and the antibodies against HCV present in said biological sample,
- a means for detecting the immune complexes formed in the preceding binding reaction.

44. Use of composition comprising E1 proteins according to any of claims 11 to 14, or parts thereof according to claim 29, more particularly HCV single E1 proteins or E1 peptides, for *in vitro* monitoring HCV disease or prognosing the response to treatment, particularly with interferon, of patients suffering from HCV infection comprising:

- 30 - incubating a biological sample from a patient with HCV infection with an E1 protein or a suitable part thereof under conditions allowing the formation of an immunological complex,
- removing unbound components.

- calculating the anti-E1 titers present in said sample at the start of and during the course of treatment,
- monitoring the natural course of HCV disease, or prognosing the response to treatment of said patient on the basis of the amount anti-E1 titers found in said sample at the start of treatment and/or during the course of treatment.

45. Kit for monitoring HCV disease or prognosing the response to treatment, particularly with interferon, of patients suffering from HCV infection comprising:

- at least one E1 protein or E1 peptide, more particularly an E1 protein or E1 peptide according to any of claims 11 to 14 or 29,
- a buffer or components necessary for producing the buffer enabling the binding reaction between these proteins or peptides and the anti-E1 antibodies present in a biological sample,
- means for detecting the immune complexes formed in the preceding binding reaction,
- possibly also an automated scanning and interpretation device for inferring a decrease of anti-E1 titers during the progression of treatment.

46. A serotyping assay for detecting one or more serological types of HCV present in a biological sample, more particularly for detecting antibodies of the different types of HCV to be detected combined in one assay format, comprising at least the following steps :

- (i) contacting the biological sample to be analyzed for the presence of HCV antibodies of one or more serological types, with at least one of the E1 and/or E2 and/or E1/E2 protein compositions according to any of claims 11 to 14 or at least one of the E1 or E2 peptide compositions according to claim 29, preferentially in an immobilized form under appropriate conditions which allow the formation of an immune complex,
- (ii) removing unbound components,
- (iii) incubating the immune complexes formed with heterologous antibodies, with said heterologous antibodies being conjugated to a detectable label under appropriate conditions.

- (iv) detecting the presence of said immune complexes visually or mechanically (e.g. by means of densitometry, fluorimetry, colorimetry) and inferring the presence of one or more HCV serological types present from the observed binding pattern.

5 47. Kit for serotyping one or more serological types of HCV present in a biological sample, more particularly for detecting the antibodies to these serological types of HCV comprising:

- at least one E1 and/or E2 and/or E1/E2 protein according to any of claims 11 to 14 or E1 or E2 peptide according to claim 29,
- 10 - a buffer or components necessary for producing the buffer enabling the binding reaction between these proteins or peptides and the anti-E1 antibodies present in a biological sample,
- means for detecting the immune complexes formed in the preceding binding reaction,
- 15 - possibly also an automated scanning and interpretation device for detecting the presence of one or more serological types present from the observed binding pattern.

48. A peptide or protein composition according to any of claims 11 to 14 or 29, for immobilization on a solid substrate and incorporation into a reversed phase
20 hybridization assay, preferably for immobilization as parallel lines onto a solid support such as a membrane strip, for determining the presence or the genotype of HCV according to a method of any of claims 42 or 46.

1/59




FIGURE 1




FIGURE 2

3/59




FIGURE 3

4/59




FIGURE 4

Anti-E1 levels in NON-responders to IFN treatment

Series 1





FIGURE 5

6/59

Anti-E1 levels in RESPONDERS to IFN treatment

SERIES 1



7/59

Anti-E1 levels in patients with COMPLETE response to IFN

SERIES 2





FIGURE 7



SERIES 2



months after start of treatment

9/59

Anti-E2 levels in NON-RESPONDERS to IFN treatment

SERIES 1





FIGURE 9

10/59

Anti-E2 levels in RESPONDERS to IFN treatment

SERIES 1



Anti-E2 levels in INCOMPLETE responders to IFN treatment

SERIES 2




FIGURE 11

Anti-E2 levels in COMPLETE responders to IFN treatment

SERIES 2




FIGURE 12

FIGURE 13

Human anti-E1 reactivity competed with peptides









FIGURE 14

Competition of reactivity of anti-E1 Mabs with peptides



Anti-E1 (epitope 1) levels in NON-RESPONDERS to IFN treatment


SERIES 1



weeks after start of treatment


Anti-E1 (epitope 1) levels in RESPONDERS to IFN treatment

SERIES 1



nti-E1 (epitope 2) levels in NON-RESPONDERS to IFN treatment

SERIES 1



17/89

18/59

Anti-E1 (epitope 2) levels in RESPONDERS to IFN treatment

SERIES 1




FIGURE 19

Competition of reactivity of anti-E2 Mabs with peptides




FIGURE 20

Human anti-E2 reactivity competed with peptides




Figure 21

5' GGCATGCAAGCTTAATTAATT3' (SEQ ID NO 1)
3'ACGTCCGTACGTTCGAATTAATTAATCGA5' (SEQ ID NO 94)

5'CCGGGGAGGCCTGCACGTGATCGAGGGCAGACACCATCACCACCATCACTAATAGT
TAATTAAGTCA 3' (SEQ ID NO 2)
3'CCTCCGGACGTGCACTAGCTCCCGTCTGTGGTAGTGGTGGTAGTGATTATCAATTAATTG
5' (SEQ ID NO 95)

SEQ ID NO 3 (HCC19A)

ATGCCCCGGTTGCTCTTTCTCTATCTTCCTCTTGGCTTTACTGTCTGTCTGACCATTCCA
GCTTCCGCTTATGAGGTGCGCAACGTGTCCGGGATGTACCATGTCACGAACGACTGCT
CCAAGTCAAGCATTGTGTATGAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGT
GCCCTGCGTTCGGGAGAACAACCTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTC
GCAGCTAGGAACGCCAGCGTCCCCACCACGACAATACGACGCCACGTGATTTGCTCG
TTGGGGCGGCTGCTCTCTGTTCCGCTATGTACGTGGGGGATCTCTGCGGATCTGTCTTC
CTCGTCTCCAGCTGTTACCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCA
ATTGCTCAATCTATCCCGGCCACATAACAGGTACCGTATGGCTTGGGATATGATGAT
GAACTGGTCGCCTACAACGGCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCT
GTCGTGGACATGGTGGCGGGGGCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATT
CCATGGTGGGGAAGTGGGCTAAGGTTTTGATTGTGATGCTACTCTTTGCTCTCTAATAG

SEQ ID NO 5 (HCC110A)

ATGTTGGGTAAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAGGACGGCGTGAAGTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT
ATCTTCCTCTTGGCTTTGCTGTCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG
CAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCCAAGTCAAGCATTGTGTAT
GAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCGGGAGAAC
AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG
TCCCCACCACGACAATACGACGCCACGTGATTTGCTCGTTGGGGCGGCTGCTTTCTG

ATGTC CGGTGCTCTTTCTCTATCTTCCTCTTGGCCCTGCTGTCCTGTCTGACCATACCA
GCTTCCGCTTATGAAGTGCGCAACGTGTCCGGGGTGTACCATGTACGAACGACTGCT
CCAACTCAAGCATAGTGTATGAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGT

GCCCTGCGTTTCGGGAGGGCAACTCCTCCCGTTGCTGGGTGGCGCTCACTCCCACGCTC
GCGGCCAGGAACGCCAGCGTCCCCACAACGACAATACGACGCCACGTCGATTTGCTC
GTTGGGGGCTGCTGCTTTCTGTTCCGCTATGTACGTGGGGGATCTCTGCGGATCTGTTTT
CCTTGTTTCCCAGCTGTTACCTTCTCACCTCGCCGGCATCAACAGTACAGGACTGCA
ACTGCTCAATCTATCCCGGCCATGTATCAGGTCACCGCATGGCTTGGGATATGATGAT
GAACTGGTAATAG

SEQ ID NO 13 (HCCI17A)

ATGCTGGGTAAGGCCATCGATACCCCTTACGTGCGGCTTCGCCGACCTCGTGGGGGTACA
TTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAAGACGGCGTGAACCTATGCAACAGGGAATTTGCCTGGTTGCTCTTTCTCTA
TCTTCCTCTTGGCTTTACTGTCTGTCTAACCATTCCAGCTTCCGCTTACGAGGTGCGC
AACGTGTCCGGGATGTACCATGTCAAGAACGACTGCTCCAACCTCAAGCATTGTGTATG
AGGCAGCGGACATGATCATGCACACCCCGGGTGCGTGCCCTGCGTTCCGGGAGAAÇA
ACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCGGGCTAGGAACGCCAGCAT
CCCCACTACAACAATACGACGCCACGTGATTTGCTCGTTGGGGCGGCTGCTTTCTGTT
CCGCTATGTACGTGGGGGATCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTGTTCAACC
ATCTCGCCTCGCCGGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCC
ACATAACGGGTCACCGTATGGCTTGGGATATGATGATGAACTGGTACTAATAG

SEQ ID NO 15 (HCP:51)

ATGCCCGGTTGCTCTTTCTCTATCTT

SEQ ID NO 16 (HCP r52)

ATGTTGGGTAAGGTCATCGATACCCT

SEQ ID NO 17 (HCP r53)

CTATTAGGACCAGTTCATCATCATATCCCA

SEQ ID NO 18 (HCP r54)

CTATTACCAGTTCATCATCATATCCCA

SEQ ID NO 19 (HCP_r107)

ATACGACGCCACGTCGATTCCCAGCTGTTCAACATC

SEQ ID NO 20 (HCP1103)

GATGGTGAACAGCTGGGAATCGACGTGGCGTCGTAT

SEQ ID NO 21 (HCC137)

ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAGGACGGCGTGAACATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT
ATCTTCCTCTTGGCTTTGCTGTCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG
CAACGTGTCCGGGATGTACCATGTACGAACGACTGCTCCAACCTCAAGCATTGTGTAT
GAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCCGGGAGAAC
AACTCTTCCCGCTGCTGGGTAGCGCTACCCCCACGCTCGCAGCTAGGAACGCCAGCG
TCCCCACCACGACAATACGACGCCACGTGATTCCCAGCTGTTACCATCTCGCCTCG
CCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGT
CACCGTATGGCTTGGGATATGATGATGAACTGGTCGCTACAACGGCCCTGGTGGTAT
CGCAGCTGCTCCGGATCCCACAAGCTGTCTGGACATGGTGGCGGGGGGCCATTGGGG
AGTCCTGGCGGGTCTCGCCTACTATTCCATGGTGGGGAACCTGGGCTAAGGTTTTGATTG
TGATGCTACTCTTTGCTCCCTAATAG

SEQ ID NO 23 (HCC138)

ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAGGACGGCGTGAACATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT
ATCTTCCTCTTGGCTTTGCTGTCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG
CAACGTGTCCGGGATGTACCATGTACGAACGACTGCTCCAACCTCAAGCATTGTGTAT
GAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCCGGGAGAAC
AACTCTTCCCGCTGCTGGGTAGCGCTACCCCCACGCTCGCAGCTAGGAACGCCAGCG
TCCCCACCACGACAATACGACGCCACGTGATTCCCAGCTGTTACCATCTCGCCTCG
CCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGT
CACCGTATGGCTTGGGATATGATGATGAACTGGTAA
TAG

SEQ ID NO 25 (HCC139)

ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAGGACGGCGTGAACATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT

ATCTTCCTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG
CAACGTGTCCGGGATGTACCATGTCAAGAACGACTGCTCCAACCTCAAGCATTGTGTAT
GAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCGGGAGAAC
AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG
TCCCCACCACGACAATACGACGCCACGTCGATTCCCAGCTGTTACCATCTCGCCTCG
CCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGT
CACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTAT
CGCAGCTGCTCCGGATCCTCTAATAG

SEQ ID NO 27 (HCC140)

ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCCCGACCTCGTGGGGTACA
TTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTCTGAGGACGGCGTGAACCTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT
ATCTTCCTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG
CAACGTGTCCGGGATGTACCATGTCAAGAACGACTGCTCCAACCTCAAGCATTGTGTAT
GAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCGGGAGAAC
AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG
TCCCCACCACGACAATACGACGCCACGTCGATTCCCAGCTGTTACCATCTCGCCTCG
CCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGT
CACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTAT
CGCAGCTGCTCCGGATCGTGATCGAGGGCAGACACCATCACCACCATCACTAATAG

SEQ ID NO 29 (HCC162)

ATGGGTAAGGTCATCGATACCCTTACGTGCGGATTCCCGATCTCATGGGGTACATCC
CGCTCGTCGGCGCTCCCGTAGGAGGCGTCGCAAGAGCCCTTGCGCATGGCGTGAGGGC
CCTTGAAGACGGGATAAATTTGCAACAGGGAATTTGCCCGGTTGCTCCTTTTCTATTT
TCCTTCTCGCTCTGTTCTCTTGCTTAATTCATCCAGCAGCTAGTCTAGAGTGCGGAAT
ACGTCTGGCCTCTATGTCCTTACCAACGACTGTTCCAATAGCAGTATTGTGTACGAGGC
CGATGACGTTATTCTGCACACACCCGGCTGCATACCTTGTGTCCAGGACGGCAATACA
TCCACGTGCTGGACCCCAGTGACACCTACAGTGGCAGTCAAGTACGTGCGGAGCAACCA
CCGCTTCGATACGCAGTCATGTGGACCTATTAGTGGGCGCGGCCACGATGTGCTCTGC
GCTCTACGTGGGTGACATGTGTGGGGCTGTCTTCCTCGTGGGACAAGCCTTCACGTTCA
GACCTCGTCGCCATCAAACGGTCCAGACCTGTAAGTGTGCTGTAACCCAGGCCATCT
TTCAGGACATCGAATGGCTTGGGATATGATGATGAACTGGTAATAG

TGGGATATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTATCGCAGCTGCTCC
GGATCCCACAAGCTGTCGTGGACATGGTGGCGGGGGCCCATTTGGGGAGTCCTGGCGG
GCCTCGCCTACTATTCCATGGTGGGGAAGTGGGCTAAGGTTTTGGTTGTGATGCTACTC
TTTGCCGGCGTCGACGGGCATACCCGCGTGTGAGGAGGGGCAGCAGCCTCCGATACCA
GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTGGCTCAGAAAATCCAGCTCGTAAACAC
CAACGGCAGTTGGCACATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAAC
AGGGTTCTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAG
CGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTT
ACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACC
GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCC
CTGTTGTGGTGGGGACGACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAA
CGACTCGGATGTGCTGATTCTCAACAACACGCGGCCGCGCGAGGCAACTGGTTCGGC
TGTACATGGATGAATGGCACTGGGTTCACCAAGACGTGTGGGGGGCCCCCGTGCAACA
TCGGGGGGGGCCGGCAACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCC
CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT

CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT
TAGGATGTACGTGGGGGGCGTGGAGCACAGGTTTGAAGCCGCATGCAATTGGACTCG
AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTG
TCTACAACAGAGTGGCAGATACTGCCCTGTTCTTACCACCCTGCCGGCCCTATCCA
CCGGCCTGATCCACCTCCATCAGAACATCGTGGACGTGCAATACCTGTACGGTGTAGG
GTCGGCGGTTGTCTCCCTTGTTCATCAAATGGGAGTATGTCCTGTTGCTCTTCTCTCT
GGCAGACGCGCGCATCTGCGCCTGCTTATGGATGATGCTGCTGATAGCTCAAGCTGAG
GCCGCCTTAGAGAACCTGGTGGTCCCTCAATGCGGGCGGCCGTGGCCGGGGCGCATGGC
ACTCTTTCCTTCTTGTGTTCTTCTGTGCTGCCTGGTACATCAAGGGCAGGCTGGTCCC
TGGTGCGGCATACGCCCTTCTATGGCGTGTGGCCGCTGCTCCTGCTTCTGCTGGCCTTAC
CACCACGAGCTTATGCCTAGTAA

SEQ ID NO 37 (HCCI41)

GATCCACACAAGCTGTCGTGGACATGGTGGCGGGGGGCCATTGGGGAGTCCTGGCGGG
CCTCGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCT
TTGCCGGCGTGCACGGGCATACCCGGGTGTCAGGAGGGGCAGCAGCCTCCGATACCA
GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTGGGCTCAGAAAATCCAGCTCGTAAACAC
CAACGGCAGTTGGCACATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAAC
AGGGTTCTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAG
CGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTT
ACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACC
GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTACCCCCGAGCC
CTGTTGTGGTGGGGACGACCGATCGSTTTGGTGTCCCCACGTATAACTGGGGGGCGAA
CGACTCGGATGTGCTGATTCTCAACAACACGCGGGCCGCGGAGGCAACTGGTTCGGC
TGTACATGGATGAATGGCACTGGGTTACCAAGACGTGTGGGGGGCCCCCGTGCAACA
TCGGGGGGGGCCGGCAACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCC
CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT
CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT
TAGGATGTACGTGGGGGGCGTGGAGCACAGGTTTGAAGCCGCATGCAATTGGACTCG
AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTG
TCTACAACAGAGTGGCAGAGTGGCAGAGCTTAATTAATTAG

SEQ ID NO 39 (HCCI42)

GATCCACACAAGCTGTCGTGGACATGGTGGCGGGGGGCCATTGGGGAGTCCTGGCGGG
CCTCGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCT

262160 262580

TTGCCGGCGTTCGACGGGCATACCCGCGTGTTCAGGAGGGGCAGCAGCCTCCGATACCA
GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACAC
CAACGGCAGTTGGCACATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAAC
AGGGTTCTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAG
CGCTTGGCCAGCTGTGCTCCATCGACAAGTTTCGCTCAGGGGTGGGGTCCCCTCACTT
ACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACC
GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCC
CTGTTGTGGTGGGGACGACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAA
CGACTCGGATGTGCTGATTCTCAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGC
TGTACATGGATGAATGGCACTGGGTTCACCAAGACGTGTGGGGGGCCCCCGTGCAACA
TCGGGGGGGGCCGGCAACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCC
CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT
CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT
TAGGATGTACGTGGGGGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCG
AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCCGCTGCTGCTG
TCTACAACAGGTGATCGAGGGCAGACACCATCACCACCATCACTAATAG

SEQ ID NO 41 (HCCI43)

ATGGTGGGGAAGTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTGCACG
GGCATACCCGCGTGTGAGGAGGGGCGAGCCTCCGATACCAGGGGCGCTTGTGTCCCT
CTTTAGCCCCGGGTGCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCAC
ATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCAC
TATTCTACAAACACAAATTCAACTCGTCTGGATGCCAGAGCGCTTGGCCAGCTGTGCG
CTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGC
TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCG
CGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGAC
GACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTG
ATTCTCAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATG
GCACTGGGTTCACCAAGACGTGTGGGGGCCCCCGTGCAACATCGGGGGGGCCGGCA
ACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGC
CAGATGCGGTTCTGGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGG
CTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGG
GGGCGTGGAGCACAGGTTTGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGA
CTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGAGTGG
CAGAGCTTAATTAATTAG

SEQ ID NO 43 (HCCI44)

ATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACG
GGCATACCCGCGTGTTCAGGAGGGGCGAGCAGCCTCCGATACCAGGGGCGCTTGTGTCCCT
CTTTAGCCCCGGGTTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCAC
ATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCAC
TATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTGCG
CTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCTCACTTACACTGAGCCTAACAGC
TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCG
CGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGAC
GACCGATCGGTTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTG
ATTCTCAACAACACGCGGCCGCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATG
GCACTGGGTTCACCAAGACGTGTGGGGGCCCCCGTGCAACATCGGGGGGGCCGGCA
ACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGC
CAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGG
CTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGG
GGGCGTGGAGCACAGGTTTGAAGCCGCATGCAATTGGA CTGAGGAGAGCGTTGTGA
CTTGGAGGACAGGGATAGATCAGAGCTTAGCCCCGCTGCTGCTGTCTACAACAGGTGAT
CGAGGGCAGACACCATCACCACCATCACTAATAG

SEQ ID NO 45 (HCCL64)

ATGGTGGCGGGGGGCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGG
GGA ACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGGCATAC
CCGCGTGTTCAGGAGGGGCGAGCAGCCTCCGATACCAGGGGCGCTTGTGTCCCTCTTTAGC
CCCGGGTTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAAC
AGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCT
ACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTGCTCCAT
CGACAAGTTCGCTCAGGGGTGGGGTCCCTCACTTACACTGAGCCTAACAGCTCGGAC
CAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTC
AGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGA
TCGGTTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTC
AACAACACGCGGCCGCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACT
GGGTTACCAAGACGTGTGGGGGCCCCCGTGCAACATCGGGGGGGCCGGCAACAAC
ACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGAT
GCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGG
CACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGCG

TGGAGCACAGGTTTGAAGCCGCATGCAATTGGAAGTGGAGGAGAGCGTTGTGACTTGGA
GGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGAGTGGCAGATA
CTGCCCTGTTCTTCACCACCCTGCCGGCCCTATCCACCGGCCTGATCCACCTCCATCA
GAACATCGTGGACGTGCAATACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTC
ATCAAATGGGAGTATGTCTGTTGCTCTTCCTTCTCCTGGCAGACGCGCGCATCTGCGC
CTGCTTATGGATGATGCTGCTGATAGCTCAAGCTGAGGCCGCCTTAGAGAACCTGGTG
GTCCTCAATGCGGCGGGCGTGGCCGGGGCGCATGGCACTCTTTCCTTCCTTGTTCTT
CTGTGCTGCCTGGTACATCAAGGGCAGGCTGGTCCCTGGTGCGGCATACGCCTTCTAT
GGCGTGTGGCCGCTGCTCCTGCTTCTGCTGGCCTTACCACCACGAGCTTATGCCTAGTAA

SEQ ID NO 47 (HCCI65)

AATTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG
GGTTCTGGAGGACGGCGTGAACATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT
ATCTTCCTCTTGGCTTTGCTGTCTGTCTGACCGTTCCAGCTTCGGCTTATGAAGTGCG
CAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCCAACCTCAAGCATTGTGTAT
GAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCGGGAGAAC
AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG
TCCCCACCACGACAATACGACGCCACGTGATTTGCTCGTTGGGGCGGCTGCTTTCTG
TTCCGCTATGTACGTGGGGGACCTCTGCGGATCTGTCTTCCTCGTCTCCAGCTGTTCA
CCATCTCGCCTCGCCGGCATGAGACGCTGCAGGACTGCAATTGCTCAATCTATCCCGG
CCACATAACGGGTCACCGTATGGCTTGGGATATGATGATGAACTGGTGCCTACAACG
GCCCTGGTGGTATCGCAGCTGCTCCGGATCCACAAGCTGTGCTGGACATGGTGGCGG
GGGCCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGGGGAACTGGGC
TAAGGTTTTGTTGTGATGCTACTCTTTGCCGGCGTGCACGGGCATACCCGCGTGTGAG
GAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTTAGCCCCGGGTGCGC
TCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAACAGGACTGCCCT
GAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTACAAACACAAA
TTCAACTCGTCTGGATGCCAGAGCGCTTGGCCAGCTGTGCTCCATCGACAAGTTCC
CTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGGCCCTA
CTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGT
CCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTTTGGTGT
CCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTCAACAACACGCGG
CCGCCGCGAGGCAACTGGTTCCGCTGTACATGGATGAATGGCACTGGGTTACCAAGA
CGTGTGGGGGCCCCCGTGAACATCGGGGGGGCCGGCAACAACACCTTGACCTGCC

089203 094297

CCACTGACTGTTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTCTGGGCC
CTGGCTGACACCTAGGTGTATGGTTTATTACCCATATAGGCTCTGGCACTACCCCTGCA
CTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGCGTGGAGCACAGGTT
CGAAGCCGCATGCAATTGGAAGGAGAGCGTTGTGACTTGGAGGACAGGGATAG
ATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGAGTGGCAGATACTGCCCTGTTCC
TTCACCACCCTGCCGGCCCTATCCACCGGCCTGATCCACCTCCATCAGAACATCGTGG
ACGTGCAATACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTCATCAAATGGGA
GTATGTCTGTTGCTCTTCTCTCTCTGGCAGACGCGCGCATCTGCGCCTGCTTATGGA
TGATGCTGCTGATAGCTCAAGCTGAGGCCGCTTAGAGAACCTGGTGGTCTCAATGC
GGCGGGCGTGGCCGGGGCGCATGGCACTCTTCTCTCTCTGTGTTCTTCTGTGCTGCCT
GGTACATCAAGGGCAGGCTGGTCCCTGGTGGCGCATACGCTTCTATGGCGTGTGGCC
GCTGCTCCTGCTTCTGCTGGCCTTACCACCACGAGCTTATGCCTAGTAAGCTT

SEQ ID NO 49 (HCC166)

ATGAGCACGAATCCTAAACCTCAAAGAAAAACCAAACGTAACACCAACCGCCGCCCA
CAGGACGTCAAGTTCCCGGGCGGTGGTCAGATCGTTGGTGGAGTTTACCTGTTGCCGC
GCAGGGGGCCCCAGGTTGGGTGTGGCGCGGACTAGGAAGACTTCCGAGCGGTGCAAC
CTCGTGGGAGGCGACAACCTATCCCCAAGGCTCGCCGACCCGAGGGTAGGGCCTGGG
CTCAGCCCGGGTACCCTTGGCCCCCTCTATGGCAATGAGGGCATGGGGTGGGCAGGATG
GCTCCTGTACCCCCGCGGCTCTCGGCCTAGTTGGGGCCCTACAGACCCCCGGCGTAGG
TCGCGTAATTTGGGTAAAGGTCATCGATACCTTACATGCGGCTTCGCGGACCTCGTGG
GGTACATTCCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGGCCCTGGCGCATGG
CGTCCGGGTTCTGGAGGACGGCGTGAACATGCAACAGGGAATTTGCCCGGTTGCTCT
TTCTCTATCTTCTCTTGGCTTTGCTGTCTGTCTGACCGTTCCAGCTTCCGCTTATGAA
GTGCGCAACGTGTCCGGGATGTACCATGTACGAACGACTGCTCCAACCTCAAGCATTG
TGTATGAGGCAGCGGACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCCGGGA
GAACAACCTTCCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCC
AGCGTCCCCACCACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTT
TCTGTTCCGCTATGTACGTGGGGGACCTCTGCGGATCTGTCTTCTCTCGTCTCCCAGCTG
TTCACCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATC
CCGGCCACATAACGGGTACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTAC
AACGGCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCTGTCGTGGACATGGTG
GCGGGGGGCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGGGGAACT
GGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGGCATACCCGCGT
GTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTTAGCCCCGGG

2025-09-19 14:22:59

TCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAACAGGACT
GCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCACTATTCTACAAAC
ACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGACAA
GTTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGG
CCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGT
GCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTT
TGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTGATTCTCAACAAC
ACGCGGGCCGCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCA
CCAAGACGTGTGGGGGGCCCCCGTGCAACATCGGGGGGGCCGGCAACAACACCTTGA
CCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTC
TGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTAC
CCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGCGTGGAGC
ACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACA
GGGATAGATCAGAGCTTAGCCCCGCTGCTGCTGTCTACAACAGAGTGGCAGATACTGCC
CTGTTCCCTTACCACCCTGCCGGCCCTATCCACCGGCCTGATCCACCTCCATCAGAAC
ATCGTGGACGTGCAATACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTCAATCA
AATGGGAGTATGTCCTGTTGCTCTTCTCTCTCTGTCAGACGCGCGCATCTGCGCCTGC
TTATGGATGATGCTGCTGATAGCTCAAGCTGAGGCCGCGCTTAGAGAACCTGGTGGTCC
TCAATGCGGCGGCGCGTGGCCGGGGCGCATGGCACTCTTTCCTTCTTGTGTTCTTCTGT
GCTGCCTGGTACATCAAGGGCAGGCTGGTCCCTGGTGCGGCATACGCCTTCTATGGCG
TGTGGCCGCTGCTCCTGCTTCTGCTGGCCTTACCACCACGAGCTTATGCCTAGTAA

254150" 2523580


33/59

Figure 22

OD measured at 450 nm
construct

Fraction	volume	dilution	39 Type 1b	40 Type 1b	62 Type 3a	63 Type 5a
START	23 ml	1/20	2.517	1.954	1.426	1.142
FLOW THROUGH	23 ml	1/20	0.087	0.085	0.176	0.120
1	0.4 ml	1/200	0.102	0.051	0.048	0.050
2			0.396	0.550	0.090	0.067
3			2.627	2.603	2.481	2.372
4			3	2.967	3	2.694
5			3	2.810	2.640	2.154
6			2.694	2.499	1.359	1.561
7			2.408	2.481	0.347	1.390
8			2.176	1.970	1.624	0.865
9			1.461	1.422	0.887	0.604
10			1.286	0.926	0.543	0.519
11			0.981	0.781	0.294	0.294
12			0.812	0.650	0.249	0.199
13			0.373	0.432	0.239	0.209
14			0.653	0.371	0.145	0.184
15			0.441	0.348	0.151	0.151
16			0.321	0.374	0.098	0.106
17			0.525	0.186	0.099	0.108
18			0.351	0.171	0.083	0.090
19			0.192	0.164	0.084	0.087

34/59



35/59 Figure 24

Fraction	volume	dilution	OD measured at 450 nm			
			construct			
			39 Type 1b	40 Type 1b	62 Type 3a	63 Type 5a
20	250 μ l	1/200	0.072	0.130	0.096	0.051
21			0.109	0.293	0.084	0.052
22			0.279	0.249	0.172	0.052
23			0.093	0.151	0.297	0.054
24			0.080	0.256	0.438	0.056
25			0.251	0.100	0.457	0.048
26			3	1.649	0.722	0.066
27			3	3	2.528	0.889
28			3	3	3	2.345
29			3	3	2.849	2.580
30			2.227	1.921	1.424	1.333
31			0.263	0.415	0.356	0.162
32			0.071	0.172	0.154	0.064
33			0.103	0.054	0.096	0.057
34			0.045	0.045	0.044	0.051
35			0.043	0.047	0.045	0.046
36			0.045	0.045	0.049	0.040
37			0.045	0.047	0.046	0.048
38			0.046	0.048	0.047	0.057
39			0.045	0.048	0.050	0.057
40			0.046	0.049	0.048	0.049

36/59




FIGURE 25




Figure 2S




Figure 27





Figure 28



Lane 1: Crude Lysate
Lane 2: Flow through Lentil Chromatography
Lane 3: Wash with EMPICEN Lentil Chromatography
Lane 4: Eluate Lentil Chromatography
Lane 5: Flow through during concentration lentil eluate
Lane 6: Pool of E1 after Size Exclusion Chromatography

Figure 29: Western Blot Analysis with anti-E1 mouse monoclonal 5E1A10

41/59




FIGURE 30

A: NON - REDUCED

E2 + CONTAMINANTS (AGGREGATES)



**B: REDUCED**

FIGURE 31

43/59






FIGURE 32

FIGURE 33:
SILVER STAIN OF PURIFIED E2



1. 30 mM IMIDAZOLE WASH Ni-IMAC
2. 0.5 μ g E2

45 59 Figure 34



No.	Ret. (ml)	Peak start (ml)	Peak end (ml)	Dur (ml)	Area (ml* μ AU)	Height (μ AU)
1	-0.45	-0.46	-0.43	0.04	0.0976	4.579
2	1.55	0.75	3.26	2.51	796.4167	889.377
3	3.27	3.26	3.31	0.05	0.0067	0.224
4	3.33	3.32	3.33	0.02	0.0002	0.018

Total number of detected peaks = 4

Total Area above baseline = 0.796522 ml*AU


Total area in evaluated peaks = 0.796521 ml*AU

Ratio peak area / total area = 0.999999


Total peak duration = 2.613583 ml

46/59

FIGURE 35A




47/59

FIGURE 35B

48/59

Figure 36

E1 Ab



E2 Ab




FIGURE 37





Figure 38

Relative Map Positions of
anti-E2 monoclonal antibodies



PARTIAL DEGLYCOSYLATION OF HCV E1 ENVELOPE PROTEIN

Endoglycosidase H (Endo H)		Glycopeptidase F (PNGase F)	
0µg	0.6µg	0µg	0.04µg
6µg	60µg	4µg	40µg
0.6µg	0.6µg	40µg	400µg

106.0
80.0
49.5
32.5
27.5
18.5

↑↑↑↑↑↑↑
6 5 4 3 2 1 0

Figure 39

PARTIAL TREATMENT OF HCV E2/E2s ENVELOPE PROTEINS BY PNGase F




Figure 40

Fig. 41

In Vitro Mutagenesis of HCV E1 glycoprotein





Fig. 42A *In Vitro* Mutagenesis of HCV E1 glycoprotein



1. First step of PCR amplification (Gly-# and Ovr-# primers)





Fig. 42B

2. Overlap extension and nested PCR

a. Overlap extension



b. Nested PCR amplification (GPT-2 and TKr-2 primers)





Fig. 43 *In Vitro* Mutagenesis of HCV E1 glycoprotein



		HeLa cells									RK 13 cells									
		1	2	3	4	5	6	7			2	1	3	4	5	6	7	8		
80.0	—								—	80.0									—	80.0
49.5	—								—	49.5									—	49.5
32.5	—								—	32.5									—	32.5
27.5	—								—	27.5									—	27.5
18.5	—								—	18.5									—	18.5

Figure 44A

08928757.091297




Figure 448




Figure 45

kDa
— 119
— 67
— 43
— 29
— 18



Figure 46

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(c))--SMALL BUSINESS CONCERN

Docket Number (Optional)

Applicant or Patentee: Geert MAERTENS et al.Serial or Patent No.: PCT/EP95/03031Filed or Issued: PCT DATE : 31 JULY 1995Title: PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE**COPY**

I hereby declare that I am

- ☐ the owner of the small business concern identified below;
- ☒ an official of the small business concern empowered to act on behalf of the concern identified below;

NAME OF SMALL BUSINESS CONCERN INNOGENETICS N.V.ADDRESS OF SMALL BUSINESS CONCERN Industriepark Zwijnaarde 7, Box 4
B-9052 GHENT, BELGIUM

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

- ☐ the specification filed herewith with title as listed above.
- ☒ the application identified above.
- ☐ the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention must file separate verified statements averring to their status as small entities, and no rights in the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization having any rights in the invention is listed below:

- ☒ no such person, concern, or organization exists.
- ☐ each such person, concern or organization is listed below.

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Hugo VAN HEUVERSWEYNTITLE OF PERSON IF OTHER THAN OWNER Managing DirectorADDRESS OF PERSON SIGNING Colmanstraat 80, B-9270 KALKEN, BELGIUMSIGNATURE [Signature]

DATE

March 6, 1996

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(b))--INDEPENDENT INVENTOR

Docket Number (Optional)

Applicant or Patentee: Geert MAERTENS, Fons BOSMAN, Guy DE MARTYNOFF and
Marie-Ange BUYSE

Serial or Patent No.: PCT/EP95/03031

Filed or Issued: PCT DATE : 31 July 1995

COPY

Title: PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees to the Patent and Trademark Office described in:

- ☐ the specification filed herewith with title as listed above.
☒ the application identified above.
☐ the patent identified above.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☐ No such person, concern, or organization exists.
☒ Each such person, concern or organization is listed below.

FULL NAME : INNOGENETICS N.V.
ADDRESS : Industriepark, Zwijnaarde 7, Box 4
B-9052 GHENT, BELGIUM
SMALL BUSINESS CONCERN

Separate verified statements are required from each named person, concern or organization having rights to the invention availing to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Geert MAERTENS

NAME OF INVENTOR

Signature of inventor

Date

27/2/96

Fons BOSMAN

NAME OF INVENTOR

Signature of inventor

Date

27/2/96

Guy DE MARTYNOFF

NAME OF INVENTOR

Signature of inventor

Date

27/2/96

Marie-Ange BUYSE

NAME OF INVENTOR

Signature of inventor

Date

27/2/96

NAME OF INVENTOR

Signature of inventor

NAME OF INVENTOR

Signature of inventor

RULE 63 (37 C.F.R. 1.53)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE

the specification of which (check applicable box(es)):

☐ is attached hereto
☐ was filed on _____ as U.S. Application Serial No. _____
☒ was filed as PCT international application No. PCT/EP95/03031 on July 31, 1995
and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Prior Foreign Application(s):




Application Number	Country	Day/Month/Year Filed
94870132.1	EUROPE	29 July 1994

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior applications and the national or PCT international filing date of this application:

Prior U.S./PCT Application(s):

Application Serial No.	Day/Month/Year Filed	Status: patented, pending, abandoned
PCT/EP95/03031	31 July 1995	pending

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And I hereby appoint NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 3th Floor, Arlington, VA 22204-4714, telephone number (703) 818-4000 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Rosmer, 30184; Robert W. Fans, 31352; Richard G. Besha, 22770; Mark E. Nussbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Paul J. Menon, 33526; Jeffrey H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr., 29366; Thomas E. Byrne, 32205; Mary J. Wilson, 32965; J. Scott Davidson, 33489.

1.	Inventor's Signature: 	Date: <u>27/2/96</u>
Inventor:	Geert MAERTENS (first) (last)	Belgian (citizenship)
Residence: (city)	B-8310 BRUGGE 3 (state/country)	Belgium
Post Office Address:	Zilverpaarrenstraat 64, B-8310 BRUGGE 3, Belgium	
(Zip Code)	B-8310	
2.	Inventor's Signature: 	Date: <u>27/2/96</u>
Inventor:	Fons BCSMAN (first) (last)	Belgian (citizenship)
Residence: (city)	B-1745 OPWIJK (state/country)	Belgium
Post Office Address:	Hulst 165, B-1745 OPWIJK, Belgium	
(Zip Code)	B-1745	
3.	Inventor's Signature: 	Date: <u>27/2/96</u>
Inventor:	Guy DE MARTYNOFF (first) (last)	Belgian (citizenship)
Residence: (city)	B-1410 WATERLOO (state/country)	Belgium
Post Office Address:	Mattotstraat 71, B-1410 WATERLOO, Belgium	
(Zip Code)	B-1410	

FOR ADDITIONAL INVENTORS, check box ☒ and attach sheet with same information and signature and date for each.

4. Inventor's Signature: [Signature]
Inventor: Marie-Ange Date: 29/2/96
(first) MI BUYSE
Residence: (city) B-9820 MERELBEKE (last)
Post Office Address: E. Ronsestraat 23, B-9820 MERELBEKE, Belgium (state/country) Belgium
(Zip Code) B-9820 (citizenship) Belgian

FOR ADDITIONAL INVENTORS, check box ☐ and attach sheet with same information and signature and date for each.

66150 66150 66150